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PROTEIN QUALITY CONTROL SYSTEM IN NEURODEGENERATION 
Neurodegenerative diseases: a clinical overview 
Neurodegenerative diseases (NDs) are the third cause of mortality among the world population according to the World 
Health Organization after cardiovascular diseases and cancer (Rowinska-Zyrek et al. 2015). Approximately 30 million 
individuals are affected by a ND (Sheikh et al. 2013). NDs are a heterogeneous group of diseases that affect the central 
nervous system (CNS), and each disease is characterized by the progressive loss of a different subset of neurons. Among 
these diseases the most represented are Parkinson disease (PD), Alzheimer diseases (AD), Huntington’s diseases (HD), 
amyotrophic lateral sclerosis (ALS); another NDs characterized by a lower incidence is spinal and bulbar muscular 
atrophy (SBMA). All NDs differ from each other by the central nervous region affected, and consequently by clinical 
outcomes and signs.  
PD was initially described as “shaking palsy” by a physician named Parkinson. Nevertheless, reports on this disease 
appeared already in before Christ population, as documented by some Chinese medical texts (Rowinska-Zyrek et al. 
2015). Nowadays, PD is affecting the 1% of the over sixties world population (Elbaz et al. 2016). Clinical symptoms of PD 
are bradykinesia, shuffling gait, micrographia, memory lapses, a ‘masked’, expressionless face, trembling in the hands 
and forearms, loss of spontaneous movement, difficulty swallowing, and impaired coordination. A considerable fraction 
of PD patients also develop depression and dementia (Jankovic 2008). The most affected part of the brain is substantia 
nigra and the dopaminergic neurons present in this part of the brain (Davie 2008). The histopathological hallmark is the 
presence of Lewy bodies (LBs) inside neurons. The major component of these LBs is α-synuclein protein whose function 
has not yet been elucidate (Spillantini et al. 1998). 
AD is a debilitating disease first described by Alois Alzheimer, a German psychiatric in 1906 (Berchtold & Cotman 1998). 
Nowadays, AD is affecting about 26 million people worldwide. Usually, AD is diagnosed in people that are in their 
sixties, but in literature are also described juvenile case of AD (Brookmeyer et al. 2007). The first clinical sign of AD is 
forgetfulness. Eventually, signs become more severe leading to confusion, personality changes, anxiousness, irritability, 
memory loss, and intellectual disturbances (Oddo et al. 2003). The most affected neural population are cholinergic 
neurons. Histologically, this disease is characterized by deposition of β amyloid deposition around neurons (amyloid 
plaques) (Oddo et al. 2003). Usually, in these patients death come after 8-12 years post diagnosis (Brookmeyer et al. 
2007).  
HD had been always classified as chorea since George Huntington in the 19
th 
(Yerbury et al. 2016; Novak & Tabrizi 2010) 
century firstly vividly described the hereditary character of this pathology. HD affects people at every age, but most 
frequently the age of onset is in middle age (Walker 2007; Novak & Tabrizi 2010). The spreading of this pathology leads 
to change of personality, impairment in cognition and of motor control. The most affected regions are striatal nuclei, 
basal ganglia and cerebral cortex (Novak & Tabrizi 2010). HD is caused by a CAG repeat expansion in the huntingtin (htt) 
gene (Novak & Tabrizi 2010).  
SBMA and ALS are neurodegenerative diseases in which motor neurons are mainly affected. Motor neurons (MNs) 
degeneration lead to paralysis, and death come for respiratory failure. ALS appears as sporadic or familial, but in both 
cases there are proteinaceous accumulations in affected motor neurons (Neumann et al. 2006; Rosen et al. 1993; Vance 
et al. 2009)  
SBMA in caused by a mutation (CAG repeat expansion) present in the androgen receptor (AR) gene that is translated 
into a polyglutamine tract in the AR protein (ARpolyQ) (Katsuno et al. 2006). 
ALS and SBMA will be discussed more in detail in the sections below as the main diseases studied in this thesis.  
Even if NDs do not share common clinical signs, morphological and pathological features, and aetiology, many studies 
have evidenced some common toxic events that lead to pathogenic manifestations of all NDs. One of the most 
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important factors of neurotoxicity is the presence of misfolded and aggregating proteins. Other factors involved in the 
pathogenesis are mitochondrial dysfunction, free radical formation, ER stress; RNA metabolism abnormalities etc... 
(Sheikh et al. 2013). 
Another common feature of NDs is the absence of a cure that may slow down, stop or even revert the disease 
progression (Rowinska-Zyrek et al. 2015). This lack of therapeutic strategy is, mostly, due to the fact that the molecular 
mechanisms are still largely unknown, but also because the region affected are very difficult to target due to the brain 
blood barrier. 
Protein misfolding diseases 
Correct protein activity is essential for cell life, and protein functions are strictly correlated to protein folding. Protein 
folding is a process that enables proteins to reach the secondary structure from the polypeptides chain, and the tertiary 
structure from the secondary structure. There are millions of possible structures in which a protein can be folded, but 
there is only one (or few more) structure in which the protein is biochemically and functionally active (Dobson 2003; 
Dobson et al. 1998). Since folding process of proteins is vital for cells, several systems assist polypeptides maturation 
when they are produced from polyribosomes (these systems will be discussed below) (Dobson 2003). There is large 
fraction of polypeptides that do not reach the native fold but they are promptly degraded and removed from the cell 
environment. 
Misfolded proteins are proteins that have a different conformation from the native and correct one and can be present 
in cytoplasm, nucleus, ER and many other cellular compartments (Ciechanover & Kwon 2015). 
Several reasons have been postulated for the generation of excessive amounts of misfolded proteins in cells: i) somatic 
mutation leading to a different primary structure, ii) errors in the transcription or translation processes, iii) failure of the 
folding systems, iv) mistakes of the post-translational modifications and in proteins trafficking, v) environmental 
changes and vi) mechanisms of seeding or cross seeding that lead to the loss of conformation, (Prusiner 1998; Soto 
2001; Mastrianni & Roos 2000; Duyckaerts et al. 2007). Misfolded proteins are a serious treat for cell function and 
viability (Taylor et al. 2002). 
When a protein looses the correct conformation, some hydrophobic sites that normally are buried inside the protein 
are exposed to cell hydrophilic environment (Ines Moreno-Gonzalez & soto 2012). β-sheets structures are highly 
hydrophobic structures and, when exposed, they try to self-dimerized with other hydrophobic structures. This process 
may starts to recruit a large number of polypeptides and it is called aggregation; depending on their size and structural 
conformation, the products of this aggregation are called oligomers, proto-fibrils and fibrils (Soto 2003; Soto & Estrada 
2008). Initially, protein misfolding and nucleation are processes thermodynamically unfavourable and they start slowly. 
The rate of progression increases when few oligomers are formed acting as seeding nuclei. This process is mediated by 
prion like ability of misfolded proteins that drives other proteins to assume a pathogenic conformation and aggregate 
(Sweeney et al. 2017). 
The elongation phase, in which aggregates are formed, is much more rapid than the initial lag-phase and the growing of 
aggregates is faster. In addition, this process is accelerated by high protein concentration. The resulting membrane-less 
structures can be more or less well organized, but are more thermodynamically stable than misfolded proteins, due to 
the high number of hydrophobic contacts between misfolded monomers (Soto et al. 2006; Link et al. 2008). Moreover, 
these aggregates can propagate from the affected cells to neighbours ones (Sweeney et al. 2017). It has been shown 
that covalent binding induces the formation of aggregates. Oxidative modifications as well as phosphorylation and 
SUMOylation are known to increase the rate of aggregation of misfolded proteins (Conway 2001). 
Oligomers and misfolded species are the basis for the development of more structured and bigger formations but they 
are also the most toxic forms (Caughey & Lansbury 2003; Glabe 2006). 
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The exact mechanism by which different misfolded proteins exert toxicity and cause different neurodegenerative 
disease is still unclear (Sweeney et al. 2017). A minor part of the toxicity is linked to the previous function of the protein 
(that is generally lost when protein is misfolded), but protein toxicity is mainly exerted by a gain-of-function of the 
misfolded protein or by a dominant-negative effect of these species on the functional protein (Sweeney et al. 2017). 
The presence of misfolded proteins also causes other signs of stress that are believed to be both cause and 
consequence of NDs. Indeed, cellular distress and protein misfolding and aggregation are bidirectional and mutually 
exacerbating (Sweeney et al. 2017).  
Aggregates contribution to the disease is still very controversial. Many studies have shown that compromising 
aggregates formation leads to enhanced cell toxicity, suggesting a possible protective role of aggregates against 
oligomeric species (Sweeney et al. 2017). On the contrary, there are evidence that the prolonged presence of these 
aggregates in cells causes several deleterious events, such as sequestration of others proteins, disruption of synaptic 
functions and impairment of degradative systems (Olzscha et al. 2011).  
The connection between NDs and protein misfolding raises from the presence of familial forms of these diseases. It has 
been noticed that misfolded proteins found in the aggregates, are causative of the disease in the familial cases. The fact 
that encoded mutated proteins misfold draws a strong link between NDs and protein misfolding. The importance of 
protein misfolding on NDs leads to name them “proteinopathies” (Ines Moreno-Gonzalez & soto 2012). Moreover, 
neurons and all CNS cells are particularly vulnerable to the presence of these toxic species. In fact, neurons are post-
mitotic cells and thus they can not dilute these species by self-division (Sooyeon, Lee; Sato & Ralph 2013). 
The protein quality control system: chaperones 
The chaperone network 
Molecular chaperones are an essential part of the protein quality control (PQC) system whose role is to monitor protein 
homeostasis (Ciechanover & Kwon 2017). When mutated, damaged proteins are present in the cell they may activate 
the PQC system. The first line of response of the PQC system is the chaperone network. Molecular chaperones 
constitute approximately the 10% of all the proteome (Kampinga & Craig 2010). They have important physiological 
functions also during stress and in presence of toxic proteins. Many chaperones are called heat shock proteins (HSPs) 
because they are induced by heat, but they are also upregulated during various stress stimuli including presence of 
misfolded proteins, oxidative damage, presence of toxic chemicals and inflammation (Garrido et al. 2001). The HSPs 
family is a large family of proteins in which HSPs are classified on the basis of size, functions, localization and substrates 
specificity (Ciechanover & Kwon 2017).  
The main functions of HSPs are assisting the folding and the assembly of newly synthetized proteins and 
preventing/dissolving aggregates by refolding damaged proteins. HSPs act in the refolding by mean of three main 
mechanisms: first, they can hold protein until the folded state is spontaneously reached (Rüdiger et al. 1997; Hartl et al. 
2011); second, they can use ATP to unfold stable misfolded proteins and then refold them in their correct folding; third, 
using ATP hydrolysis they can act as “disaggregase” by forcing substrates in an unfold state (Itoh et al. 2002). 
Subsequently, unfolded proteins will be refolded in the mature folding. HSPs activity can be ATP dependent or ATP 
independent (Mosser et al. 2004; Arimon et al. 2008). Usually when HSPs need ATP hydrolysis to work they are assisted 
by other proteins that are named co-chaperones (Ciechanover & Kwon 2017). On the other side, ATP-independent 
chaperones, especially in neurons, directly bind the client recruiting them in a complex with other chaperones 
(D’Andrea & Regan 2003) 
HSPs can also work with proteolytic machineries that degrade proteins unable to fold. Historically, HSPs have been 
classified in three classes based on structures similarities (class I, class II, and class III) but this classification does not 
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correlate with biochemical function and mechanisms. A more recent classification has been published by Dr. Kampinga, 
that clarify HSPs name and function. This nomenclature system is based on gene named assigned by HUGO Gene 
Nomenclature Committee and has been recognized by NCBI. In this classification proteins preceded by sc refer to yeast 
and if preceded by hs refer to human (Figure 1) (Kampinga & Bergink 2016; Kampinga et al. 2009). 
HSP90 
HSP90 family members are proteins constitutively expressed, which localized in almost all cellular compartments: 
nucleus, cytoplasm, mitochondria, and endoplasmic reticulum (Lindquist 2009). 
There is also an inducible HSP90, called HSP90α, that differently from constitutively expressed HSP90β is induced upon 
certain conditions (Lackie et al. 2017). There have been identified more than 2000 HSP90’s interactors belonging to very 
different protein families such as steroid receptors, transcription factors and kinases (Lackie et al. 2017).  
HSP90s are involved in a wide range of cellular functions such as telomerase maintenance, cell cycle progression, 
apoptosis, vesicles transport, innate immunity, protein target degradation. Moreover, HSP90, interacting with a wide 
range of co-factors, brings a large number of proteins to the correct conformation (Lackie et al. 2017). HSP90 activity is 
strictly related to its homo-dimerization that allows the formation of three regions with different roles: a nucleotide 
binding region (NBD), a middle region (MD) responsible for client binding, and a C-terminal region, that is the surface 
for HSP90 dimerization (Prodromou et al. 1997; Taipale et al. 2010).  
The exact mechanism by which HSP90s recruit the clients is still enigmatic, but the folding cycle relies on ATP hydrolysis. 
HSP90 dimers have a V-shaped conformation due to the C-terminal dimerization (Figure 2). When a client is bound to 
the MD, ATP catalyses N-terminal HSP90 dimerization and this complex is the functional dimer (Ciechanover & Kwon 
2017; Prodromou et al. 1997; Pearl & Prodromou 2006). This complex is very dynamic and each monomer twists around 
the others to correctly dimerize. Finally, when ATP is hydrolysed, N-terminal dimerization is lost and the client is 
released (Pearl & Prodromou 2006).  
Each phase of HSP90 cycle is assisted and ruled by various co-chaperones and by post-translational modification of 
HSP90 like acetylation, nitrosylation, phosphorylation and methylation (Zuehlke & Johnson 2011; Buchner & Li 2013). 
There are some co-factors that stabilize the dimer such as p23 (Picard 2002; Whitesell & Lindquist 2005), others like 
HOP that inhibits HSP90 dimerization, by a non-competitive bound to the NBD on HSP90 (Prodromou et al. 1999). There 
are also co-factors that act on the ATPase activity (CDC37) (Taipale et al. 2010) or on ATP hydrolysis (AHA1) (Zuehlke & 
Johnson 2011) 
HSP70 
The subfamily of the HSP70 comprises several types of heat shock proteins of 70 kDa (now also renamed HSPA). There 
are several HSP70 isoforms localized in nucleus, cytoplasm and organelles such as mitochondria (Kampinga & Bergink 
2016). HSC70 localize in the cytosol, while the Bip/GRP78 localize in the ER. HSP70 is composed of two main subunits: 
the nucleotide binding domain (NBD) of 40 kDa and the substrates binding domain (SBD) of 25 kDa, that recognized 
hydrophobic structure exposed by proteins (Bukau et al. 2006). 
HSP70 family carries out several functions: they assist native proteins in the correct folding, they drives proteins across 
the membrane and they also rule protein-protein interaction by modulating the conformational changes of proteins 
(Kampinga & Craig 2010). Almost every HSP70 activity is orchestrated by various members of the HSP40 family 
(Kampinga & Craig 2010) and their interaction is mediated by the J domain in HSP70 structure. J domain is a non-
homologous region that is the first determinant of HSP70 activity (Kampinga & Bergink 2016). 
The HSP70s act in the folding of new polypeptides and of misfolded proteins and it can also disaggregate already 
formed inclusions and drives misfolded proteins to degradation. HSP70 binds misfolded proteins in the hydrophobic 
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regions that they exposed (Rüdiger et al. 1997; Kampinga & Craig 2010). The refolding mechanism of HSP70 relies on 
the switch between open and closed conformations of the SBD (Mayer & Bukau 2005). ATP hydrolysis regulates HSP70 
conformational change thanks to the action of members of the HSP40 family (see below) and thanks to other co-
chaperones that are nucleotide exchange factors (NEF) (Kampinga & Craig 2010) (Figure 3). SBD is composed of several 
β-sheet structures and by a α-helix that acts as a lid. The lid is open when HSP70 is bound to ATP and is closed when 
HSP70 is bound to ADP (Hartl et al. 2011). The hydrolysis of ATP in ADP is accelerated by HSP40 leading to SBD high 
affinity for substrates, while the exchange between ATP and ADP is ruled by NEF leading to low affinity for the 
substrates. The HSP70 cycle starts with HSP70 in the open conformation (high on rates and off rates for the peptide) 
(Rüdiger et al. 1997; Mayer & Bukau 2005). After ATP hydrolysis the substrates is tightly bound to HSP70 and SBD is in 
the closed conformation. Then, when ATP is replaced by ADP, the substrate is released and, if it is a fast folding protein, 
the hydrophobic domain are immediately buried in the inner core of the protein. If the folding does not happen in few 
seconds, the protein is immediately rebound to HSP70. It is possible that the re-bounding to HSP70, not only prevents 
aggregation, but also facilitates the refolding of these slow-folding proteins (McCarty et al. 1995; Szabo et al. 1994; 
Laufen et al. 1999; Kampinga & Bergink 2016).  
HSP40 
HSP40 proteins, also known as DnaJ proteins are a large group of HSP70 co-chaperone. Even if they are all grouped 
under the name of “HSP of 40 kDa”, many components of this family do not weight 40 kDa but they all share the J 
domain. This domain is composed of 70 well conserved aminoacids, and it is the surface for interaction with HSP70. J 
domain is also crucial for the interaction of HSP70 flexible region with clients (Kampinga & Bergink 2016).  
Members of HSP40 family (here called DNAJ proteins) activity is both client dependent or independent. If DNAJ does 
not bind any client, due to the lack of a client binding domain, it acts only as an activator of HSP70 through J domain. On 
the other side, DNAJs, that can bind clients targeting directly the nascent unfolded polypeptides. Moreover, some 
DNAJs can also prevent aggregates formation or dissolve already formed aggregates (Kampinga & Bergink 2016).  
DnaJB6 and DnaJB8 are expressed in neurons and have a protective role against misfolded proteins. In fact, all HSP40s 
not only hydrolyse ATP on HSP70 but also binds misfolded substrates and brings them close to HSP70’s SBD. 
Chaperonin 
Chaperonins are a heterogeneous group of protein that usually function by forming a double ring structure that 
encloses protein up to 60 kDa for refolding. Chaperonins are divided into two subgroups (Hartl et al. 2011). The first are 
also call HSP60 and they are usually localized on mitochondria, but upon some stressful condition they can migrate in 
the cytoplasm (Itoh et al. 2002; Ranford et al. 2000; Tutar & Tutar 2010) . Inside double ring structure there is a pore in 
which unfolded substrates are enclosed for refolding. The disclosure of this cavity is regulated by a lid formed by the co-
chaperone HSP10. When the lid is open peptides are released in a native conformation (Itoh et al. 2002; Ranford et al. 
2000; Tutar & Tutar 2010).  
The second subgroup is independent by HSP10 and proteins of this family usually form eight-membered rings. One 
important member of this family is TCP-1 Ring Complex (TRiC), alternatively called TCP1 complex (CCT). This protein 
interacts with several newly synthetized proteins, such as actin and tubulin, assisting their correct folding (Frydman 
2001; Walker et al. 2009). 
Small HSPs  
The small heat shock proteins (sHSPs) are also known as HSPBs. This family account for 10 members that are similar in 
size from each other. They all contain a conserved sequence of 80-100 aminoacids that is called α-crystallin domain and 
that is at the basis of sHSPs dimerization/oligomerization as well as recognition of the clients (Horwitz 1992; Kim et al. 
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1998). These dimers/oligomers can be formed by a various number of monomers (from 12 up to 48), but the 
oligomerization process starts with the formation of a dimer via the α-crystallin domain, and involves the C-terminus 
and the N-terminus, which stabilize the dimer (Lambert et al. 1999). Many sHSPs contain, in the C-terminal region, a 
triad of aminoacids (usually the triad contains proline) that are at the basis of the dimer formation. If this triad is not 
present chaperones can only form small oligomers and this is the case for HSP22 and HSP20 (HSPB8 and HSPB6). sHSPs 
differ from each other by tissue expression and by biochemical activity (Boncoraglio et al. 2012) (Figure 4). The main 
activities of sHSPs are: cytoskeleton stabilization (all these proteins bind elements of the cytoskeleton, thus determining 
their stabilization or destabilization (Boncoraglio et al. 2012; Brown 2007; Sharma et al. 2017; Iwaki et al. 1994)), 
chaperone activity and anti-apoptotic activity; sHSPs exert their activity in an ATP-independent fashion. The 
cytoskeleton activity of sHSPs is strictly dependent on the phosphorylation state of the sHSPs that then influence their 
oligomerization (During et al. 2007). 
The chaperone activity of sHSPs prevents the formation of high oligomers or aggregates by preventing the nucleation 
(Rusmini et al. 2013; Crippa et al. 2010; Boncoraglio et al. 2012). In some cases, sHSPs also promote the refolding of 
substrates. Especially upon stress condition, sHSPs dimers are released from oligomers to promote the binding to the 
unfolded/misfolded substrates; sHSPs hold them in a soluble form preventing their aggregation (Rusmini et al. 2013; 
Crippa et al. 2010; Cristofani, Crippa, Vezzoli, et al. 2017). Then, sHSPs act with ATP-dependent chaperone allowing 
protein folding, when stressful condition is gone. It is also known that their chaperone ability varies between sHSPs 
family members and it is highly dependent also on substrate properties (Boncoraglio et al. 2012). 
Lastly, some HSPBs may also act as anti-apoptotic factors. The most well studied member in this context is HSPB1. 
HSPB1 prevents apoptosis by acting upstream and downstream to the mitochondria inhibiting the activation or release 
of the pro-apoptotic signals by sequestering the released cytochrome-C during apoptotic stimuli (Chauhan et al. 2003; 
Arrigo 2017). It also prevents the function and the formation of the aptosome (functional structure for apoptosis).  
All these sHSPs functions can co-operate during stress and their beneficial role is achieved by the co-existence between 
these different functions. 
The co-chaperones family of BAG 
Among the large family of the nucleotide exchange factors (NEFs), there is BAG family whose members associate with 
HPSs to accelerate the hydrolytic ATP cycle; indeed, they promote the release of ADP and the subsequent bound of ATP 
(Young et al. 2003; Behl 2011; Kettern et al. 2011). 
Human BAGs (Bcl-2 associated AthanoGenes) are proteins that have anti-apoptotic activity and have been initially 
associated with Bcl-2 family. Bcl-2 family is a heterogeneous group of proteins that can have anti- or pro-apoptotic 
function. Since some of BAG proteins act in complex with HSP70, that is a chaperone, they are usually called co-
chaperones (Behl 2016).  
The first BAG protein discovered was BAG1 and subsequently other 5 members were described in humans (BAG2, 
BAG3, BAG4, BAG5, and BAG6). All BAGs share a conserved aminoacids sequence of 40-50 aminoacids, named the BAG 
domain and differ from the N-terminus structure (later studies say that this domain span for 110-120 aminoacids). BAG 
domain is responsible for BAG interaction with other proteins such as HSP70 (Figure 5). These six proteins greatly differ 
from each other by structure and function (Takayama et al. 1999).  
BAG1 exists in four different isoforms depending on the initiation of translation (Takayama et al. 1999). Through its BAG 
domain BAG1 interacts with HSP70, and exerts its NEF activity driving ADP exchange into ATP, thus allowing the release 
of the substrates from HSP70 (Bukau et al. 2006; Sondermann 2001; Höhfeld & Jentsch 1997). BAG1 also possesses an 
ubiquitin binding domain, that allows the delivery of HSP70-bound substrate to proteasome (Luders et al. 2000). BAG1 
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also interacts with steroids receptors, particularly the glucocorticoid receptor, influencing their activities. It has been 
shown that BAG1 has a role in the developing nervous system (Behl 2016). 
BAG2 function is strictly correlated with its interaction with CHIP. CHIP (carboxyl-terminus of HSP70-interacting protein) 
is also known as STUB3 and acts both in protein folding and in protein degradation by proteasome, since it is an E3 
ubiquitin ligase. There are also evidence that link CHIP to CASA-complex involved in autophagy selective routing (Crippa 
et al. 2010). BAG2 is known as a CHIP inhibitor and through this function it rules some processes (Arndt et al. 2005; Dai 
et al. 2005). The main role of BAG2 is ruling the switch between foldase activity on pro-degradative activity of HSP70. It 
was also shown that BAG2, positively regulates ubiquitin independent degradation by proteasome (Carrettiero et al. 
2009). 
BAG3 exists in two isoforms: a full-length form (70 kDa) and a shorter form of 40 kDa (Bruno et al. 2008). The shorter 
form is expressed only in synaptosome where the full-length form is poorly expressed. Full-length BAG3 is mainly 
expressed in transformed cells such as myoblast, tumour cells etc..(Gentilella & Khalili 2011; Felzen et al. 2015; Sherman 
& Gabai 2015; Rosati et al. 2007; Liao et al. 2001)  In non-transformed cells, BAG3 is expressed upon stressful signals 
like oxidative stress or proteasome inhibition. BAG3 interacts with a wide range of proteins thanks to the presence of 
many different domains in its structure. In addition to BAG domain (essential for the interaction with Bcl-2), BAG3 also 
has a PxxP domain (that interacts with the SH3 domain of phospholipaseC γ and with dynein) a WW domain (that binds 
proline rich domains on target structure, such as adenovirus penton base protein) and two IPV domains (designate for 
the interaction with HSPB8, HSPB6 and HSPB5) (Fuchs et al. 2015; Doong et al. 2003). BAG3 contains also two sites, 
regulated by phosphorylation, which binds to 14-3-3 proteins (Ge et al. 2010). 
BAG4 mainly interacts with the tumour necrosis factor (TNF) and mainly acts as a silencer of death domains (Jiang et al. 
1999).  
BAG5 has 4 BAG domains (it is the only BAG with this particular structure). BAG5 is not a well-studied protein, but is 
seems to have a pro-apoptotic role, differently form the other BAG proteins (Kalia et al. 2004). 
BAG6 is the largest member of BAG proteins (1229 aminoacids), also known as Scythe in D. Melanogaster or BAT3 when 
associated to the major histocompatibility complex (MHC) of class III (Thress et al. 1998; Spies et al. 1989). BAG6 has a 
BAG domain, but its action on HSP70 is not explicated through that domain and is CHIP independent. BAG6 also 
possesses a UBL domain that helps in driving substrates to proteasome. Through its interaction with HSP70, BAG6 also 
has a role in cell stress, viability and development (Behl 2016; Corduan et al. 2009). 
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Figura 1: HSPs nomenclature (Kampinga et al. 2009) 
 
 
Figure 2: HSP90 cycle (Hartl & Hayer-Hartl 2002) 
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Figure 3 HSP70 cycle (Kampinga & Craig 2010) 
 
 
Figure 4 Classification of small heat shock proteins (Boncoraglio et al. 2012) 
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Figure 5 BAG family (Behl 2016) 
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The protein quality control system: the degradative systems 
The ubiquitin proteasome system  
Proteasome is the preferential route for degrading short-living proteins, and the 80% of the total amount of proteins is 
degraded by proteasome (Hershko & Ciechanover 1998). 
The functional part responsible for enzymatic activity is a multi-heteromeric complex named “20S subunit” hereafter 
referred as proteasome (it is called 20S due to its sedimentation coefficient) (Hough et al. 1987). Proteasome is well 
conserved among eukaryotics (yeast, plant, mammalian) and also between some bacteria. The proteasome is composed 
of α and β subunits arranged in four rings: two rings are made of only α subunits and two rings made only of β subunits 
(T. Jung et al. 2009). The four rings are piled one onto the other with the two α rings outside (first and last) and the two 
β rings inside (α β β α structure) (T. Jung et al. 2009). Ancestral form of proteasome found in Archea have α and β 
subunits with only one secondary and tertiary structure; while in yeast plants and mammalians both α and β subunits 
display 7 different conformations present in each ring. Indeed, each ring is composed of seven different subunits whose 
weight spans around the 20 kDa. The whole proteasome has an overall mass of 700 kDa (T. Jung et al. 2009). 
Proteasome inner part is divided in three spaces: two fore chambers resulting from the space between α and β subunits 
and a main chamber resulting from the space between the two β rings. The main chamber is the core of the proteolytic 
activity of the proteasome. Subunits β1, β2 and β5 show proteolytic activity and can be replaced by β1i, β2i and β5i 
induced by interferon-γ under certain conditions. Proteasome with these different β subunits is called immune-
proteasome and produces protein fragments of different lengths compared to the physiological proteasome (Hirano et 
al. 2008). Usually, the fragments lengths spans between 2-35 amino acids with an average of 8-12 aminoacids per 
fragment (Köhler et al. 2001; Luciani et al. 2005). β1, β2 and β5 show different kind of proteolytic activity: β1 has a 
peptidyl-glutamyl-peptide-hydrolysing-activity; β2 has a trypsin-like activity; β5 has a chymotrypsin-like activity (Loidl et 
al. 1999; Groll & Huber 2004). The catalytic centre of each subunit is the threonine residue at the N-terminal. The 
proteolytic activity is most important in β5 and less significant in β2 and β1 (Heinemeyer et al. 1997).  
The α rings are recognition domain and regulate the access to the inner core. The N-terminal region of subunits α2 α3 
and α4 form a gate that prevents the access of protein to the catalytic core (Groll et al. 2000). Each N-terminal residue 
involved in this gating process has its own tertiary structure adapt for closing the channel. The diameter of the pore is 
13 A° enough to allow the processing of one misfolded substrate as a single chain (T. Jung et al. 2009). 
When a contact between α subunits and substrates is established the N-terminal residues closing the pore, undergo a 
conformational change leaving the channel open. There are various cofactors that interact with α subunits to regulate 
the opening and the closing of the pore and the specificity for the substrate. One of these is the 19S cofactor: the 
binding with this cofactor increases the access to the catalytic core of 100 times and regulates substrates specificity 
(Adams et al. 1998; Glickman et al. 1998). The 19S is also called PA700 (proteasome activator of 700 kDa) (Figure 6A) 
and has a base structure made of Rpt subunits (10 different conformations with ATPase activity) and a lid structure that 
acts as a channel gate made of Rpn subunits (9 different conformation with no ATPase activity) (Liu et al. 2002; Tanaka 
2009). Each α ring is bound with one 19S subunit (T. Jung et al. 2009). The complex between 20S and the two 19S 
subunits is called 26S proteasome and weights approximatively 2MDa (Glickman & Ciechanover 2002).  
26S proteasome only recognizes and degrades proteins that are ubiquitinated (T. Jung et al. 2009). The 26S proteasome 
acts together with the enzymes responsible for the ubiquitination of substrates composed the ubiquitin proteasome 
system (UPS). Ubiquitin is a small protein of 76 aminoacids (8,5 kDa) highly conserved in eukaryotic and is regarded as 
post-translational modification. Ubiquitin acts as a signal to direct protein to proteasomal degradation (Wilkinson et al. 
1980).  
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The ubiquitination process is composed of 3 main steps: activation, conjugation and transfer of the ubiquitin (Figure 
6B). The enzymes responsible of these porcesses are E1, E2, E3 and E4 that act as single enzymes and not in a complex, 
even if they catalysed reactions of the same system. 
E1 is an ATP dependent enzyme that activates ubiquitin. To activate ubiquitin the glycin76 at the C-terminus of 
ubiquitin is bound to a cysteine on the E1 enzyme (Sun 2003). Then ubiquitin is transferred on E2 enzyme on a 
homologous cysteine residue. The catalytic core of E2 is composed of an asparagine residue in addition to the cysteine 
residue. Often E2 enzyme is found in a homo-dimer complex, especially when one of the two E2 is already bound to an 
ubiquitin residue (Hershko & Ciechanover 1998). 
After the loading of ubiquitin on E2 enzyme, both the substrates and the E2 enzyme are bound to the E3 enzyme. If E3 
possesses the RING motifs, ubiquitin loaded on E2 is directly transferred to the substrate (RING E3) creating a bound 
between a cysteine on ubiquitin and a lysine on the substrate (Hershko & Ciechanover 1998; Hochstrasser 2006). If E3 
does not possess the RING motif (HECT E3), ubiquitin is firstly transferred to E3 enzyme and then, from the E3 enzyme 
to the substrate. E3 enzymes are also called ubiquitin-ligase and are the most abundant proteins of the UPS 
(Hochstrasser 2006).  
Human genome encodes for more than 500 E3s (Hershko & Ciechanover 1998), and often these ubiquitin-ligases act in 
collaboration with chaperones (Ciechanover & Kwon 2015). CHIP is an ubiquitin ligase and HSP70 and HSP90 co-
chaperone. When is bound to HSP70, CHIP binds and ubiquitinates misfolded substrates (Demand et al. 2001). To 
facilitate proteasomal degradation CHIP also interacts with Rpn10 a subunit of the 19S complex (Connell et al. 2001). 
Proteasomal degradation of CHIP clients is further facilitated by binding with BAG1, that acts as NEF of HSP70, 
enhancing the releasing of the substrate from HSP70 (Takayama et al. 1997). BAG1 also has a domain for the interaction 
with the proteasome, thus strictly directing substrates to proteasome (Alberti et al. 2003) (Figure 7). Also HSPB1, that is 
a small HSP interacts directly with proteasome and modulates the ubiquitination of client (Garrido et al. 2006). 
Two other important ubiquitin-ligases are UBR1 and UBR2 (that mediate the ubiquitination of misfolded cytosolic 
proteins) and RNF126 (that collaborates with the BAG6 family ubiquitinates proteins of the membranes) (Heck et al. 
2010; Prasad et al. 1992; Eisele & Wolf 2008).  
Substrates can be bound to a single moiety of ubiquitin (mono-ubiquitination), to single moieties of ubiquitin in 
different protein sites (poly-mono-ubiquitination) or to an ubiquitin chain (poly-ubiquitination). The polymerization of 
ubiquitin occurs after the attachment of the first ubiquitin to the substrates. Polymerization is based on the conjugation 
of single ubiquitin moieties to the growing chain: a lysine on the new ubiquitin is bound to a methionine on the last 
ubiquitin of the chain (Hershko & Ciechanover 1998; Ciechanover & Kwon 2015). There are several lysine residues 
located in the ubiquitin that can be involved in polymerization (K6, K11, K27, K29, K33, K48, or K63 (Ikeda & Dikic 
2008)). The elongation of the poly-ubiquitin chain is achieved by a new cycle of E1, E2 and E3 enzymes. Occasionally 
also E4 mediates the attachment of ubiquitin moieties mainly through K48 linkage (Upadhya & Hegde 2007).   
Now it is known that almost every ubiquitinated protein is degraded by proteasome, and that there is not a threshold 
for chain length: even a single ubiquitin is enough for targeting substrates to proteasome (Boutet et al. 2007).  
The most common ubiquitination that leads to proteasomal degradation is in Lys48 (K48). K48 linkage are the most 
abundant in proteins and this modification drives most of the proteins towards proteasomal degradation; indeed, K48 
linkage changes upon proteasome inhibition (Yau & Rape 2016) (Figure 10). K48 linked proteins are produced by various 
E3 ligases also involved in other degradative processes, such as ERAD (Yau & Rape 2016). Also K11 linkage in involved in 
proteasomal degradation, especially of proteins involved in cell cycle (Yau & Rape 2016; Jin et al. 2008; Song et al. 2014; 
Ling Song and Michael Rape 2011). 
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Ubiquitin is also a mediator of protein-protein interaction. Ubiquitin chains that explicit this function have different 
position and conformation like Lys63 (K63) (Spence et al. 1995). 
Ubiquitinated substrates are recognized by 19S subunit (Thrower et al. 2000). 19S subunit plays three main different 
functions. First of all, it recognizes the poly-ubiquitinated substrates thanks to the action of the Rpn subunits (T. Jung et 
al. 2009). Once the substrate is recognized, 19S subunit unfolds it in order to let it in the central core of the 20S subunit 
(Ciechanover 1994). Meanwhile, 19S complex acts also as a deubiquitinase enzyme mainly through the ATPase activity 
of the Rpn11 . Indeed, ubiquitin is released in the cytosol as long chains. In the cytosol are present deubiquitinating 
enzymes (DUBs) that reduce chains into ubiquitin monomers, in order to prevent a competition between these chains 
and ubiquitinated substrates for the proteasome. DUBs also catalysed the shortening of ubiquitin chain on substrates 
modulating proteasomal degradation. Free ubiquitin moieties  can deposit on aggresome where they are recognized by 
HDAC family and used for proteasomal routing (Hao et al. 2013). 
Physiologically the UPS is involved in many cellular functions. In cell cycle progression UPS has an important role since 
degradation of specific cyclin rules the transition from a phase to another (Takeuchi & Toh-e 2001). In antigen 
processing the immune proteasome is responsible for the production of small fragments of 8-10 aminoacids of length 
that will be exposed on cell surface and presented as antigen to the immune cells (Osterloh et al. 2006). This process 
gains particular importance in presence of viral infection, when viruses produce the protein for the assembly of new 
viruses (Osterloh et al. 2006). Proteasome is also responsible for the degradation of newly synthetized proteins that do 
not reach the correct folding (Dick et al. 1996). A fraction of these proteins has to be extracted from the ER (Schmitz & 
Herzog 2004). There are various proteins that assist the extraction of these proteins such as p97/VCP (Valosin 
Containing Protein). VCP forms a channel that extracts proteins from the ER directing them to UPS degradation 
(DeLaBarre & Brunger 2005; Brodsky & McCracken 1999; Hampton 2002). UPS also degrades proteins that misfold due 
to mutations, oxidation etc...(Brégégère et al. 2006) In this context, UPS is relevant in aging, since proteasomal activity 
decreases in old cells compared to young cells (Chondrogianni et al. 2015). If proteasome is no longer functional, 
misfolded proteins may accumulate forming toxic aggregates.  
Autophagy 
The term autophagy was created in 1963 by Christian Reneè De Duve (Nobel Prize in 1974 for his studies on lysosomes), 
from the greek language “auto” meaning self and “phagos” meaning eating. Autophagy was firstly identified as a 
cellular process whose function was to degrade part of the cell itself. Vesicles that are the basis of the autophagic 
process had been yet characterized in 1950, when by electron microscopy scientists observed the formation of double 
membrane structures surrounding other cellular components, like mitochondria (Tooze & Dikic 2016). These vesicles 
were called autophagosomes. During the following years research on the cellular pathway involving these vesicles was 
carried on only by few groups of scientists that biochemically characterized the content of this autophagy related 
vesicles, called autophagosomes (Tooze & Dikic 2016). During 1980s, Yoshimori Ohsumi found that autophagy was 
correlated with nutrient deprivation and in particular he found that autophagy was increased during starvation (Ohsumi 
2013). From these first evidence Ohsumi kept on studying these process in yeasts (Saccharomyces cerevisiae) and 
characterized many proteins with a key role in autophagy that were called ATGs (AuTophagy related Genes) (Klionsky et 
al. 2003). Ohsumi also described an autophagy regulatory mechanism involving mTOR, and the entire process required 
for autophagosomes formation (Mizushima et al. 1998; Ichimura et al. 2000). In the past two decades, many studies 
evidenced that autophagy is not only a physiological mechanism, but that is also involved in the pathogenic mechanism 
of many severe diseases like cancer, NDs, metabolic disorders, inflammation, virus and bacterial infections (Mizushima 
et al. 2004; Liang et al. 1999). Now autophagy has gained importance and is a very widely studied pathway. 
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In 2016 the Royal Swedish Academy of Sciences awarded Yoshimori Ohsumi the Nobel prize, for the description and the 
characterization of autophagy (Tooze & Dikic 2016). 
Macro-Autophagy or “Autophagy” 
The formation of the autophagosome 
Macro-autophagy, hereafter referred as autophagy, is a process present in yeast, plant and mammalian cells. Its main 
role is supplying nutrient during starvation, degrading big organelles and proteinaceous material, and eliminating 
infecting bacteria and viruses (Parzych & Klionsky 2014; Tanaka & Matsuda 2014). The capacity of autophagy to degrade 
proteinaceous formation highlight its importance in NDs. 
The basic difference between autophagy and other vesicle related pathways is that autophagosomes are “de novo” 
formed by membrane elongation and not by membrane budding already containing cargo (Zhifen & Klionsky 2010). 
Autophagosomes are round shaped vesicles with a diameter of 0.4-0.9 µm in yeast, and 0.5-1.5 µm in mammals 
(Takeshige et al. 1992).  
Autophagosomes formation is a process composed of three distinct steps: induction, nucleation and elongation (Figure 
8). 
Induction of autophagy involves the recruitment of factors around the phagophore assembly site (PAS). Factors that 
complex together for induction are ULK1/ULK2 (Unc-51-like kinase 1/2, homologs of Atg1), Atg13 and RB1-inducible 
coiled-coil 1 (RB1CC1/FIP200) (Hosokawa et al. 2009; C. H. Jung et al. 2009; Ganley et al. 2009; Mizushima 2010; 
Mizushima 2007). Atg13 also binds C12orf44/ATG101 required for a correct functioning of the complex (Noda & 
Mizushima 2016; Mercer et al. 2009). ULK1-Atg13-FIP2000 complex is stable and does not depend on nutrient levels 
(Hosokawa et al. 2009; C. H. Jung et al. 2009). ULK1 and Atg13 activity is regulated by phosphorylation. In normal 
conditions, MTORC (mechanistic target of rapamycin complex) maintains ULK1 and Atg13 phosphorylated and thus in 
an inactive status. Upon starvation or following rapamycin treatment MTORC disassociates from the ULK1-Atg13-
FIP2000 complex leaving the complex available for yet unknown phosphatases. When ULK1 and Atg13 are 
dephosphorylated they are activated and this process induces autophagy (Hosokawa et al. 2009). 
After induction, nucleation of the phagophore relies on the formation of PtdIns3K complex (ATG14-containing class III 
phosphatidylinositol 3-kinase). This complex is formed by PIK3C3/VPS34, PIK3R4/p150, and BECN1. If BECN1 is not 
associated to the complex, autophagy is inhibited. BCL-2 interaction with BECN-1 prevents its association to the 
complex, thus inhibiting autophagy (Itakura & Mizushima 2010). When, upon nutrient deprivation, BECN-1 is released 
from BCL-2, autophagy starts. There are two positive regulators of PtdIns3K complex formation that are AMBRA and 
SH3GLB1/Bif-1; these proteins positively regulate BECN-1 association to the complex (Kihara et al. 2001; Itakura et al. 
2008; Furuya et al. 2005; Liang et al. 1999). PtdIns3K complex produces PtdIns3P (phosphatidylinositol 3-phosphate) 
that has a role in forming lipid raft on membrane before the recruitment at autophagosomes (Liang et al. 2006). 
There are two systems required for the elongation phase. The first one is the complex formed by ATG5, ATG12 and 
ATG16L1, where the ubiquitin like (UBL) protein is covalently bound to ATG5, and this action is mediated by ATG7 (E1 
activating enzyme) and ATG10 (E2 conjugating enzyme). Then, ATG16L1 binds not covalently ATG5 and dimerizes 
forming a bigger complex. There are two negative regulators of this complex. The first one is RAB33A, a Golgi protein 
that inhibits ATG16L1; the second one is KAT2B/p300, that acetylates ATG5, ATG7 and ATG12 resulting in their 
inactivation (Ohsumi 2001; Shintani et al. 1999; Mizushima et al. 2003; Lee & Finkel 2009; Kim et al. 1999). 
The second system required for elongation of the phagophore is the LC3 system. LC3 (MAP1LC3B, Microtubule-
associated proteins 1A/1B light chain 3B) and GABARAP (γ-aminobutyric acid receptor-associated protein) are ATG8-like 
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protein. These two subfamilies have different roles in phagophore maturation and elongation; LC3 is the subfamily 
better characterized.  
Initially, LC3 undergoes to the action of the ATG4 protease that causes the exposure of a glycine residue at C-terminus 
of the LC3 protein (LC3-I). Subsequently, the action of the E1-like protein, ATG7 transfers LC3 on ATG3, an E2-like 
enzyme. Then, the ATG5-ATG12 complex, that acts as E3-like complex, conjugates LC3 with a molecule of 
phosphatidylethanolamine (Ichimura et al. 2000; Kirisako et al. 1999; Kirisako et al. 2000). LC3 lipidation is accelerated 
under starvation. Lipidated LC3 (LC3-II) is present both in the inner and in the outer side of the forming phagophore. 
Despite the knowledge about the activating mechanism of LC3, the exact role of this protein in phagophore maturation 
is still unknown (Kirisako et al. 1999). There is third system involved in phagophore formation based on ATG9 shuttling 
from Golgi to the phagophore in formation. This system is still largely unknown, but its role seems to involve the 
recruitment of membranes for the formation of the phagophore (He et al. 2008; Reggiori et al. 2004). Membrane 
utilized for the formation of the autophagosomes may be derived from the ER, the Golgi apparatus, the mitochondria, 
and even the plasma membrane (Ravikumar et al. 2011; Hayashi-Nishino et al. 2009). Lipid rafts enriched by PtdIns3P, 
produced by PtdIns3K, are called omegasomes and are recruited as membrane sources for autophagosome formation 
(Axe et al. 2008). 
The process activated after closure of the phagophore is still largely unknown, but it may be dependent on GABARAP 
action that allows autophagosome maturation (Weidberg et al. 2010). The autophagosome can fuse to late endosome, 
already containing vesicles, and lastly with lysosomes forming the autolysosome (Monastyrska et al. 2010). The fusion 
between autophagosomes and lysosomes is not clearly understood. Recent studies show that RAB7, a GTPase protein, 
and VAM7 and VAM9 (Liang et al. 2008), belonging to the SNARE family, are involved in the formation of the 
autolysosome (Fader et al. 2009; Furuta et al. 2010). 
Autophagy is primarily regulated by nutrient intracellular concentration. There are two systems that sense carbon and 
nitrogen that are the major regulator of autophagy. The first one is based on the action of the PKA (c-AMP dependent 
protein kinase A) and the second one is associated with mTOR activity (Stephan et al. 2010).  
When a cell is under starvation, the concentration of AMP increases and this event activates the AMP kinase (AMPK). 
AMPK phosphorylates and activates TSC1/2 , which in turn phosphorylates MTORC, preventing its association to the 
nucleation complex, and activating autophagy. On the other side, the presence of the aminoacids positively regulates 
mTORC1 that prevents the formation of the nucleation complex (Inoki et al. 2003; Gwinn et al. 2009). 
Since autophagy is a highly dynamic process, it is pivotal that formation and degradation of autophagosomes, called 
autophagic flux, is balanced. An imbalanced autophagic flux is detrimental for cells in both senses. If autophagy is 
excessively active, it degrades relevant cytoplasmic components involved in physiological functions, thus potentially 
leading to cell death. On the other side, impairment of autophagosomes formation or failure in autophagosome 
degradation (fusion with lysosome) are at the basis of the appearance of many diseases such as neurodegenerative 
diseases.  
The CASA complex and selective autophagy 
For many years autophagy has been regarded as an unspecific process that degrades entire portion of cytoplasm in 
response to nutrient starvation. Recent works showing the involvement of autophagy in degradation of disease-
associated proteins has evidenced the existence of selective pathways for the routing of substrates to autophagy. 
The chaperone assisted selective autophagy (CASA) is a pathway of routing substrates to autophagic degradation that 
involved chaperones (Gamerdinger, Carra, et al. 2011; Gamerdinger, Kaya, et al. 2011).  
The CASA complex is formed by HSP70, CHIP, HSPB8 and BAG3 (Figure 9). Initially, HSP70 in cooperation with HSPB8 
recognizes misfolded substrates that need to be degraded. As a second step, CHIP that is an E3 enzyme associated to 
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HSP70, ubiquitinates these substrates (Figure 10). Finally, BAG3 that is part of the complex as HSPB8 and HSP70 co-
chaperone, via its dynein interacting domain, drives HSP70-CHIP-HSPB8 complex to the autophagic receptor p62, 
usually localized at the microtubule organization centre (MTOC). P62 displays an ubiquitin binding domain, and is thus 
capable of recognizing substrates ubiquitinated by CHIP (Gamerdinger, Carra, et al. 2011; Gamerdinger, Kaya, et al. 
2011). Moreover, BAG3 by its activity as NEF, allows the release of the ubiquitinated substrates from HSP70. 
Accumulation of ubiquitinated proteins delivered by CASA complex is called aggresome. When an aggresome is formed, 
p62 drives its internalization into the forming autophagosomes. Indeed, p62 also has a domain which interacts with LC3, 
acting as a bridge between the aggresome and the autophagic vesicles (Gamerdinger, Carra, et al. 2011; Gamerdinger, 
Kaya, et al. 2011).  
Microautophagy and chaperone mediated autophagy 
Microautophagy and chaperone-mediated autophagy (CMA) are two processes independent of macro-autophagy 
(usually referred as autophagy) that involved the degradation of substrate through the lysosomes.  
Microautophagy is gaining more importance in the recent year because some studies reveal its connection with some 
human diseases. Microautophagy is a self-eating process less known and less important than macro-autophagy. 
Microautophagy relies on the direct engulfment of soluble substrates into the lysosomes through invagination of the 
lysosome membrane (Li et al. 2012). Microautophagy can be induced by both starvation and rapamycin. There are three 
types of selective microautophagy: micropexophagy, piecemeal microautophagy of the nucleus, and micromitophagy (Li 
et al. 2012). Studies aimed to better understand the mechanisms regulating microautophagy are still ongoing. 
On the other side, CMA is better characterized and more widely studied. CMA is a degradative pathway found only in 
mammals. Dysfunction of CMA is related to human disease especially NDs and cancer. CMA has also a relevant role in 
aging process (Liu et al. 2015; Cuervo & Wong 2014). If microautophagy and in some case macro-autophagy have low 
specificity for substrates, CMA is highly selective. Substrates of CMA must display a sequence of 5 aminoacids K-F-E-R-Q. 
KFERQ sequence is present on the 30% of the whole proteome and normally is hidden or is located in the internal core 
of the protein, sometimes on the surface of protein-protein interaction (Cuervo & Wong 2014). Therefore, to unmask 
the KFERQ targeting sequence, these proteins have to be unfolded. KFERQ sequence is recognized by heat shock 
cognate 70 (Hsc70/HSPA8) and by other co-chaperones. Hsc70 targets the proteins to lysosomes where it is recognized 
by the substrate receptor LAMP-2A (lysosomal-associated membrane protein 2A) (Bandyopadhyay et al. 2008). When 
LAMP-2A interacts with the substrates, it oligomerizes with homologous proteins forming the translocation complex. 
This complex is stabilized by the HSP90 present in the lumen of lysosomes. Meanwhile Hsc70 assists the unfolding of 
the substrate. The translocation of the unfolded substrate is assisted and partially mediated by a luminal isoform of 
Hsc70 (Bandyopadhyay et al. 2008). After the translocation, the LAMP-2A complex is disassembled by action of the 
cytosolic Hsc70, and LAMP-2A return in its monomeric form. The rate-limiting step of the whole process is LAMP-2A 
interaction with the substrate that modulates CMA activity and degradation power (Cuervo & Wong 2014). Regulation 
of CMA process is still largely unknown. 
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Figure 6 A) proteasome structure B) the ubiquitin proteasome system. Adapted from (Nandi et al. 2006; Glickman & Ciechanover 2002) 
 
 
Figure 7 Chaerone network and targeting to proteasome (Kampinga & Bergink 2016) 
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Figure 8 The autophagic machinery (Parzych & Klionsky 2014) 
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Figure 9 Selective targeting to autophagy: the CASA complex (Kampinga & Craig 2010) 
 
 
 
 
Figure 10 The ubiquitin signaling (Shaid et al. 2013) 
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AMYOTROPHIC LATERAL SCLEROSIS 
Epidemiology and clinical signs 
Amyotrophic lateral sclerosis (ALS) is a neurological disease that has gained attention in the last 30 years. Only in the 
last four years 5940 publications were related to ALS (almost 29% of all the papers regarding NDs) (Zufiría et al. 2016).  
In USA, ALS is also known as Lou Gehrig diseases for the football player that was affected by this disease. ALS was 
described in 1874 by Jean-Martin Charcot who firstly started using the term “amyotrophic lateral sclerosis” to indicate 
the denervation and the waste of muscle that follows the degeneration of the corticospinal motor neurons in the lateral 
spinal cord (lateral sclerosis) (Taylor et al. 2016). Indeed, ALS is characterized by the loss of both upper and lower motor 
neurons.  
ALS is a very heterogeneous disease that shows variability in site of onset (spinal or bulbar), age of onset, progression 
rate, and heritability (sporadic or familial ALS) (Robberecht & Philips 2013).  
Usually, ALS leads to death in 3-5 years for respiratory failure. Some patients have shown a prolonged survival even 
until 20 years, but the majority of affected inviduals die in a very short period of time (Taylor et al. 2016). ALS is regard 
as an orphan disease, since it affects 1-2 individuals in 100,000 all over the world population. In Europe, the incidence is 
of 2-16 individuals among 100,000 people (Logroscino et al. 2010). The prevalence (5 individuals in 100,000) reflects the 
lethality of this disease (Taylor et al. 2016). ALS is generally an adult onset disease in which the first signs typically show 
up in the fifth decade. Indeed, the mean peak of incidence is between 57 and 60 (Zufiría et al. 2016). Nevertheless, 
there are some case of juvenile ALS (with an onset between the 10-20 years of age and with a longer survival 
(Robberecht & Philips 2013)) and some case in which ALS appears very late in life (Taylor et al. 2016). Epidemiological 
studies have also suggested a slighter predominance of the disease in male than in female (1,5-1,2/1) (Logroscino et al. 
2010).  
ALS starts focally in the CNS and then spread in the surrounding areas. Clinical features and signs are very 
heterogeneous depending on the CNS area affected and depending on the stadium of degeneration. Generally, ALS 
clinical outcomes are distinguished in two main categories: spinal-ALS and bulbar-ALS (Robberecht & Philips 2013)  
- Spinal-ALS starts with painless limb weakness (two third of the affected patients) in which spinal neurons or 
lower motor neurons degenerate first. This form of ALS is followed by hyperreflexia and spasticity of the limb 
muscle. This type of ALS is often preceded by cramps. 
- Bulbar-ALS (one third of the ALS population) primarily affects brainstem motor neurons. The first signs that 
characterize this kind of ALS are difficulty in swallowing, paralysis and atrophy of the tongue, difficulty in 
chewing and articulation of the tongue muscle. In this case speech is highly compromised, since the very 
beginning of the disease. 
Less than 5-6 % of the all ALS cases show pure upper motor neurons or pure lower motor neurons involvement. In some 
rare cases ALS onset is anticipated by cognitive impairment, behavioural changes and respiratory failure (Taylor et al. 
2016; Ajroud-Driss & Siddique 2014). 
ALS diagnosis is based on the history and physical examination, followed by electrophysiological studies, neuroimaging 
and laboratory tests. Since ALS shares common features with frontotemporal dementia (FTD) it is very important to 
exclude mimickers and false positives (Brooks BR, Miller RG 2000; Chaudhuri et al. 1995).  
Familial and sporadic ALS: causative factors 
There are many factors that are thought to be causative of ALS, but actually it has not been identified an absolute and 
unique cause of all form of ALS. ALS is a multifactorial and heterogeneous disease and there have been identified two 
classes of potential risk factors: environmental factors and genetic factors. Heritable genetic factors are at the basis of 
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familial ALS (fALS), while sporadic ALS (sALS) can be caused in some cases by gene mutations whose appearance is still 
largely unknown. sALS occurs without a family history of the disease and without an inherited gene mutation (Ajroud-
Driss & Siddique 2014). In some cases, sALS are linked to an incomplete penetrance of a fALS or an incomplete familial 
history (Ajroud-Driss & Siddique 2014). Some hypothesis have been put forward suggesting that sALS may result from a 
mixture of genetic susceptibility and environmental risk factors (Ajroud-Driss & Siddique 2014). Various genome wide 
association analysis (GWAS) led to the identification of risk loci, and also brought to the possible identification of loci 
connected to the age of disease onset (Wills et al. 2009). Since in several cases there are many factors that occur 
simultaneously, it has been postulated that 6 risk factors should occur in the same patient to develop ALS (Al-Chalabi et 
al. 2014), and the nature of these factors determine the age of onset, the symptoms and the severity of the disease. 
Undoubtedly, the penetrance of a heritable mutation in causing the disease in the fALS is higher than the other factors. 
ENVIRONMENTAL FACTORS  
There are many environmental factors that different studies have identified over the years. The most studied are 
exposure to pesticide toxins and heavy metals, physical exercise, alcohol, viral and fungal infections (Fang & Ye 2010; 
Trojsi et al. 2013; Al-Chalabi & Hardiman 2013; Beghi et al. 2010). 
One of the most studied and well identified toxins is β-N-methylamino-L-alanine (BMAA) that is produced by 
cyanobacteria (Vega & Bell 1967). This toxin has been identified in a special root used to make flavour between people 
in Guam. Other evidence showed that toxins produced by cyanobacteria can cause severe degeneration in the CNS, 
indeed there have been found cluster of patients in areas next to places where these cyanobacteria live (Masseret et al. 
2013). 
Another environmental risk factor is the exposure to heavy metals like lead, mercury and selenium. Lead has been 
found in ALS patient brain, but its real role as a risk factor is still discussed (Fang et al. 2010). On the other hand, some 
studies have demonstrated that mercury can deposit in both upper and lower MNs and that its presence abruptly 
exacerbates disease course (Arvidson 1992). Also selenium is highly toxic for MNs and for cholinergic neuron in general. 
Moreover, in seleniferous population (that assume selenium for example by tap water) ALS incidence is higher than in 
non-exposed population (Vinceti et al. 2010). Among the pesticides, the most widely used are organophosphates that 
are known to induce brain damage by inhibiting acetylcholinesterase (Chen 2012). Physical exercise, in particular 
prolonged and strenuous training, causes prolonged stress in muscle cells and sometimes this stress overflows the 
system capability to preserve a correct and functional neuromuscular junction. On the other hand, it has been 
demonstrated that mild physical exercise is beneficial. A recent study confirmed that regular physical exercise is linked 
to a very low risk of ALS; while extensive physical exercise can cause a continuous and severe stress on the nervous 
system, and in predisposed subjects this vigorous exercise could be detrimental, indeed there are many athletes in ALS 
cohorts. There are also studies that showed the strenuous exercise since early age is associated with two folds risk of 
developing ALS (Beghi et al. 2010; Gallo et al. 2016). To better understand the relationship between risk factors and the 
pathology, further epidemiological studies are needed. 
GENETIC FACTORS 
Genetic factors are involved in ALS at various levels. There are some genes that are directly implicated in ALS onset, and 
they are called causative genes (Figure 11). There is another group of genes, called susceptibility genes, which are 
associated to a higher risk of developing sporadic ALS. Moreover, recently epigenetics factors are gaining importance in 
understanding ALS genetic implications. 
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Causative genes 
SOD1 
Cu/Zn superoxide dismutase 1 (SOD1) was the first gene described as causative of familial ALS.(Rosen et al. 1993). SOD1 
gene is localized on chromosome locus 21q22.1 and is composed of five exons separated by four introns (Figure 12). 
This gene encodes for a protein of 22kDa (153 aminoacids) that exerts an antioxidant function through the inactivation 
of the radical O
2−
 (SOD1 transforms O
2−
 into hydrogen peroxide and hydroxide) thanks to the presence of Cu/Zn cations. 
The presence of the Cu/Zn cofactors induces also a tight dimerization, since they enable an intramolecular disulphide 
attachment. Indeed, SOD1 regulates an important defence against oxidative stress and its importance is underlined by 
its high concentration in the CNS. In fact, SOD1 represents the 0,5-0,8% of all brain proteins (Pardo et al. 1995).  
Nowadays, more than 155 mutations in the SOD1 gene have been identified related to fALS and the most common and 
widely described are D90A, A4V and G93A (Kaur et al. 2016). 
D90A causes and exchange of the aspartic acid in position 90 with an alanine. Usually, this mutation is linked to a 
recessive form of fALS, but it can also appear as dominant heterozygous (rarely) or as homozygous (Andersen 2006).  
A4V is a mutation in which alanine in position 4 is substituted by a valine. Patients bearing this mutation usually show 
bulbar symptoms at onset and the disease progression is aggressive and rapid (Cudkowicz et al. 1997). 
G93A mutation (glycine in 93 is changed in alanine) is relatively rare, but it gained importance, since it was utilized for 
the production of an heterozygous mouse model in which SOD1 activity was mostly unchanged, but that developed 
motor neuron disease (Valentine & Hart 2003).  
In general, all SOD1 mutations are divided in two groups: those in which metal binding is affected and those that leave 
metal binding unaffected and thus similar to that of the wild type SOD1. In both cases, SOD1 mutation lead to a change 
in the overall negative charge of the protein (normally protein have a net surface charge balanced to the pH of the 
cytosol; this prevent self-oligomerization) (Shaw & Valentine 2007). This modification of the charge and conformation 
eventually leads to self-oligomerization and aggregation. 
Mutated SOD1 (mutSOD1) exerts its toxicity through both mechanisms of loss and gain of function. Many studies 
reported that mutSOD1 has a reduced antioxidant power that leads to motor neuron exposure to peroxide radicals. This 
reduction could be linked to a decreased half-life of mutSOD1 mRNA, but also to a decreased presence of SOD1 in the 
nucleus (thus causing DNA damage and altered proteins expression) (Sau et al. 2007). The nuclear deprivation of SOD1 
is linked to the formation of SOD1 aggregates that prevent SOD1 from nuclear translocation (Sau et al. 2007).  
On the other hand, other studies claim that mutated SOD1 can also act through both mechanisms of loss/gain of 
function (Sau et al. 2007). Gain of toxic function is linked to increased protein/protein interactions and increased 
antioxidant activity that leads to the formation of excessive hydrogen peroxide radicals, detrimental for MNs (Allen et 
al. 2003). Moreover, mutSOD1 directly exerts toxicity on affected motor neurons (Shefner et al. 1999), and is thus 
possible that the loss of function (diminished nuclear protection against free radicals) and the gain of function 
(increased neuronal toxicity) work in cooperation in leading to MNs degeneration. 
Moreover, recent studies also sho an involvement of the endoplasmic reticulum (ER) in the SOD1 toxicity. Another site 
of SOD1 toxicity are mitochondria that are damaged following SOD1 aggregation (Soo et al. 2015b). In several ALS 
mouse models it has been reported an abnormal mitochondria transport along motor neurons axons (Ikenaka et al. 
2012). These mechanisms are tightly linked since mitochondria have a role in axon maintenance. Finally, mutated SOD1 
also aggregates in glial cells, leading to gliosis and immune defence aberrant response (Boillée et al. 2006). 
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FUS 
Fused in sarcoma (FUS) is a gene whose mutations account for the 4% of ALS familial cases and for the 1% of sporadic 
cases (Mackenzie et al. 2010; Deng et al. 2014). FUS gene is located on chromosome 16 and is composed of 15 exon. 
This gene encodes for a DNA/RNA binding protein composed of many functional domains including two RNA binding 
regions and one C-terminal nuclear localization signal in which most mutations occur (Nolan et al. 2016; Mackenzie et 
al. 2010) (Figure 13). The exact function of this protein is still unknown (Nolan et al. 2016). It seems that it has a role in 
RNA processing and exporting from the nucleus, as well as in DNA repair (Wang et al. 2017; Lagier-Tourenne et al. 2013; 
Tan et al. 2012).  
FUS mislocalization in the cytoplasm is one feature described in some ALS patients, but it also occurs in some FTD 
patients, enforcing the theory of a loss of function mechanism, due to nuclei deprivation of FUS. Nevertheless, it seems 
that FUS toxicity is exerted by a gain of toxic function of mutated FUS on RNA homeostasis, that is most affected 
process in presence of FUS mutations (Nolan et al. 2016). Indeed, recent studies have assessed FUS as one of the major 
and most important component of stress granules (SGs), and it also regulates its assembly (Bentmann et al. 2012). SGs 
are structures that are assembled under stress condition in order to protect mRNA from damage, allowing the 
translation only of necessary proteins. These SGs are formed by liquid-liquid demixing, process eased by the presence of 
mRNA and by the presence of low complexity domains at the C-terminus or various RNA-binding proteins such as FUS 
(Patel et al. 2015). It has been shown that FUS mutations alter stress granules dynamics by increasing the stability of 
these structures, that possibly act as seeds of aggregation. Moreover, mutant FUS can recruit wild type FUS into 
abnormal stress granules. Nevertheless, the exact function of these stress granules has yet to be fully assessed; indeed 
there are also theories that postulate that abnormal SGs production prevents irreversible FUS aggregation, giving to SGs 
a protective function (Shelkovnikova et al. 2013). 
Since now 50 ALS related mutations on FUS have been described and the most of them are frameshift mutation or 
missense mutation (Deng et al. 2014). They have all dominant traits. The most common is the R521C mutation in which 
an arginine in 521 in changed in a cysteine. The P525L mutation (in which a proline in 525 is substituted with a leucine) 
sometimes occurs as sporadic and cause a juvenile ALS with a very severe phenotype (Huang et al. 2010; Nolan et al. 
2016). There are no case of pure FTD clearly associated to FUS mutation, but many cases of FTD associated to FUS 
mutation show also ALS insurgence (Nolan et al. 2016).  
Many studies also reported that no post-translational modifications affect FUS activity, and an aberrant cleavage of the 
protein is not described. The unique post-translational modification associated to FUS toxicity is methylation in 6 
regions of the protein. These data indicate that FUS methylation is linked to FUS import into the nucleus. If methylation 
is inhibited FUS is transported inside the nucleus, if it is hypermethylated FUS cannot bind the protein for the nuclear 
import (Trasportin-1) (Du et al. 2011). 
C9ORF72 
Chromosome 9 Open Reading Frame 72 is described as the major ALS associated gene in 2011 (DeJesus-Hernandez et 
al. 2011; Renton et al. 2011). Abnormal expansion of G4C2 in this gene has been associated to both familial and sporadic 
ALS and FTD (10%–50% of familial ALS, 5%–7% of sporadic ALS, 12%–25% of familial FTD, and 6%–7% of sporadic FTD) 
(Majounie et al. 2012). The clinical phenotype of patients bearing these mutations is often a mixture of ALS and FTD and 
the age of onset and the severity of the disease vary considerably between patients (Gendron & Petrucelli 2017). A 
possible cause of this variability is the length of the expansion; usually, patients bear elongation of 10-100 repeats 
(DeJesus-Hernandez et al. 2011; Renton et al. 2011). Notably, expansion length varies also between different tissues of 
the same patient, owing gene instability. The presence of this expansion often causes the presence of TDP-43 pathology 
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(that will be discussed later in details) in frontal and temporal cortex, in hippocampus and pyramidal motor system 
(Beck et al. 2013; Buchman et al. 2013; Dols-Icardo et al. 2014; Blitterswijk et al. 2013).  
G4C2 expansion exerts its toxicity both through a mechanism of loss of function and gain of function. G4C2 expansions 
are located between exon 1a and exon 1b of C9ORF27 gene that can be differently transcribed. If transcription starts 
from exon 1a the repeat will be transcribed, while if the transcription begins from exon 1b the repeat fall in the 
promotor region of the gene so it is not inserted into the C9ORF72 mRNA (DeJesus-Hernandez et al. 2011; Ciura et al. 
2013). There are strong evidence of a reduction in C9ORF72 mRNA levels in many post mortem brain tissues of 
C9ORF72 patients (van Blitterswijk et al. 2015). The alteration in mRNA production can be linked to the presence of 
these repeat in the DNA. DNA regions rich in cytosine and guanosine are prone to form G-quadruplex structures. In vitro 
studies on DNA bearing this elongation demonstrate that DNA can fold in G-quadruplex structure of different shapes 
depending on the repeat length. Both in DNA and mRNA these structures lead to abortion of the 
transcription/translation (Fratta et al. 2012). This is supported by the evidence that a large amounts of transcripts of the 
region upstream the repeat, while regions downstream the repeat are found downregulated (van Blitterswijk et al. 
2015; Haeusler et al. 2014). Moreover, there are evidence of epigenetic regulation. It has been shown that 
trimethylated histones (repressor of the transcription) are strongly bound to the expanded region in pathogenic cells 
(Belzil et al. 2014). Counterintuitively, G-quadruplex have a negative effect, since they repress C9ORF72 expression 
causing a loss of function, while silencing of the gene caused by trimethylated histones has beneficial effect (Belzil et al. 
2014). 
Even if loss of function plays a role in the pathogenesis of ALS, its role remains limited compared to gain of function 
contribution. Gain of function of G4C2 expansion is exerted through two main mechanisms: i) formation of RNA foci, ii) 
RAN-translation and production of poly-dipeptides (Gendron & Petrucelli 2017).  
RNA foci are structures that arise from the transcription of the G4C2 expansion in both senses (sense and anti-sense 
transcripts: r(G4C2)
exp 
and r(G2C4)
exp
) (Belzil et al. 2013; Gendron et al. 2014) (Figure 14). These mRNA bearing these 
repeats are prone to sequester essential transcription factors forming these foci in cells nuclei. These foci have been 
found throughout the CNS, especially in neurons, and at a lower level in astrocytes, glia, and microglia (Gendron et al. 
2013; DeJesus-Hernandez et al. 2011). The most abundant RNA binding proteins found in these foci are hnRNPs 
proteins (Donnelly et al. 2014; Mori et al. 2013). Interestingly, nucleolin is another protein highly represented in RNA 
foci, possibly because this protein binds G-quadruplex structures (Haeusler et al. 2014). The depletion of functional 
nucleolin causes nuclear stress, one of the possible mechanisms of RNA foci toxicity. 
G4C2 mRNA also undergoes RAN translation. RAN translation is a non-canonical translation process that starts without 
the presence of an ATG start codon (Repeat-Associated Non ATG). It was first discovered studying microsatellite 
expansion in muscle dystrophy type 1. RAN translation can start at any point along the transcript without frameshift or 
truncation (Zu et al. 2010). The products of RAN translation of sense-mRNA are three poly-dipeptides: polyGA, poly GP 
and polyGR; on the other side the translation of antisense-mRNA produce polyPA, polyPR and polyGP (Gendron et al. 
2013; Ash et al. 2013; Mori et al. 2013) (Figure 14). PolyGP dipeptides are produced from both sense and antisense RAN 
translation, but polyPA and polyPR are relatively less abundant than the other dipeptides (Gendron et al. 2013; Mori et 
al. 2013). The reasons of this difference are the minor presence of anti-sense transcript in the cytoplasm and the lower 
efficiency of RAN translation on the anti-sense transcript as compare to the sense transcript. These dipeptides are 
highly aggregation prone forming inclusions in cytoplasm and nucleus of cells, but, polyPR and polyPA have a different 
aggregation propensity compared to the other three dipeptides (polyGA, polyGR, polyGP), possibly because of their 
different biochemical properties and toxicity (Mackenzie et al. 2015; Gendron & Petrucelli 2017). It is unclear whether 
the DPRs coaggregate or aggregates in different inclusions, but they rarely coaggregate with TDP-43 (Davidson et al. 
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2014) (Figure 15). These inclusions are often detectable in the CNS, but rarely in the lower motor neurons. Since 
C9ORF72 ALS patients have a strong motor neuron phenotype, the contribution of these dipeptides to the pathology is 
still controversial (we will see some hypothesis above) (Mackenzie et al. 2015; MacKenzie et al. 2013; Proudfoot et al. 
2014).  
TARDBP 
TARDBP gene is located on chromosome 1 (1p36.22) and is composed of 6 transcribed exons, which usually, are 
translated from exon2 to exon 6 (Pesiridis et al. 2009). Exon 6 represents the 60% of the gene and the 70% of the entire 
mRNA. The coded protein of 414 kDa is named TAR (transactivation response element) DNA binding protein of 43 kDa 
(TDP-43). TDP-43 is composed of two RNA recognition motifs (RRM), RRM1 and RRM2, a nuclear localization signal, a 
nuclear export signal and a glycine rich domain (Buratti et al. 2005; Hebron et al. 2013; Ignatius et al. 1995; Winton et 
al. 2008). TDP-43 has multiple functions both in the nucleus and in the cytoplasm. The two localization signals allow the 
shuttling of TDP-43 from nucleus to cytoplasm and viceversa (Winton et al. 2008). In the nucleus TDP-43 is a splicing 
regulator and a modulator of microRNA biogenesis. TDP-43 also influences the stability of various mRNA, thus 
regulating different cellular pathways. In addition, TDP-43 regulates the stability of its own mRNA providing a self-
regulation of its own protein levels (Polymenidou et al. 2011; Ayala et al. 2011; Gregory et al. 2004; Xu 2012). A recent 
study has demonstrated that TDP-43 plays its role on RNA maturation by forming oligomeric structures through the 
interaction of the N-terminal domain. TDP-43 oligomerization depends upon RNA quantity and oligomeric forms of TDP-
43 have a strong affinity to RNA compared to the monomeric form (Afroz et al. 2017).  
In the cytoplasm, TDP-43 takes part in stress granules assembly and disassembly as its efflux is often a consequence of a 
stress. Nevertheless, TDP-43 has also a function in neuron plasticity as it takes part to RNA granules transport to 
dendrites extremities. This process allows the synthesis of protein in loco (Diaper et al. 2013; Alami et al. 2014; Liu-
Yesucevitz et al. 2014; Colombrita et al. 2009).  
TDP-43 was associated to ALS in 2006 and after this breakthrough discovery many mutations were described in TDP-43 
(Neumann et al. 2006). Nowadays 29 ALS-associated missense mutations have been identified, 18 associated to fALS 
and 30 associated to sALS. They are mostly located in the C-terminal domain of TDP-43, with the exception of the 
D169G (Figure 16). The most frequent mutations are A382T (in which alanine in 382 is substituted with tyrosine) that is 
present both in fALS and in sALS and G348C (glycine in 348 is changed with cysteine) (Rutherford et al. 2008; Pesiridis et 
al. 2009). 
TDP-43 abnormalities are found both in fALS (1-2% of total ALS cases) and in sALS (Sreedharan et al. 2008). Inclusions 
positive for TDP-43 have been found in cortical and spinal neurons of patients. This event is called “TDP-43 
proteinopathy” and is found in 97% of ALS cases, with the exception of SOD1 and FUS associated ALS, where TDP-43 
proteinopathy is absent. Either in presence and or in absence of TDP-43 mutation, these deposits are morphologically 
indistinguishable (Mackenzie et al. 2007; Mackenzie & Rademakers 2008; Maekawa et al. 2009) (Figure 16). 
The formation of these inclusions prevents TDP-43 full length from exerting its normal and physiological function inside 
the nucleus. The consequence is a dysregulation of mRNA maturation and consequently alteration of cellular pathways, 
suggesting a loss of function of the mislocalized protein (Alami et al. 2014). Some studies demonstrated that TDP-43 
mislocalization is toxic per se even in absence or prior to inclusions formation. It is still unclear if TDP-43 mislocalized in 
the cytoplasm is folded or misfolded and how it exerts toxicity in cell (Winton et al. 2008; Scotter et al. 2015). 
TDP-43 inclusions also contain TDP-43 fragments of various size, caused by caspase cleavage. The most represented are 
the those of 35 and 25 kDa (Zhang et al. 2007). Inclusions containing these fragments are also found in FTD affected 
regions. Fragmentation of TDP-43 is a physiological process for the degradation of TDP-43, but the C-terminal fragments 
are highly aggregation prone being intrinsically disordered (prion-like) and owing the glycine-rich domain (Figure 19). In 
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addition, these fragments are mislocalization prone, since they entirely (TDP-35) or partially (TDP-25) loose the NLS. 
Since it is known that TDP-43 exerts its toxicity through a binding with the mRNA and aggregation is present also before 
fragmentation, the contribution of these fragments to TDP-43 toxicity is still controversial (Fuentealba et al. 2010; 
Scotter et al. 2015). It was demonstrated that TDP-35 causes defects in the splicing process (Che et al. 2011) while TDP-
25 caused ubiquitinated and hyperphosphorilated inclusions of TDP-43. Phosphorylation is not a pre-requisite for TDP-
25 aggregation, but TDP-25 exert a toxic gain of function on TDP-43 leading it to hyperphosphorilation and aggregation. 
These findings highlight TDP-25 as hallmark of the disease even if the exact mechanism of its toxicity is still unclear 
(Zhang et al. 2009). Caccamo et al., recently generate a mouse model homozygous for TDP-25 in which they show that 
this murine model shows ALS feature. Along with these findings they also demonstrate that TDP-25 forms insoluble 
inclusions  and that in this model proteasome and autophagic power are weaker than in the control (Caccamo et al. 
2015).  
TDP-43 found in these inclusions often is hyper-phosphorylated and ubiquitinated (Figure 19). We still know little about 
the role of these post-translational modifications in the TDP-43 pathology. Phosphorylation is better studied, and it is 
now clear that hyper-phosphorylation is not a prerequisite for aggregation, but its presence is always associated with 
mislocalization and misfolding (Inukai et al. 2008; Neumann et al. 2010; Hasegawa et al. 2008). 
TDP-43 inclusions also play dominant negative role recruiting other physiological and functional proteins in the 
cytoplasm. This gain of function further exacerbates the loss of function not only of TDP-43 proteins, but also of the 
other co-aggregating proteins (Scotter et al. 2015) (Figure 17). 
 
Other causative genes. 
Other genes have been linked to fALS and are involved in various cellular functions. Only a very small group among fALS 
patients present these mutations. Nevertheless, the identification of these genes shade new light in understanding the 
mechanisms involved in ALS. Some of these genes are involved in RNA metabolism, degradative systems functioning 
and routing, neurofilaments dynamics, cytoskeleton assembly, stress granules formation etc.. (Figure 17) Here are 
reported some of the most important one. 
OPTINEURIN 
Optineurin (OPTN) is an adaptor receptor involved in many cellular functions that require protein-protein interaction. 
Among these functions OPTN acts as autophagic receptor that has a specific binding site for poly-ubiquitinated proteins 
and for autophagosomes. OPTN specifically recognizes the damaged cargo and drives it to the forming autophagosomes 
(Figure 18). The discovery of OPTN as an ALS gene suggests that the damage of a degradation systems could be as 
possible toxic mechanism. In 2010 there had been found 40 Japanese ALS cases, caused by mutation in OPTN 
(Maruyama et al. 2010). Typically, these mutations are frameshift mutations (that lead to truncated proteins) and non-
sense mutations (that lead to not functional protein) which cause a dysregulation of the autophagic flux due to defects 
in autophagosomes maturation. Moreover, since OPTN activity regulates NF-kB functioning, mutations on OPTN lead to 
dysregulated NF-kB activity (Maruyama et al. 2010). 
VCP 
Valosin containing protein (VCP) is a multifunctional protein that is involved in various cellular functions, like proteins 
extraction from ER, protein routing to proteasome, stress granules dynamics, chromatin extraction etc… (Meyer & 
Weihl 2014; Ju & Weihl 2010; Bug & Meyer 2012). VCP exerts all these activities co-operating with a large group of co-
factors (Papadopoulos et al. 2016; DeLaBarre & Brunger 2003). Mutations on this gene were firstly associated to 
inclusion body myopathy with Paget’s disease of bones and frontotemporal dementia (IBMPFD); IBMPFD is a complex 
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disease that starts from muscle, in which mutations of VCP lead to the formation of not functional multivesicular bodies 
(Watts et al. 2004; Bayraktar et al. 2016; Guyant-Marechal et al. 2006). IBMPFD has some overlapping feature with ALS, 
and when VCP is present, the phenotype of the two pathologies often coexist (Koppers et al. 2012). VCP mutations do 
not lead to a complete loss of function of VCP. Instead they lead to the loss of one particular function. This loss of 
function is often connected to a loss of binding capability with one specific co-factor (Fernández-Sáiz & Buchberger 
2010). Nowadays, researchers identified two major mutations associated with ALS: R155H (arginine in 155 is 
substituted by a histidine) and R191Q (arginine in 191 is substituted with a glutamine) (Badadani et al. 2010; Johnson et 
al. 2010). 
SQSTM1 
SQSTM1 is a gene that encodes for the protein of 62 kDa (p62). As already described above, P62 is a protein involved in 
autophagic recruitment of substrates. P62 structure comprises an ubiquitin associated (UBD) binding domain that 
recognises ubiquitinated proteins. P62 then drives these substrates to autophagosomes for the internalization (Rea et 
al. 2013; Bjorkoy et al. 2006; Johansen & Lamark 2011) (Figure 18). P62 mutations were firstly associated to Paget 
disease of bones (PDB) with the majority of the mutations found in the C-terminal UBA domain (Rea et al. 2014). there 
is a screening ongoing to found mutation also in ALS/FTD patients on p62 gene, since the relevance of this protein in 
neuroprotection suggest the possibility of mutation on p62 gene. 
PFN1 
Profilin 1 (PFN1) is a small protein associated to actin dynamics. It was identified as a causative ALS gene in 2010, and 
after that actin dynamics are regards as possible disease mechanism. Mutations in PFN1 lead to accumulation of TDP-43 
in cells (Figley et al. 2014; Wu et al. 2012). 
UBQLN2 
Ubiquilin-2 (UBQLN2) is an adaptor protein that has a binding domain for ubiquitinated proteins and a binding domain 
for proteasome. Some recent studies also showed that UBQLN2 interacts with autophagic proteins (Lee & Brown 2012; 
Ko et al. 2004) (Figure 18). Initially, mutations on this gene were associated to an X-linked form of ALS and to ALS 
dementia (H. X. Deng et al. 2011). In 2014, UBQLN2 was assessed as causative gene of fALS, sALS and FTD-ALS, in 
individuals of both sexes. UBQLN-2 mutations cause accumulation of TD43 in affected cells, and this suggests a relevant 
role for the degradative systems in ALS pathogenesis (Majcher et al. 2015a; Williams et al. 2012; Morris et al. 2012). 
 
There are several other genes causatives of ALS that account for a very small percentage of patients (ALSIN, SETX, VAPB, 
DCTN1, ANG, CHMP2B, FIG4, ATXN2, hnRNPA2B1, hnRNPA2A1). It is common that the prevalence of these rare 
mutations changes between populations, ethnises, etc… (Zufiría et al. 2016; Ajroud-Driss & Siddique 2014; Peters et al. 
2015) 
 
Susceptibility genes 
Studies like Genomic Wide Association Study (GWAS) also tried to identify genes associated to a higher probability of 
developing the disease. These susceptibility genes are very difficult to identify; indeed susceptibility genes associated to 
specific cohort of patients often cannot be associated to similar cohorts (Zufiría et al. 2016; Li et al. 2014; van Rheenen 
et al. 2013). 
The protein Ataxin 2 (ATX2), causative of spinocerebellar ataxia 2 (SCA2) is a typical example of these genes. In fact, a 
polymorphic variant of ATX2, with polyglutamine tract in the highest normal range, but not pathologic has been found 
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linked to ALS in a particular cohort of ALS patients since it increases disease susceptibility. Other genes like UNC13A, 
ELP3, EPHA4, CYP27A1, ZNF512B, CX3CR1, KIFAP3, HTR2B, TMEM106B have been associated to different progression 
rate and survival time in ALS (Zufiría et al. 2016). 
Epigenetic factors 
DNA modifications and miRNAs expression are the most studied epigenetic factors related to ALS development.  
DNA modifications lead to modulation of the expression of various genes. In many sALS patient the percentage of 
methylated DNA is higher than in the control cohort (Tremolizzo et al. 2014). Moreover, the activity and the expression 
of the histone deacetylase (an enzyme that promotes the deacetylation of histone leading to gene suppression) is 
higher in ALS brain and spinal cords respect to the control (Janssen et al. 2010; Valle et al. 2014). On the other hand, 
also miRNA are genetic modifiers involved in ALS even if their role is still controversial. Some miRNAs are reported to be 
protective, like miRNA-206 and miRNA-155. Indeed, mice deficient of miRNA-206 are more prone to develop ALS 
(Williams et al. 2009b) and miRNA-155 has been found in surviving MNs of patients dead for sporadic ALS (Koval et al. 
2013). Other miRNAs are detrimental; for example miRNA-365 and miRNA-125b seem to exacerbate the disease while 
miRNA-1 and miRNA-206 have been also found in protein aggregates since they are bound to TDP-43 (Parisi et al. 2013; 
King et al. 2014; Gascon & Gao 2014). 
Pathogenic mechanisms 
Protein misfolding and aggregation 
Protein misfolding is an important event in ALS pathogenesis. Misfolded proteins have lost their native and correct 
conformation and for this reason they are prone to form oligomeric structures, dimerizing with themselves and 
sequestering other soluble proteins (Soto & Estrada 2008; Rowinska-Zyrek et al. 2015). Oligomeric structures eventually 
become aggregates/inclusions that are a typical hallmark of ALS, detectable in many CNS areas such as spinal cord, 
cerebellum, hippocampus, thalamus, brainstem frontal and cerebral cortex (Watanabe et al. 2001; Al-Chalabi et al. 
2012). As mentioned above, it is still unclear whether these inclusions are beneficial or detrimental. Some studies claim 
that these inclusions are not toxic, but protective in cells and acting as a sink to remove the most toxic species. These 
toxic species are believed to be the oligomeric forms or the misfolded protein itself (Ciechanover & Kwon 2015; Guo et 
al. 2010). In fALS mutated proteins encoded by the causative genes are more likely to lose their proper conformation. 
Indeed, they are found in inclusions either with or without the wild type counterpart. Moreover protein aggregation is 
poorly dependent on protein structure. For instance, mutated SOD1, TDP-43 and FUS formed skein-like inclusions in 
patient and animal tissues, as well as in in vitro models, even if they have very different structures (Parakh & Atkin 
2016; Rosen et al. 1993; Neumann et al. 2006) (Figure 19).  
In sALS cytoplasmic inclusions can contain wild type misfolded SOD1 as well as TDP-43 or FUS. Optineurin and ubiquilin2 
are also occasionally found in sALS inclusions. TDP-43 inclusions, ubiquitinated and hyperphosphorilated are very 
common in almost every case of sALS, while FUS immunoreactive inclusions are found in a smaller percentage. 
C9ORF72 inclusions are not always positive for TDP-43, and sometimes co-aggregate with ubiquilin2 and p62 (Ajroud-
Driss & Siddique 2014; H. X. Deng et al. 2011; Deng et al. 2010; D. H.-X. Deng et al. 2011).  
Impaired protein degradation 
There are two main evidence that correlate degradative systems functionality with ALS pathogenesis: the presence of 
misfolded protein inclusions and the ALS associated mutation on many genes involved in the degradative pathways 
(Parakh & Atkin 2016). 
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As stated above, proteins that loose their normal conformation are targeted to the degradative pathways: proteasome 
and autophagy. Formation of proteinaceous aggregates means that the normal degradation of these proteins is less 
functional or totally abrogated (Figure 19-20). The causes of this dysfunction are different: overwhelming of the 
degradative pathways, dysfunction of the pathways due to presence of mutated protein linked to these pathways, that 
caused both haploinsufficiency of key proteins as well as dysfunctional activities. Proteins bearing ALS mutation are less 
functional (thus causing impaired degradation) and are also removed from the cellular environment, since they are 
mutated, causing haploinsufficiency. There are mutated proteins linked to proteasome activity (VCP, ubiquilin) and 
mutated proteins linked to autophagic pathway (p62) (Majcher et al. 2015a). The role of autophagy in ALS pathogenesis 
is more difficult to assess. There are some studies in which treatment with autophagic inducers rescues some of ALS 
phenotype such as neurite outgrowth, motor neuron loss and protein aggregation. On the other side, abnormal 
enhancement of autophagic flux is fatal to neurons and increases mortality in mouse models (Parakh & Atkin 2016).  
 Cellular transport impairment 
Failure of the axonal transport is one of the earliest feature detected in ALS in vivo models, in particular in the most 
widely used ALS mouse model SOD1-G93A mice (Figure 20) (Williamson & Cleveland 1999). Mutated SOD1 co-
aggregates with important component of the transport machinery like KAP3, causing shortening of the neurite as well 
as detachment and dysfunction of the axon (Tateno et al. 2009). Also, TDP-43 and FUS damage axonal transport due to 
the formation of resistant stress granules and the co-aggregation with neurofilaments (Li et al. 2013). In addition, 
supporting intracellular transport as pathogenic mechanism, there are some rare mutations of dynactin1, a component 
of the anterograde transport, and of profilin1, a small actin like protein (Puls et al. 2003; Wu et al. 2012). Even if the 
most widely studied processes regarding cellular transport are axonal dynamics, there are evidence about the 
impairment of the cellular transport that connect ER to Golgi apparatus. Disruption of this transport is an early event in 
tg ALS SOD1 mice that even precedes onset of the disease (Soo et al. 2015a; Atkin et al. 2014). Nevertheless, 
dysfunction of this mechanism causes ER stress, Golgi fragmentation, protein aggregation and apoptosis. For instance, 
TDP-43 and FUS aggregation cause disruption of ER-Golgi transport as well as aggregated dipeptide repeats associated 
to C9ORF72 expansions (Soo & Atkin 2015; Atkin et al. 2014; Sundaramoorthy et al. 2015). 
Oxidative stress 
Oxidative stress was firstly studied in relation to SOD1 mutation, since it was initially thought as a dysfunctional protein 
unable to correctly handle aberrant oxygen radicals. During years, it has emerged that mutated SOD1 exerts a toxic 
dominant gain of function (Akbar et al. 2016). Mutated SOD1 takes radicals form the other cellular antioxidants and 
gives them to the oxygen thus creating free oxygen radicals. The presence of these free radicals induces oxidative post-
translational modifications of the other soluble proteins (Barber & Shaw 2010). Oxidative post-translational 
modifications alter proteins solubility and folding driving them to the formation of aggregates (Beckman et al. 2001; 
Bonafede & Mariotti 2017; Grune et al. 2004). Interestingly, the levels of glutathione are strongly reduced is brain tissue 
of affected patients, either fALS or sALS patients, also in those cases characterized by TDP-43 inclusions (Iguchi et al. 
2012). These evidence suggest that oxidative stress is a pathogenic mechanism related both to mutated SOD1, and to 
other form of ALS. Oxidative stress is also present when TDP-43 and FUS are bearing mutations, and the dynamics 
(especially regarding stress granules formation) of these two proteins are changed in presence of oxidative stress 
(Colombrita et al. 2009).  
ER stress 
ER stress is not widely implicated in fALS or sALS and it is still largely discussed which is its contribution to the 
pathogenesis. ER stress is caused by the presence of mutated and unfolded proteins, but it is also a consequence of ER-
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Golgi transport disruption (Chen et al. 2005) (Figure 20). Nevertheless. it has been demonstrated that most of ALS-
related protein caused the activation of the unfolded protein response (an event downstream ER stress) and that 
inhibition of UPR is beneficial in many animal model of ALS (Cuanalo-Contreras et al. 2013; Parakh & Atkin 2016).  
Mitochondrial dysfunction 
Mitochondrial abnormalities have been firstly identified in muscle and in neurons innervating muscle of sALS patients. 
In these tissues mitochondria form large clusters and alteration in their morphology. The mechanism that drives to 
mitochondria dysfunctions have been studied in SOD1 cases since a fraction of SOD1 is localized in mitochondria. In 
these models, mitochondria appear vacuolated, the mitochondrial membrane is depolarized, and calcium storage and 
ATP production are disrupted (Boillée et al. 2006). Mutated SOD1 can mediate the fusion of peroxisome with 
mitochondria, thus forming vacuolated mitochondria. Moreover, SOD1 aggregates on the outer mitochondrial 
membrane impair TOM complex and thus many mitochondrial functions (Liu et al. 2004; Pasinelli et al. 2004). 
RNA metabolism and stress granules dynamics 
In the ALS field, RNA biology has gained attention after the identification of ALS related mutations in four genes that 
regulates RNA metabolism. RNA metabolism relies upon the formation of membrane less structure, formed via a 
process of liquid-liquid demixing (Taylor et al. 2016). This liquid coalescence is driven by the presence of RNA binding 
proteins with a low complexity domain (Molliex et al. 2015; Lin et al. 2015; Patel et al. 2015). TDP-43, FUS and hnRNPs 
possess this domain, and usually it is the domain that contains ALS-related mutations (Figure 20). Liquid coalescence 
form structures named nucleoli or stress granules (SGs); these structures are highly dynamic and are formed to 
preserved RNA from degradation. On the other hand, the formation of these structures brings these proteins very 
closed. The low complexity domain of these proteins is highly aggregation prone and tends to form amyloid like fibrils, if 
the phase transition is impaired. Mutations can alter this transition influencing the material properties and the function 
of these granules. Furthermore, the formation of these insoluble structures, not only is toxic to cells, but also sequester 
proteins reducing their normal activity (Molliex et al. 2015; Patel et al. 2015; Lin et al. 2015). 
Accumulation of neurofilaments 
Another important hallmark of ALS is the cytoplasmic accumulation of hyper-phosphorylated neurofilaments. 
Mutations on gene encoding for neurofilaments are found both in fALS and in sALS cases. Physiologically, 
neurofilaments regulate axon diameter and axonal transport (Yuan et al. 2006). Their activity is inversely correlated to 
their phosphorylation. The hyperphosphorylation of these neurofilaments lead to axonal disruption and to their 
accumulation in the perinuclear region or in the axon proximal region (Xiao et al. 2006). Overexpression of these 
neurofilaments is able to slow down the progression of the disease in animal model (Kong & Xu 2000). 
Excitotoxicity 
Glutamate is the most abundant excitatory effector of the central nervous system. Glutamate excitotoxicity was one of 
the first mechanism proposed for understanding ALS. Nowadays, we know that there is a state of hyper-excitability due 
to an increase in the concentration of glutamate in the synapses (Bendotti & Carrì 2004). This increase of glutamate is 
caused by the reduced levels of the excitatory amino acid transporters (EAAT2) that normally reduces glutamate 
concentration at synapsis after glutamate excitatory action. The reduced presence of EAAT2 at synapsis is probably 
caused by aberrant EAAT2 mRNA that also leads to impaired calcium permeability that is another toxic event (Lin et al. 
1998; Guo et al. 2003).  
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Neuroinflammation: involvement of the non-autonomous system 
The main effectors of neuroinflammation in ALS are microglia and astrocytes, they coordinates the immune response 
after neuron injury. It has been demonstrated that these non-autonomous cells play a pivotal role in pathogenesis fALS 
(Figure 20).  
Microglia is the immune effector in the CNS and the cross talk between microglia and neurons is very well established. 
It has been demonstrated that dysfunctional microglia is determinant in ALS onset. In fact, mutated SOD1 expressed 
only in motor neuron is not able to induce neurodegenerative phenotype, while wild type glia is able to prevent onset 
and progression of ALS (Bonafede & Mariotti 2017; Clement 2003). It has been demonstrated that, in the first stage of 
the pathology, the M2 phenotype of glia (neuroprotective and anti-inflammatory) prevails. Then, during the progression 
of the disease, SOD1 is released by affected neurons in the extracellular matrix as well as other toxic factors. This event 
triggers the switch of M2 microglial cells into M1 microglial cells (pro-inflammatory and neurotoxic cells that secerns 
ROS and cytokines) (Zhao et al. 2009; Appel et al. 2011; Almer et al. 1999).  
The other components of glia are astrocytes and they have a role in supporting neuron viability. They have the function 
of maintaining low levels of glutamate at the synapses. In fALS and sALS patients, astrocytes reduce the levels of EAAT2 
thus increasing the concentration of glutamate and exacerbating the excitotoxicity (Howland et al. 2002). 
Prion like spreading of toxicity 
ALS is a pathology that starts focally in the CNS and then spreads in the surroundings areas. It has been proposed that 
the spreading of the pathology is linked to a prion like spreading mechanism and that ALS-associated proteins have 
prion-like properties (Kanouchi et al. 2012; Nonaka et al. 2013; Ravits & La Spada 2009). It has been demonstrated that 
aggregates of TDP-43 are able to induce aggregation in other cells. TDP-43 also possesses a prion like domain that 
justifies this property (Polymenidou & Cleveland 2012). Nevertheless, some studies demonstrate that also SOD1 is a 
prion like protein even without a prion like domain (Healy 2017).  
 
ALS and Fronto-temporal lombar dementia (FTLD) 
Fronto temporal lombar dementia (FTLD) is a cognitive impairment raised from degeneration of the V layer of the 
frontal region. Over decades, this disease has been associated with ALS. 25% of ALS patients are likely to manifest also 
FTLD even if often FTLD precedes motor signs and only retrospectively FTLD and ALS are associable in these patients 
(Swinnen & Robberecht 2014; Mioshi et al. 2014; Rippon et al. 2006). ALS and FTLD form a spectrum, a continuum in 
which the extremities are pure ALS (without cognitive dementia) and pure FTLD (without motor signs) (Ferrari et al. 
2011; Swinnen & Robberecht 2014) (Figure 21). In the middle of this spectrum there is ALS with behavioural impairment 
(ALSbi, in which dementia has a mild severity), ALS with cognitive impairment (ALSci, in which patients show mild 
executive and language dysfunction). ALS patients that meet Neary criteria (Neary criteria is a scale of clinical signs to 
classify the gravity FTLD) develop ALS-FTLD. The last part of the spectrum is FTLD that develop motor signs. This is very 
common between FTLD patients: up to 50% develop ALS. This mixed disease is called FTLD-MND. The boundary 
between these categories is very blurry, but it helps in individuating which disease is the prevalent (Strong & Yang 
2011). Patients belonging to these categories show different rate of progression. Patients with pure ALS have a longer 
prognosis compare to the ones that develop also dementia. The reason of this difference is still unclear, but one 
hypothesis relies on the different compliance to the therapy. In fact, patients that developed also FTD, are less 
compliant to the cure, due to the developing of dementia that makes them uneasy to treat (Mioshi et al. 2014). 
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ALS and FTLD show a significant overlap in clinical signs and this lead to the possibility that also some pathogenic 
mechanisms are common between the two disease. In this view understanding a feature of one of the two pathologies 
can help in shading light on the other. 
Evidence of muscle involvement 
The role of skeletal muscle cells and of muscle tissue in ALS onset and progression is still very controversial. It very well 
known that a dying back mechanism from muscle to motor neuron exists due to their very strict crosstalk. Moreover, 
neuromuscular junction waste occurs prior to motor neuron loss and symptoms development. There are indeed several 
evidence of muscle damage prior to disease onset (Halter et al. 2010). In ALS mouse models, muscle are smaller and 
more atrophic than in controls. In addition, electrophysiological studies on neuromuscular junction show severe 
impairment already at week 4 (for in vivo model 4-6 week is pre-symptomatic stage). Moreover, in these muscles there 
is a decreased myogenesis due to a reduction of CDK5 activity (Park & Vincent 2009).  
There are molecular mechanisms similar in motor neuron and in muscle that lead to cell toxicity and death; the most 
important ones are the accumulation of misfolded proteins and the excessive oxidative stress (Bhattacharya et al. 
2014). Some in vivo studies reported that in affected muscle there is a down regulation of the heat shock proteins 
(protective players in motor neurons), and thus the hypothesis of protein toxicity gains relevancy. On the other hand, 
oxidative stress has been found before onset of the pathology and is thought to be exacerbated by an excessive 
oxidative metabolism. There are evidence of boosted fatty acid metabolism also in the pre-symptomatic ALS stage. 
Interestingly, diet with high content of fatty acid shows beneficial effects on ALS disease (Dupuis et al. 2004). Another 
important event in mutant muscle is mitochondrial dysfunction, revealed by biochemical abnormal activity, 
ultrastructural modification and alteration in mitochondrial activity. It has been shown that, in mutant SOD1 muscle, 
the expression of PGC-1α is enhanced, suggesting that mitochondrial biogenesis is always active to improve muscle 
functions also at the end stage of the disease (Cruz et al. 2013). 
Importantly, since miRNA circuits are highly involved in muscle maturation and functions, it has been shown that 
reduction in miRNA206 expression caused an accelerated ALS progression in SOD1-G93A mice (Gascon & Gao 2014; 
Williams et al. 2009a).  
While is evident that muscle is damaged during ALS disease, its role in the pathogenesis is still controversial. The 
expression of mutated SOD1 in muscle cells is able to induce atrophy and muscle weakness but does not trigger ALS 
disease and motor neuron death (Wong & Martin 2010). In line with these evidence the suppression of mutated SOD1 
in muscle by means of antisense oligonucleotide (ASO) increases muscle growth, but does not recue the survival. 
Contrasting with these studies, many groups reported that restricted overexpression of SOD1 in muscle, caused muscle 
atrophy, destabilization of neuromuscular junction (NMJ), axonopathy and by a retrograde process motor neuron loss 
(Dobrowolny et al. 2008). Indeed, it has been shown that IGF-1 overexpression, alleviate all this symptoms slowing 
down ALS progression in mice models (Dobrowolny et al. 2005; Dobrowolny et al. 2008). Recent studies also 
demonstrated that restricted muscle expression of mutated SOD1, changes transcriptome of miRNAs in motor neurons 
(Dobrowolny et al. 2015), thus confirming role for muscle in motor neuron impairment.  
Another in vitro evidence is that the overexpression of SOD1 in satellite cells (muscle stem cells) damages satellite cell 
capacity of becoming mature muscle cells that can fuse and form a functional contractile unit. It is still largely unknown 
if there is a type of fiber (slow- or fast-twitch) that is primarily affected in ALS. 
The protein quality control system in ALS 
Many studies have evidenced the role of the protein quality control (PQC) system in ALS. Proteasome is heavily involved 
in the degradation of almost all ALS-associated protein. Some pharmacological approaches try to suggest an induction 
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of proteasome activity in order to counteract the presence of these toxic proteins. Nevertheless, increasing the 
proteasome activity may have devastating effects on cells, since many physiological proteins are degraded by 
proteasome.  
In vitro studies demonstrated that SOD1-G93A could be specifically degraded by autophagy through the CASA complex. 
Indeed, the overexpression of HSPB8 caused a significant reduction of aggregated SOD1-G93A in motorneuronal model 
of ALS and to support this data, it has been shown that surviving motoneurons in G93A mice at the end stage, display an 
increased HSPB8 expression, indicating a protective role for the HSPB8, and possibly for the CASA complex (Crippa et al. 
2010). Moreover it has been demonstrated that HSPB8 reduces also the aggregation of dipeptide repeats produced in 
presence of C9ORF72 mutation (Cristofani, Crippa, Vezzoli, et al. 2017)  
Direct induction of autophagy by rapamycin is detrimental for the progression of ALS in G93A mice, since autophagy is 
also an unspecific process that degrades organelles, cytoplasm and proteins (Zhang et al. 2011). On the other hand, 
targeting of specific misfolded proteins to degradation by autophagy is promising strategy. In fact increasing selective 
autophagy by increasing CASA complex activity leads to the degradation only of aggregation-prone, toxic and damaged 
proteins. This is further confirmed by compounds that increasing the overexpression of HSPB8 counteracts the 
formation of aggregate in mutant TDP-43 models (Crippa, D’Agostino, et al. 2016).  
In in vivo ALS models, some studies have also identified the difference between motor neurons and muscle regarding 
the protein quality control system activation. Mice G93A, at the END stage, show and an increased activation of the 
PQC system especially in muscle. Indeed, at the end stage the expression of HSPB8 and BAG3 (CASA complex) as well as 
the expression of LC3 and p62 were significantly increased. These results suggest an important role of the whole protein 
quality control system in development of ALS (Crippa et al. 2013).  
Therapeutic approaches  
ALS is still a disease for which a cure that stops the progression is not available. All therapeutic approaches available are 
obviously aimed at the extension of the survival, to slowing down the progression of the disease and to ameliorate the 
clinical complexity of the disease. The first drug approved by US Food and Drug Administration (FDA) was Riluzole, an 
inhibitor of the glutamate release that reduces the excitotoxicity on neurons (Miller et al. 2012). Riluzole has also been 
studied in association to other drugs like Rasigiline (a MAO inhibitor) that has an antioxidant action (Waibel et al. 2004). 
The study demonstrated that the co-treatment of the two drugs is more efficient than the treatment of the single drug. 
Very recently FDA also approved edavarone (Radicava™) for the treatment of ALS. Edavarone is an antioxidant drug that 
brings an extension of lifespan in treated patients (Ikeda & Iwasaki 2015).  
Since pharmacological approaches are not giving striking results, gene therapy and stem cells therapy are gaining 
attention (Bonafede & Mariotti 2017). These two strategies for the moment are mainly studied in animal models and 
few clinical studied are available.  
Gene therapy for ALS aims at silencing mutated genes associated to toxicity. Some clinical studies in phase I are treating 
patients with antisense oligonucleotide (ASO) to reduce the expression of mutated SOD1. The problem associated with 
this strategy is mainly the compliance of the patient: the infusion of ASO should be continuous and administration must 
be intrathecal (Smith et al. 2006). 
Stem cells are becoming a promising therapy thanks to stem cell ability to differentiate in various tissues (upon specific 
signals) and thanks to stem cell paracrine activity. Nowadays various type of stem cells are available and they differ for 
the source and for the ability to differentiate. The type of stem cell is chosen by their ability to engraft, differentiate, 
survive, and migrate to the damage tissue. Moreover, stem cells are neuroprotective since they secrete many trophic 
factors that can prevent motor neurons loss. For the moment only animal models have been treated with stem cells. 
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The results are promising, but there still many issues that needed to be solved before administering stem cells to 
patients (Faravelli et al. 2014). 
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Figure 11 Gene involved in hereditary ALS (Taylor et al. 2016) 
 
 
 
Figure 12 Structure of SOD1 gene and ALS- associated mutations (Turner & Talbot 2008) 
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Figure 13 Structure of FUS gene and position of ALS-related mutations (Nolan et al. 2016) 
 
 
Figure 14 DPR production by RAN-translation on sense and anti-sense transcript of G4C2 expansion (Gendron & Petrucelli 2017) 
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Figure 15: C9ORF72 mechanisms of toxicity (Todd & Petrucelli 2016) 
 
 
 
 
Figure 16 TDP-43 ALS-associated mutation and TDP-43 inclusions in motor neurons of both SALS and fALS patients (Pesiridis et al. 2009) 
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Figure 17 pathway affected by aberrant TDP-43 (Jovicic & Gitler 2014) 
 
 
Figure 18 Physiological role of p62, OPTN and UBQLN (Majcher et al. 2015b) 
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Figure 19 TDP-43 aberrant behaviour in presence of ALS-related mutated gene (Scotter et al. 2015) 
 
 
 
Figure 20 ALS related pathogenic mechanisms (Taylor et al. 2016) 
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Figure 21 ALS-FTD spectrum (Swinnen & Robberecht 2014) 
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SPINAL AND BULBAR MUSCULAR ATROPHY 
Spinal and bulbar muscular atrophy (SBMA) is a MND characterized by the loss of lower motor neuron in the anterior 
horn of the spinal cord and in the brainstem motor nuclei. Only third, fourth and sixth cranial nerves are not target of 
the disease (Banno et al. 2012). It is also known as Kennedy disease, from Dr. William R. Kennedy who described clinical 
signs, pattern of inheritance and pathological feature of the disease. In 1989, Fischbeck and colleagues found out that 
the cause of the disease was linked to chromosome X and in 1991 La Spada discovered the genetic cause of the disease: 
the presence of a polyCAG repeat in the androgen receptor gene (La Spada AR et al. 1991). This CAG repeat is translated 
in a polyglutamine (polyQ) tract.  
After the identification of CAG expansion in SBMA, this type of mutation has been found on other genes, unrelated to 
AR, that are at the cause of other NDs. This group of diseases are called polyglutamine diseases and they share not only 
the mutation, but also some clinical phenotype such as age of onset and rate of progression, suggesting the existence of 
a common mechanism between all of these pathologies (Giorgetti & Lieberman 2016a).  
So far, 9 members of this family have been identified (Figure 22): Huntington’s disease (HD), SBMA, DentatoRubral–
PallidoLuysian Atrophy (DRPLA) and 6 spinocerebellar ataxias (SCA) (Fischbeck 2001). There are also other diseases 
caused by the presence of repeated triplets (100-3000 repetitions) in the untranslated region of genes. Some of these 
diseases are fragile X syndrome, myotonic dystrophy and Friedreich ataxia (Poletti 2004).  
SBMA is affecting only male subjects and is inherited in a recessive fashion. Age of onset and severity of the disease 
seem to be linked to the length of the repetition. Usually, CAG repeats are from 11 to 25-27. The tract is described as 
pathological when it contains more than 38 repetitions. Subjects with medium CAG size (27-37) are borderline subjects 
(Kuhlenbäumer et al. 2001). 
Epidemiology and clinical sign  
SBMA is a rare disease affecting 1/400000 patients per year (Fischbeck 1997). The prevalence of this disease varies a lot 
among different areas (Querin et al. 2017). Moreover, SBMA is often misdiagnosed with ALS.  
SBMA is an adult onset disease (30-50 years of age) and its progression is very slow (Katsuno et al. 2012; Fratta et al. 
2014). Indeed, life expectations after diagnosis are in avarage 27 years (Guidetti et al. 2016). The CAG elongation seems 
to not interfere with the disease progression (Fratta et al. 2014).  
The main clinical manifestations can be divided in spinal signs and bulbar signs. Spinal signs, that are muscle weakness 
of upper and lower limbs, often appear first compare to bulbar ones and for long time they were considered as the sole 
onset manifestations. Affected muscles are initially and more frequently lower limb followed by upper limb. Muscle 
weakness is often preceded by slighter symptoms that are frequently underestimated, like hand tremor, myalgia, breast 
enlargement, muscle cramps and premature exhaustion after physical exercise. 
Bulbar signs, due to involvement of brainstem, usually follow limb weakness and in most cases are dysphagia and 
dysarthria. Also jaw drop, caused by bulbar muscle weakness, is eventually present. Another important and 
characteristic bulbar sign is tongue fasciculation, with irregularities at the edge and deep furrowing due to wasting. 
Tongue atrophy is also linked to vocal cord atrophy, pharyngeal paresis (causing uncomplete bolus clearance) and 
palatal weakness (causing nasal voice). Even if these bulbar symptoms show up after spinal ones, they are sometimes 
present also in the pre-diagnostic phase (Finsterer & Soraru 2016; Harding et al. 1982; Fratta et al. 2014). 
SBMA patients also show other clinical signs different from neuromuscular manifestation. Most important systemic 
symptom, related to endocrine dysfunctions, is gynecomastia always accompanied by testicular atrophy, azoospermia, 
oligospermia, erectile dysfunction and reduced libido. Some patients also show dyslipidemia abdominal obesity and 
liver dysfunction. Other rare systemic signs are cardiomyopathies and urological diseases that always end up with the 
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need of a catheter. Sometimes there are also neuropsychiatric signs such as mild form of dementia and cognitive 
impairment mainly affecting memory, both short and long term (Kessler et al. 2005; Dejager et al. 2002; Querin et al. 
2016). 
Diagnosis  
SBMA diagnosis is often difficult due to the similarity with other motor neuron disease. It is misdiagnosed with the 
spinal form of ALS that also starts with limb weakness. The first diagnostic tool is finding the polyQ elongation in the AR 
gene. Even if the disease sometimes shows up as sporadic it is important to perform an analysis of the family history. 
Another laboratory analysis that can help in identifying SBMA is measuring the levels of creatine phosphokinase, 
indicators of muscle sufferance. Sometimes also muscle biopsies are performed to analyze the presence of muscular 
neurogenic atrophy (Mariotti et al. 2000; Georgiou et al. 2001).  
Androgen receptor: structure and physiological functions 
Gene structure 
Androgen receptor belongs to the steroid nuclear receptors superfamily. 
The gene encoding for the androgen receptor is located on the long arm of the chromosome X, precisely in the Xq11–
q12 position. The whole gene span for almost 54 kb and the open reading frame is composed of 8 exons (Brinkmann 
2001) (Figure 23).  
Exon 1 encodes for the N-terminal region of the AR protein. This region contains the transactivation domain, the 
polyglutamine tract and a polyglycine and a polyproline region that are poorly conserved among steroid nuclear 
receptor superfamily. Exon 2 and exon 3 encode each for a zinc finger domain that is a very well conserved DNA binding 
domain. The remaining 5 exons encode for the C-terminal region that is the ligand binding region. 5’ region of the exon 
4 codes for the hinge region while the 3’ region contains the sequence for the nuclear localization signal (NLS). Exons 5, 
6, 7 and 8 encode for the steroid binding domain. Exon 4 and exon 5 also contain 2 androgen responsive elements (ARE) 
that upregulates the synthesis of AR mRNA in target tissues (Brown et al. 2013). 
The promoter region has a GC rich region and a SP1 binding site instead of the canonical TATA box. In this region is also 
present a secondary open reading frame, 1100 upstream from the transcription starting site, that encodes for a 
polypeptides of 9 aminoacids whose role is still obscure (Georgiou et al. 2001). 
Protein structure 
The functional domains of the AR protein are: the N-terminal transactivation domain, the two Zinc fingers, constituting 
the DNA binding sites and the C-terminal steroid binding domain (Figure 23).  
The N-terminal transactivation domain contains the signal for AR dimerization, for binding with other transcriptional 
factors, and for post-translational modification. Its capacity of binding the C-terminal domain of another AR protein is 
very important for forming the functional homodimer and this dimerization is testosterone dependent. The presence of 
the polyQ tract influences this function. In fact, when polyQ tract is abnormally elongated, dimer formation is 
destabilized (Figure 24). Physiologically, the polyglutamine tract (with normal length) is associated to receptor binding 
with AREs on other genes, while polyproline and polyglycine tract role is still unclear (He & Wilson 2002). 
N-terminal region also contains strong activation function 1 (AF-1) composed of two transcription activation unit that 
mediates the binding with AR coactivators such as steroid receptor coactivator-1 (SRC-1) and c-AMP responsive element 
binding protein (CBP) belonging to the p160 superfamily. Expanded polyQ tract affects the binding of AR to its 
coactivator, thus influencing downstream pathway (Liu et al. 2003). 
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The N-terminal region also contains most of the phosphorylation, SUMOylation and acetylation sites. Phosphorylation 
occurs after AR activation and its role is still unclear. SUMOylation has a role in the regulation of the transcriptional AR 
activation. Acetylation negatively regulates Sp1 activity (Fu et al. 2002; Poukka et al. 2000; Gioeli et al. 2002). 
The DNA binding domain is composed of two zinc fingers highly conserved between nuclear receptors. Zinc finger 
domain is formed by 4 cysteines that bound a zinc ion. These two rigid structures have the function of recognizing the 
ARE region and of promoting and mediating protein-DNA interaction. Immediately downstream the DNA binding 
domain there is a hinge region that contains a PEST sequence (proline, serine, glutamic acid, threonine), that is targeted 
for proteasomal degradation (Matias et al. 2000). 
The C-terminal domain contains both the NLS and the steroid binding domain. The NLS interacts with α-importin to 
mediate AR shuttling into the nucleus (Jenster et al. 1993). 
The steroid binding domain is composed of a precise number of α-helices and β-sheets structures that form a 
hydrophobic pocket, with high affinity for testosterone and dihydrotestosterone. Binding with agonist (and also with 
antagonist) changes the spatial organization of this pocket, changing the spatial distribution of the secondary 
structures. When pocket structure changes, AR interaction with other proteins is influenced because also the second 
strong activation function 2 (AF-2) is exposed. This interaction site is less strong and less active of AF-1 in the N-
terminus. In fact, it has weak affinity for co-activators such as SRC-1. The hydrophobic structure of C-terminus is 
functional to N/C interaction (Matias et al. 2000).  
Activation of the androgen receptor 
The activation of the androgen receptor is testosterone dependent. Testosterone is AR endogenous ligand as well as 
dihydrotestosterone, synthetized directly in target cells from testosterone by the 5α-reductase (Figure 24).  
Unbound AR is localized in the cytoplasm of cells, bound to different chaperone proteins (HSP90, HSP40, HSP70) by its 
N-terminal and C-terminal domain (Cardozo et al. 2003). These proteins keep maintaining the hydrophobic pocket in 
the conformation that has the highest affinity with ligands. After testosterone binding these proteins are released by AR 
that dimerizes prior to enter the nucleus and prior to bind DNA (Jenster et al. 1993). Testosterone binding, triggering a 
conformational change, takes also to the exposure of the NLS in the C-terminal domain. When AR enters in the nucleus 
it binds several transcription activators in its N-terminal region (Figure 24). This complex recognizes the target DNA and 
recruits the RNA polymerase that starts the transcription (Brinkmann 2001; Wong et al. 1993). When AR activity is 
ended, AR is exported into the cytoplasm, rebound to the HSPs and recycled. 
AR role in nervous tissues 
AR is differently expressed in CNS areas: while it is highly expressed in hypothalamus, in motor neuron spinal cord, in 
dorsal root ganglia and in hippocampus, its expression is very low in areas such as stria terminalis, medial preoptic area, 
dorsal and ventral zones of the periventricular nucleus. Some of these areas show sexual dimorphism in AR expression, 
that explains the differences between male and female in behavior, neural development and prevalence in neurological 
and psychiatric diseases (Fernandez-Guasti et al. 2000). 
AR is highly expressed in the spinal nucleus of the bulbo-carvernosus system (SNB) and in this neurons it mediates 
neural development, since birth, and, in adulthood, it prevents loss of SNB neurons (Goldstein & Sengelaub 1990; 
Jordan et al. 2002). AR also has a role in the growth after nerve resection of peripheral nerves (Yu 1989). In spinal cord 
AR governs neural development, formation of neuromuscular synapsis, axonal and dendrites growth. These functions 
are mainly achieved by regulating structural proteins like actin and tubulin and the gap junction channel. All these 
proteins are highly upregulated during axonal development and growth after resection (Matsumoto 1997). Also neuritin 
whose function is mediating neurites growth is upregulated by AR activity (Naeve et al. 1997).  
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Mechanisms of ARpolyQ toxicity 
Loss of function or Gain of function  
Physiological function of the AR is promoting the transcription of target genes. The presence of the polyglutamine tract 
reduces AR transcriptional activity, probably mediating negatively AR binding with other transcription co-activators 
(Figure 24). Indeed, polyQ tract is contained in the transactivation region where other coactivators should bind. It is 
anyway well established that AR loss of function account only for endocrine phenotype, but does not explained motor 
neuron loss and muscle atrophy. This notion is supported by studies showing that mutations on AR, that prevent its 
synthesis or its whole activity, causes androgen insensitivity syndrome but not motor neuron death (Neuschmid-Kaspar 
et al. 1996).  
Gain of function theory to explain AR mediated toxicity rises from the evidence that, when present, ARpolyQ caused 
death both in in vivo and in in vitro systems (Verhoef et al. 2002; Poletti 2004). Moreover, this toxicity is mediated 
uniquely by the binding with testosterone (Figure 24). This evidence was smartly demonstrated by Katsuno and 
colleagues that started investigating the importance of circulating androgens, since only males are affected by the 
disease. They showed that castrated SBMA male mice lose all SBMA symptoms. Compared to SBMA male mice, 
castrated SBMA mice show increased muscle strength, loss of tremor and increased lifespan. On the other hand, 
homozygous SBMA female mice do not show any phenotype. After treatment with testosterone, in SBMA female mice, 
starts appearing motor neuron impairment, tremor and life span is shorter than in untreated individuals. In summary, 
SBMA female subjects display phenotype only when treated with testosterone. This experiment shows that ARpolyQ 
mediates toxicity on motor neuron/muscle but only after testosterone binding. So the toxicity of the ARpolyQ is strictly 
dependent on the presence of testosterone (Katsuno et al. 2006; Katsuno et al. 2002). 
ARpolyQ aggregation 
An important histopathological hallmark of SBMA is the presence of ARpolyQ inclusions both in the nucleus and in the 
cytoplasm (Adachi et al. 2005). These inclusions are mainly found in neuronal tissue, in particular in anterior horn 
motoneurons, posterior horn neurons, the substantia nigra and the hypothalamus (Figure 25). Notably, these 
aggregates are detectable also in non-neuronal tissues such as scrotal skin, other skin, proximal tubules of the kidney, 
hepatocytes, Steroli cells of the testis, glandular epithelium and in fibroblasts of the interstitial connective tissue of the 
prostate gland (Adachi et al. 2005) (Figure 25). 
The mechanism by which ARpolyQ forms these inclusions is associated with the intrinsic capability of the polyQ tract to 
self-associate. In fact, a stretch of 20 contiguous glutamine residues form a secondary structure that is highly unstable, 
when the size of the stretch becomes longer that 40 residues or more the structure is stabilized by hydrogen bounds 
(Perutz et al. 2002). In the early stages, this process is highly reversible and controlled by several cellular mechanisms 
(chaperones). In the later stages, these structures are stabilized also by the binding between polyglycine tract. This 
process may be exacerbated by impairments of the degradative systems that lead to an increased presence of ARpolyQ 
protein in the intracellular compartments, thus facilitating the nucleation process. It is noteworthy that ARpolyQ 
aggregation is triggered by the binding with testosterone, while in absence of AR activation no aggregates are 
detectable (Poletti 2004). This finding is explained firstly by the presence of chaperone the mask the presence of the 
polyQ tract since they are bound to AR (since AR is activated by testosterone). Moreover, when these chaperones are 
associated with AR, they keep the folding of the protein in the correct conformation (Ciechanover & Kwon 2015). 
Another reason for the absence of aggregates in absence of testosterone is that the cytoplasmic environment may 
prevent aggregates formation, by degrading AR via the degradative systems, if AR does not reach the correct folding. It 
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is possible that the capacity of these systems is exceed by the continuous presence of ARpolyQ (Becker et al. 2000; 
Walcott & Merry 2002; Katsuno et al. 2002). Consequently, ARpolyQ is no more degraded and it aggregates in cells. It is 
still very controversial defining the exact role of these aggregates. Since they are present also in not dying neurons, and 
thus they are not directly linked to toxicity. On the other hand, their presence may lead to alteration of many different 
intracellular pathways (Poletti 2004). 
There are three types of intracellular aggregates: cytoplasmic aggregates, neuropil aggregates and nuclear aggregates 
(Figure 26). 
Cytoplasmic aggregates are formed after a short time. A possible function of these inclusions is to confine the toxic 
monomeric form to remove it from cytoplasmic environment. Removing testosterone, cytoplasmic aggregates 
formation can be reverted (Simeoni 2000). 
Neuropil aggregates on the other hand can play important role in SBMA pathogenesis since they block axonal transport 
of vesicles, organelles and polyribosomes (Poletti 2004; NAGAI et al. 1999). 
Nuclear aggregates, both in patients and in artificial models, are largely enriched in the N-terminal fragment of the 
ARpolyQ; since there is a site of cleavage on AR protein, it is possible that in presence of polyQ there is an aberrant 
proteolytic cleavage of ARpolyQ; species generated by this cleavage are toxic to target cells. This kind of inclusions are 
found in patient brain and can be reproduced in vitro and in vivo only by using a very long polyQ tract. ARpolyQ in these 
aggregates also sequesters steroid receptor coactivator-1 (SRC-1) and the CRE binding protein (CREB). Moreover, 
aggregates prevent ARpolyQ from its normal function as transcription activator, exacerbating the loss of function 
process (Walcott & Merry 2002; Ellerby et al. 1999; Merry 2001; Stenoien et al. 1999). 
ER and mitochondria damage 
There are several downstream pathways, regulated or affected by AR activity or by pathological AR function.  
ARpolyQ is able to cause a marked mitochondrial pathology associated with an increased apoptotic activity and an 
altered nucleolar regulation of mitochondrial DNA through PGC-1α. It has been also shown that mitochondria are found 
in ARpolyQ aggregates, meaning that aggregation process requires energy. 
Another event associated with ARpolyQ toxicity is ER stress. It has been demonstrated that AR is able to cause an 
abnormal unfolded protein response (UPR), that originate from the ER. Moreover, the ablation of any mediator of these 
pathways (like CHOP) strongly exacerbates the phenotype. 
Neuromuscular degeneration 
For decades SBMA was studied mainly as a neurological disorder, involving only motoneurons. The involvement of the 
nervous system is well established both by the presence of many ARpolyQ aggregates and also by clinical signs clearly 
associated with lower motor neurons and sensory neurons loss, even if the sensory contribution is less relevant to 
disease. Histologically, SBMA patients show a decreased axon number associated with decreased motor conduction 
velocity, compound muscle action potentials, sensory conduction velocities, and sensory nerve action potentials 
(Katsuno et al. 2006; Borgia et al. 2017; Querin et al. 2017). 
Muscle contribution to neurodegeneration was initially suggested by pre-onset clinical manifestations, such as myalgia, 
tremor, cramps and elevated serum levels of creatine kinase (Katsuno et al. 2012). In 2014 two studies clearly 
demonstrated the central role of muscle tissue in SBMA onset. 
The first study was conducted on SBMA mouse models, generated with BAC gene for AR Q 112. The exon 1 containing 
the polyQ tract was flanked by two loxP sites that allow the elicitation of the sequence in presence of a CRE enzyme. 
Transgenic mice showed decreased lifespan, body weight loss and motor neuron phenotype. Crossing BAC-ARQ112 
mice with mice ubiquitously expressing CRE, it was obtained a strain of mice that do not developed all SBMA-related 
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features, because since polyQ tract was absent. It has also been demonstrated that the elicitation of polyQ tract only in 
muscle cells, by crossing BAC-ARQ112 with mice expressing CRE only in muscle cells, rescued SBMA phenotype to same 
extent as the ubiquitous elicitation of polyQ. These data demonstrated that the selective expression of ARpolyQ in 
muscle cell is able to cause the onset of SBMA. Moreover, these data also showed that presence of ARpolyQ in motor 
neurons (even if aggregating) is not sufficient for SBMA insurgence (Cortes et al. 2014).  
The second study supporting these findings was based on the use of antisense oligo nucleotides (ASO) to suppress AR 
expression in muscle cells. After ASO administration mice displayed a rescue of the phenotype by life span measure, 
behavioral test, and histological analysis of muscle sections (Lieberman et al. 2014).   
Knowing these findings, it is likely that muscle determines SBMA phenotype in the first-stage of the pathology. Then 
during progression, muscle atrophy influences motor neuron survival also indirectly, by not providing the necessary 
trophic factors (such as neurotrophin-4 (NT-4), glial-cell derived neurotrophic factor (GDNF), and brain derived 
neurotrophic factor (BDNF), etc.). At the end stage of the pathology motor neurons are massively dying and the 
progression of the disease in mainly driven by motor neurons loss (Giorgetti et al. 2016).  
In conclusion SBMA could be considered a neuromuscular disease, since both muscle and motor neuron are directly 
involved as site of ARpolyQ toxicity (Figure 27). Muscle atrophy is especially important in the first phase of the disease, 
since it is highly involved in the onset of SBMA. During progression of the pathology, contribution of motor neurons 
gains importance determining the loss of voluntary movements and the paralysis (Giorgetti & Lieberman 2016b) (Figure 
26). 
The protein quality control system in SBMA 
In recent years the knowledge about the PQC system shed light also in SBMA disease mechanism, and many studies 
focused their attention in understanding the interaction between the PQC system and ARpolyQ, using molecules that 
inhibit or active key elements of the PQC system.  
ASC-JM1 is a small molecule that increases overall proteostasis. Indeed, it increases the expression of proteasome 
subunit by interacting with the HSF-1 (heat shock factor 1). In SBMA models, both in vitro and in vivo models, ASC-JM1 
treatment is beneficial against ARpolyQ toxicity (Bott et al. 2016). ASC-JM1 not only activates the heat shock response 
(thus counteracting protein misfolding and aggregation), but it also mediates an anti-oxidant response. Furthermore, it 
has been shown that the anti-oxidant response is essential for ASC-JM1 activity, while heat shock response is not. Anti-
oxidant effect is mediated by two factors NRF1 and NRF2 that are highly overexpressed in presence of ASC-JM1. 
Other studies investigated the role of particular heat shock proteins; HSP90 prevents ARpolyQ degradation by 
maintaining AR soluble in the cytoplasm. When proteins are released by HSP90 they can be substrates of the 
proteasome. Inhibiting HSP90 by mean of 17-DMAG (17-(dimethylaminoethylamino)-17-demethoxygeldanamycin), 
facilitates ARpolyQ degradation through the proteasome that is well preserved in SBMA models till the last stages. 
Inhibiting HSP90 activity that maintain AR in the correct conformation for testosterone binding, 17-DMAG is able to 
increase the degradation of AR monomeric form before ARpolyQ activation. Indeed, 17-DMAG also induces the 
expression of HSP70 and HSP40 (Tokui et al. 2009) thus promoting ARpolyQ degradation. 17-DMAG was also 
demonstrated to be effective in in vivo models highlighting its capacity of passing the brain blood barrier (Tokui et al. 
2009). Recent studies have also shared a light on the possibility of routing misfolded protein to proteasome, by 
modulating BAG1. It was demonstrated that increased routing to proteasome through BAG1-HSP70 complex is 
beneficial in SBMA “in vitro” models, and resulted in a strong reduction of misfolded proteins (Cristofani, Crippa, 
Rusmini, et al. 2017). 
Autophagic flux contribution in NDs has been widely assessed in CNS. In recent years many works highlight autophagy 
involvement also in muscle cells. Results show that at the end stage muscle cells overexpress autophagic markers (like 
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BECL1, ATG10, p62 and LC3) indicating a role for autophagy in the late event of the pathology. Moreover mice at the 
end stage also show increased expression of the CASA complex components (HSPB8, BAG3) in muscle cells. In motor 
neuron almost no differences has been observed in the expression of the same markers (Rusmini et al. 2015).  
If autophagy involvement in affected cells is well-established, the possibility to target autophagy with therapeutic 
strategy is still very controversial, since excessive autophagy is detrimental as well as autophagic impairment. In recent 
years, many studies focused their attention searching approaches that aim to reduce the amount of toxic proteins by 
routing them to autophagy instead of directly activating the autophagic flux. For instance, the overexpression of HSPB8, 
a co-operator of HSP70 and part of the CASA complex, is able to reduce the amount of insoluble proteins targeting 
them to autophagy, without directly activating autophagic flux (P Rusmini et al. 2013).  
 On the other side many studies tested drugs that directly activate autophagy.  
17-AAG (17-(allylamino)-17-demethoxygeldanamycin) is a compound which has been successfully tested in SBMA in 
vitro models, and was found to be able to reduce the accumulation of ARpolyQ via a mechanism mediated by 
autophagy activation (Rusmini et al. 2011). It was shown that 17-AAG was able to induce a specific overexpression of all 
heat shock protein, including HSP70 and HSP40 that drive proteins to autophagy (Rusmini et al. 2011). Another tested 
compound is trehalose, a well-known autophagic activator, different from rapamycin since it is mTOR independent. It is 
known from studies on other diseases that induction of autophagy by rapamycin has not beneficial effects in NDs, and 
trehalose has been investigated as a valuable alternative. Studies demonstrated that trehalose is able to reduce 
ARpolyQ accumulation in motor neuronal cell models of SBMA, in an autophagic dependent manner; in addition the co-
treatment with anti-androgenic drugs further increases trehalose degradation of AR; indeed, anti-androgen drugs slows 
AR translocation in to the nucleus, thus leaving AR disposable for cytosolic degradation through autophagy. Trehalose 
increases AR degradation not only by activating autophagy, but also by inducing the expression of the components of 
the CASA complex, like HSP70, HSPB8, BAG3 and CHIP; in this way, trehalose induces the degradation only of selected 
proteins (Giorgetti et al. 2014). In an HD mouse models, another disease caused by polyQ expansion, it was also 
demonstrated that trehalose has a beneficial effect on disease progression, and studies on SBMA models are now 
ongoing.  
Therapeutic approaches 
At present, no treatments are available to prevent or stop SBMA progression. Only some palliative treatments, that 
cure the symptoms (such as dysphagia, muscle weakness, infertility), but not the whole pathology, are administered to 
patients. Several clinical trials with very different read out have been performed or are in progress, but no one resulted 
in an efficient therapeutic approach for SBMA.  
Strategies that are now pursued by different investigators are based on the reduction of AR expression, androgen 
ablation, allosteric regulation of AR, regulation of AR expression and modulation of degradative pathways. 
To achieve modulation of AR expression, miRNA gained attention since they are potent gene expression modulators. It 
was demonstrated that miRNA 196a shows positive effects in SBMA mouse models; indeed, it reduces mRNA stability, 
by negatively regulating CELF2, an AR mRNA stabilizer. They also demonstrated that administration of miRNA in mouse 
models, exert protective effects on disease progression (Miyazaki et al. 2012). 
AR expression can also be regulated by the activity of the histone deacetilase (HDAC). The HDAC inhibitor sodium 
butyrate shows beneficial effect on AR expression (Minamiyama et al. 2004).  
Since testosterone triggers ARpolyQ toxicity another valuable strategy is androgen ablation from serum. Testosterone 
production is regulated by the hypothalamic–pituitary–testicular axis and the first stimulus is the gonadotropin-
releasing hormone. Leuprorelin is an analog of GnRH that prevents testosterone production. Effects of this drug on 
motor neuron degeneration are beneficial, but patients show a very low compliance to this drug due to the 
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development of depression. Another strategy is targeting testosterone conversion into dihydrotestosterone (DHT) 
(more active metabolite of testosterone) with Dutasteride (blocker of 5 α-reductase activity) that showed no significant 
efficacy on disease progression nor in other parameters like muscle waist (Fernández-Rhodes et al. 2011; Baniahmad 
2016). Other studies test drugs that targeted the dimerization of AR by N/C interaction. This process can be inhibited by 
Flutamide or others selective androgen receptor modulators (SARM) such as RTI-016 and RTI-051b. Even if  Flutamide 
does not produce any variation in SBMA onset and progression, it seems that it exerts other positive effects in SBMA 
mouse model (Nedelsky et al. 2012; Orr et al. 2010). Another strategy is to target AR co-regulators in order to regulate 
AR gene expression. Curcumin-related compound 5-hydroxy-1,7-bis[3,4-dimethoxyphenyl]-1,4,6-heptatrien-3-one (ASC-
J9) and the soybean-derived isoflavone genistein act on AR interaction with AR associated co-regulator 70 (ARA70) 
improving SBMA phenotype (Yang et al. 2007). 
Finally, since ARpolyQ is substrates of the two main degradative pathways, activating the degrading machinery could 
have beneficial effect as widely reported and described previously. 
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Figure 22 Classification of polyglutamine diseases (Poletti 2004) 
  
 
 
 
Figure 23 Transcript and protein structure of androgen receptor (Poletti 2004) 
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Figure 24 Physiological and pathological functioning of AR (Querin et al. 2017) 
 
 
 
Figure 25 Presence of AR inclusion in various tissues: A) spinal cord B) brainstem nuclei C)sensory D) nerves scrotal E) skin pancreas F) cerebral cortex G) cerebellum H) spinal cord of 
ARQ97 mice (Katsuno et al. 2012) 
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Figure 26 AR inclusions localization in motor neurons (Poletti 2004) 
 
 
 
Figure 27 Different contribution of muscle and motor neurons to SBMA onset and progression (Giorgetti & Lieberman 2016b) 
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Part One: Aims 
The first part of this thesis is focused on the study of amyotrophic lateral sclerosis. As ALS is a multifactorial disease, 
there still many aspects that have not yet been clearly defined. In this context, some works highlight the possibility that 
muscle cells and muscle tissue are involved in the disease. The existence of a correlation between the onset of the 
pathology and muscle involvement is still under debate. One of the most important proteins in ALS is TDP43 since it is 
involved in both familial and sporadic ALS. Since in almost all patient motor neurons have been found inclusions of 
TDP43, degradative systems such as proteasome and autophagy gained importance since they should monitor the 
presence of misfolded and/or aggregated proteins and removed them.   
The aims of the part one of this work are: 
- Studying the behaviour of TDP43 and its disease associated fragments in both motor neuron and muscle cells.  
- Studying the involvement of proteasome and autophagy in the removal of both monomeric and aggregated 
proteins 
- Studying which protective systems could be enhanced in order to prevent or counteract aggregation of TDP43 
and its disease associated fragments.  
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CHAPTER 1: TDP-43 PATHOLOGY IN MOTOR NEURON: THE ROLE OF THE PROTEIN QUALITY 
CONTROL SYSTEM 
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Introduction  
Amyotrophic lateral sclerosis is a fatal motorneuronal disease that caused death in about five years in affected patients. 
The most important clinical feature of ALS is motor neuron death that is caused by numerous factors such as 
excitotoxicity, presence of misfolded protein, presence of free radicals etc. TDP43 is one of the most important protein 
in the study of ALS: physiologically it exert its function in the nucleus or shuttling between nucleus and cytoplasm. 
TDP43 was found mutated in a small percentage of familial ALS but it has been found mislocalized in motor neurons of 
the vast majority of sporadic ALS patients. When TDP43 mislocalized in the cytoplasm it forms aggregates that often 
contain fragments of TDP43. The most represented fragments are the one of 35 and the one of 25 kDa (Zhang et al. 
2007; Zhang et al. 2009). Once aggregates are formed they should be fast and promptly removed from cell environment 
by autophagy. In this first part, I analysed the aggregation propensity of TDP43 and of its disease associated fragments 
in mouse motor neuronal like cell line NSC34. Subsequently I analysed which degradative pathway is involved in the 
removal of both monomeric soluble protein (sometime the most toxic form) and aggregated protein. lastly I analysed 
the protective role of HspB8, a small heat shock protein, that is part of the complex that routes aggregates to 
autophagy (CASA complex). 
These data have been already published in (Crippa, Cicardi, et al. 2016) 
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Materials and methods 
 
CHEMICALS 
Z-Leu-Leu-Leu-al or MG132 was used at 10µM for 16 hrs (Sigma Aldrich, Merck, Darmstadt, Germany). DMSO was used 
as control (Sigma-Aldrich). 3-methyl-adenine or 3MA was used at 10mM for 48 hrs (Selleckem, Houston, TX, USA) and it 
was directly diluted in medium. 
 
CELL CULTURES 
NSC34 were used as motor neuronal model. Cells were routinely used in our lab. Briefly cells were maintained in high 
glucose medium (Euroclone, Pero, MI, Italy) added with glutamine (Euroclone), penicillin (SERVA, Electrophoresis 
GmbH, Heidelberg, Germany) and streptomycin (SERVA) and 5% fetal bovine serum (Sigma-Aldrich). Cells are growth at 
37°C at 5% CO2. 
GFP-TDPs-NSC34 cell lines were obtained by transiently transfecting a TR4 NSC34 cell line (kindly provided by Dr. E. 
Garattini (Mario Negri Institute, Milan, Italy)), with pcDNA5/TO-GFP-TDPs plasmids and selecting positive clones with 
200 µg/ml hygromycin for 3 weeks. GFP-TDPs-NSC34 selected clones were cultured in low-glucose DMEM (Euroclone, 
Pero, Milan, Italy) supplemented with 5% of tetracycline-free serum (Euroclone), 100 µg/ml hygromycin (Euroclone). 
GFP -TDPs expression was induced with doxycycline 1 µg/mL. 
 
PLASMIDS AND SIRNA 
The following plasmids were used: pEGFP-TDP-43 which codes for the full-length form of TDP-43, pEGFP-TDP-35 which 
codes for the 35 kDa TDP-43 fragment, pEGFP-TDP-25 which codes for the 25 kDa TDP-43 fragment, that are all kindly 
provided by Dr. Petruccelli; pCI-neo-hHSPB8 which codes for the human form of the small heat shock protein of 22 kDa; 
pCDNA3 by Addgene was used as a transfection control. 
Following siRNA duplex were used for silencing mHSPB8 endogenous expression: (sense: 5’-
CGGAAGAGCUGAUGGUAAAUU-3’; antisense: 5’-UUU ACCAUCAGCUCUUCCGUU-3’) (Dharmacon, Thermo Scientific Life 
Sciences Research, Waltham, MA, USA). A custom non- targeting siRNA duplex was used as a negative control (sense: 
5’-GGGUAAAGCUAGAGAGAAUUU-3’; antisense: 5’-AUUCUCU CUAGCUUUACCCUU-3’).  
 
TRANSFECTION PROCEDURE 
NSC34 cells were transfected using Lipofectamine® Transfection Reagent (Invitrogen, Thermo Scientific Life Sciences 
Research, Waltham, MA, USA), following manufacturer protocol. Plasmid DNA was previously incubated with 
transferrin (Sigma-Aldrich) and then mixed with Lipofectamine.  
When experiments were carried out in 12-well plates the following quantities of plasmids were used: 0.5µg of pEGFP-
TDP-43, pEGFP-TDP-35 and pEGFP-TDP-25 and 0.6µg of pCI-neo-hHSPB8 and pCDNA3 as a control. Plasmids quantities 
were halved if experiments were carried out in 24-well plate, while are doubled if experiments are carried out in 6-well 
plate.  
 
CELL LYSIS AND FRACTIONATION 
PBS extraction: Cells were plated in a 12-well plate (90,000 cell/mL). 48 hrs after transfection cells were harvested in 
culture medium and centrifuge at 100g x 5min. The supernatant was discarded and the pellet was re-suspended with 
PBS and slightly sonicated (3 hits at low intensity).  
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NP40 soluble/insoluble extraction: Cells were plated in a 12-well plate (90,000 cell/mL). 48 hrs after transfection cells 
were lysed passing each sample with 1mL syringe in the NP-40 buffer (150 mM NaCl (Sigma-Aldrich); 20mM TrisBase 
(Sigma-Aldrich); Nonidet P-40 (NP-40) 0.5% (Sigma Aldrich, Merck, Darmstadt, Germany); 1.5 mM MgCl2 (Sigma-
Aldrich); Glycerol 3% (Sigma-Aldrich), pH 7.4) with protease inhibitor (cOmplete EDTA free Tablet 25X (Sigma-Aldrich)) 
and 1,4-Dithioteitol 1Mm (DTT ; Sigma-Aldrich) to get rid of S-S bond. Samples are then centrifuged at maximum speed 
(15 minutes at 4°) and the supernatant (the NP-40 soluble fraction) is transferred in a new tube while the pellet is rinsed 
in fresh NP-40 buffer, without protease inhibitor and DTT.  NP-40 soluble fraction is quantified with bicinchoninic acid 
(BCA) assay (Euroclone). NP-40 insoluble fraction had been loaded as equal volume to NP-40 soluble fraction.  
 
FILTER RETARDATION ASSAY 
Filter retardation assay (FRA) is based on protein filtration on a cellulose acetate membrane thanks to vacuum applied 
at a Bio-Dot SF Microfiltration Apparatus (Bio-Rad, Hercules, CA, USA). The following quantities were loaded: NSC34 PBS 
extract 1.5µg; NSC34 NP-40 soluble extracts 1.5 µg; NP-40 insoluble extracts were loaded as equal volume. After 
vacuum filtration protein are fixed on the membrane with methanol and then the membrane is incubated for 1 hr at RT 
in blocking solution (5% of dried non-fat milk (Euroclone)). After two washes with TBS-T 1X the membrane is incubated 
with the HRP-conjugate anti-GFP antibody diluted in TBS-T 1X at RT (find incubation timing and antibody dilution 
above). After three washes with TBS-T 1X at RT membrane was incubated with ClarityTM Western ECL Blotting 
Substrate (Bio-Rad) to reveal the signal. Images were acquired using a ChemiDoc XRS System (Bio-Rad). 
 
WESTERN BLOT 
GFP-TDP-43 and its fragments proteins were visualized always by loading samples on 12% polyacrylamide gels. 15µg of 
PBS extracts or 15µg of NP-40 soluble extracts were loaded (insoluble NP-40 extracts were loaded as equal volume to 
NP-40 soluble extracts). Proteins were transferred to nitrocellulose membrane (Bio-Rad) thanks to TransBlot (Bio-Rad) 
following manufacturer instructions. Membrane were then incubated with blocking solution (5% of dried non-fat milk 
(Euroclone)) and with primary antibody at 4° overnight. After two washes, membrane were incubated with the HRP-
conjugated secondary antibody diluted in TBS-T 1X for 1 hr at RT. Signal was detect with ChemiDoc XRS System (Bio-
Rad) after incubation with ClarityTM Western ECL Blotting Substrate (Bio-Rad). Antibody description and dilution are 
described above. 
 
ANTIBODY DILUTION 
The following primary antibodies were used: HRP-conjugate anti-GFP antibody (MB-0712; Vector Laboratories, 
Burlingame, CA, USA) for TDPs detection in FRA and WB (1:10,000 for NSC34); home-made rabbit polyclonal anti-HSPB8 
(1:2,000); goat polyclonal anti-ACTIN (Santa Cruz Biotechnology, sc-1616) (1:1,000); rabbit polyclonal anti GAPDH (Santa 
Cruz Biotechnology, sc-25778) (1:1,000); mouse monoclonal anti-α-tubulin (Sigma-Aldrich T6199) (1:2,000). The 
following secondary antibodies were used: goat anti-rabbit HRP-conjugate secondary antibody (Santa Cruz 
Biotechnology, sc-2004); goat anti-mouse HRP-conjugate secondary antibody (Santa Cruz Biotechnology, sc-2005); 
donkey anti-goat HRP-conjugate secondary antibody (Santa Cruz Biotechnology, sc-2020) 
 
IMMUNOFLUORESCENCE 
Cells were seeded on coverslips in a 24-well plate (70,000 cells/mL). 48 hrs after transfection cells were fixed using 
paraformaldehyde and methanol. Cells were permeabilized using a solution of TRITON X-100 diluted 1:5000 in PBS. 
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After the incubation of 1hrs in blocking solution cells were incubated with primary antibody overnight at 4°C. The 
following primary antibodies were used: home-made rabbit polyclonal anti-HspB8 (1:500 kindly provided by Dr. Landry). 
After two washes with PBS cell were incubated for 1 hr at RT with goat anti-rabbit 549 Alexa (1:1000, Life Technologies, 
Thermo Fischer, A-11012). Coverslips were then mounted on a support. Images were acquired using LSM510 Meta 
system confocal microscope (Zeiss, Oberkochen, Germany) and processed with the Aim 4.2 software (Zeiss). 
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The biochemical behaviour of TDP-43 and its fragments in motor neuronal cells 
To visualize the intracellular localization of TDP-43 and of its fragments, I transfected motor neuronal NSC34 cells with 
plasmids coding for GFP-TDP-43, GFP-TDP-35 and GFP-TDP-25. NSC34 are hybrid cell line obtained by fusion of murine 
neuroblastoma and murine spinal cord; since they maintain various motor neuronal phenotypes they are a bona fide 
motor neuronal-like model. 
As control, I use a plasmid coding for GFP only. Cells were fixed and after nuclei staining observed at microscope (Figure 
28A). I observed that GFP-TDP-43 was localized in the nucleus and no cytosolic or nuclear inclusions were detectable. 
Cells transfected with GFP-TDP-35 showed fluorescence both in the nucleus and in the cytosol sometimes forming 
cytoplasmic aggregates. GFP-TDP-25 was the only protein localized exclusively in the cytosol, and its localization was 
not diffused, but it was present in an aggregated form, with large inclusions both in the cell body and in the neurites. 
I used also filter retardation assay (FRA) to detect the insoluble forms and western blot (WB) to analyse the soluble 
fraction (Figure 28B) of the GFP-TDP-43 and fragments. I observed that in FRA GFP-TDP-43 was more retained than GFP-
TDP-35 and GFP-TDP-25 (*** p<0.001 vs GFP-TDP-35 and GFP-TDP-25; (Figure 28C)). By WB I observed that GFP-TDP-25 
formed more SDS-soluble species than GFP-TDP-43 and TDP-35 (equal loading was verified by tubulin blotting). To 
better isolate the insoluble forms of GFP-TDP-25 clearly visible in IF, I performed a NP-40 fractionation and loaded 
soluble and insoluble extracts both in FRA and WB (Figure 28D). I observed that GFP-TDP-43 and GFP-TDP-35 were 
equally represented in both fractions, both with FRA and with WB. On the other side, GFP-TDP-25 was most present in 
the NP-40 insoluble fraction than in the soluble one. Indeed, the insoluble/soluble ratio of the two fractions in FRA, 
showed a significant increase for GFP-TDP-25 (### p<0.001 vs GFP-TDP-35; * p<0.05 vs GFP-TDP-43; (Figure 28E)). 
I concluded that GFP-TDP-25 and GFP-TDP-35 form aggregates in NSC34, while GFP-TDP-43 is soluble in the nucleus. To 
correctly visualize these aggregates with FRA and WB, NP-40 extraction is required. Probably, GFP-TDP-25 is more 
insoluble than GFP-TDP-43 and GFP-TDP-35, indicating that specific isolation procedure (NP-40 extraction) is required to 
discriminate these species. 
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Figure 1: GFP-tagged truncated TDP-35 and TDP-25 show different biochemical behaviour from that of full-length TDP-43. (A) Confocal microscopy analysis (63X magnification) of 
mouse motor neurone NSC34 cells transiently overexpressing GFP-TDP-43, GFP-TDP-35, GFP-TDP-25, or GFP alone (pEGFP-N1, used as a control). DAPI: nuclei staining. A 2.5x 
magnification of selected areas is shown. (B): Western Blot (WB; upper insets) and filter retardation assay (FRA, lower inset) of the PBS extracts of mouse motor neurone NSC34 cells 
transiently overexpressing the GFP-TDP-43, GFP-TDP-35 or GFP-TDP-25. (C) Quantification of the PBS extract by FRA (***P<0.001 vsGFP-TDP-43). The data represent in each case the 
mean ± sem of n=3 independent samples. (D): WB (upper insets) and FRA (lower insets) of the NP40 extracts of cells transiently overexpressing GFP-TDP-43, GFP-TDP-35 or GFP-TDP-
25 (left insets, NP40-soluble fraction; right insets, NP40-insoluble fraction). (E): Quantification of FRA NP40 insoluble/soluble ratio (°°°P<0.001 vs GFP-TDP-43; * P<0.05 vs GFP-TDP-
43; ### P<0.001 vs GFP-TDP-35). The data again represent the mean ± sem of n=3 independent samples.  
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Relevance of the degradative systems in TDP-43 clearance 
To investigate the degradative pathway responsible for the clearance of the various GFP-TDPs species, I blocked each 
degradative system in presence of TDP-43 species. 
I transfected NSC34 with plasmids coding for GFP-TDP-43, GFP-TDP-35 and GFP-TDP-25 and then I inhibited the 
proteasome with MG132 and the autophagy with 3MA. 
48 hours after transfection I collected the cells and I performed an NP-40 extraction followed by FRA and WB analyses 
(Figure 29).  
Surprisingly, analysis by FRA showed that proteasome inhibition by MG132 treatment caused a reduction of GFP-TDPs 
species in the soluble NP-40 fraction compared to control condition. On the other side, when I blocked autophagy with 
3MA, I observed that in FRA 3MA treatment did not produce any variation in GFP-TDPs presence in NP-40 soluble 
fraction (Figure 29A).  
This trend was confirmed in WB analysis of the soluble fractions of the cell lysates: in fact, after MG132 treatment there 
was a minor presence in NP-40 soluble fraction of all the three GFP-TDPs species; after autophagy inhibition, the 
protein levels of the NP-40 soluble fraction in WB were comparable to the control condition (Figure 29A).  
On the other hand, the analysis of the NP-40 insoluble fraction by FRA revealed that after MG132 treatment all the 
three GFP-TDPs species were greatly increased. Especially for GFP-TDP-35 and GFP-TDP-25, I observed the formation of 
species at higher molecular weight (possibly ubiquitinated forms) and at lower molecular weight (M.W.) (possibly 
fragments generated to increase the clearance of the two species). After 3MA treatment, the only fragment showing an 
increased presence in the insoluble fraction is GFP-TDP-25 (Figure 29B). 
WB analysis mainly reflected FRA results showing a great increased of GFP-TDPs species protein levels following 
proteasome inhibition, while 3MA treatment caused a significant increase only in levels of GFP-TDP-25 NP-40 insoluble 
fraction (Figure 29B). 
The ratio between insoluble and soluble fraction quantified after FRA showed that after proteasome inhibition all the 
three species were more represented in the NP-40 insoluble fraction (* p<0.05). On the other hand, inhibiting 
autophagy caused a shift toward the insoluble fraction only of the GFP-TDP-25 species (Figure 29C). 
From these data, I conclude that proteasome actively degrades all TDPs species. Indeed, when proteasome activity is 
inhibited by MG132, all GFP-TDPs species accumulate in NP-40 insoluble fraction, meaning that the degradation of 
these proteins is slowed down or absent. The role of the autophagy in degrading GFP-TDPs species is different from that 
of the proteasome; autophagy is apparently involved in the selective degradation of only GFP-TDP-25. Based on data 
reported above, 3MA treatment causing defective autophagy, affects only GFP-TDP-25 levels. Compared to control 
condition, GFP-TDP-25 levels in NP-40 insoluble fraction increase when autophagy is inhibited by 3MA. On the contrary, 
GFP-TDP-43 and GFP-TDP-35 levels in NP-40 soluble and insoluble fraction do not change after inhibiting autophagy 
with 3MA. Collectively these data suggest that GFP-TDP-43, and GFP-TDP-35 are not normally degraded by autophagy, 
while GFP-TDP-25 is a substrates of autophagy at basal condition.  
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Figure 28: GFP-TDP-35 and GFP-TDP-25 show different clearance from that of full-length GFP-TDP-43. (A) WB (upper insets) and FRA (lower insets) of the NP40-soluble extracts of 
mouse motor neurone NSC34 cells transiently overexpressing GFP-TDP-43, GFP-TDP-35 or GFP-TDP-25 and treated with 10mM MG132 for 16h or 10mM 3-methyladenine (3-MA) for 
32 h. (B) WB (upper insets) and FRA (lower insets) of NP40-insoluble extracts. (C) Quantification of FRA NP40 insoluble/soluble ratios (***P<0.001 vs GFP-TDP-43). The data 
represent the mean ± sem of n¼3 independent samples.  
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HSPB8 routes TDP-43 and its fragments to autophagy 
HSPB8 is a small heat shock protein whose pro-degradative role against protein inclusions has already been 
demonstrated in different proteinopathies. It was demonstrated that the overexpression of HSPB8 was able to reduce 
aggregation of SOD1 (ALS; (Crippa et al. 2010)), ARpolyQ (SBMA; (Paola Rusmini et al. 2013)) and huntingtin (HD; (Carra 
et al. 2008)). To evaluate if HSPB8 protective role was effective also against TDP-43 fragments aggregation, I co-
transfected HSPB8 with GFP-TDP-43, GFP-TDP-35 and GFP-TDP-25 in NSC34 and I performed an IF, detecting HSPB8 and 
GFP-TDPs localization. Nuclei were stained with Hoechst (Figure 30A-B). By IF I observed that the localization and the 
fluoresce intensity of the GFP-TDP-43 remained unchanged, while in presence of GFP-TDP-35 and GFP-TDP-25 HSPB8 
greatly reduced the number and the size of the aggregates, compared to control condition (pcDNA3).  
Subsequently, to better evaluate the reduction of misfolded, aggregation-prone species in presence of HSPB8 I 
performed NP-40 extraction, to measure protein levels in both soluble and insoluble fractions, transfecting NSC34 with 
GFP-TDPs and HSPB8.  
By WB analysis (Figure 30C) I noted that GFP-TDPs levels in both soluble and insoluble fractions were greatly decreased 
in presence of HSPB8 (even detected in WB). I observed that HSPB8 exerted a pro-degradative activity of the soluble 
species of all the three GFP-TDPs detectable by WB analysis performed on NP-40 soluble extracts.  
In parallel, the analysis of the NP-40 insoluble fraction, showed that the TDPs insoluble species detected in that fraction 
were greatly degreased by mean of HSPB8 activity. (Figure 30D).  
After having assessed the pro-degradative role of HSPB8 against GFP-TDP-43 fragments aggregation, I wanted to 
evaluate if depletion of HSPB8 would results in worsened GFP-TDPs species aggregation. Since I wanted to mimic 
physiological condition, I used NSC34 cell lines stably expressing GFP-TDP-43, GFP-TDP-35 and GFP-TDP-25, in which the 
expression of GFP-TDPs species is comparable to endogenous gene expression. In these cell lines, I silenced HSPB8 with 
a specific siRNA and to obtain a condition of exacerbated aggregation of GFP-TDPs species, I also inhibited proteasome 
with MG132 and autophagy with 3MA. To analyse GFP-TDPs protein levels variation, I performed an NP-40 extraction 
and I analysed the fractions by FRA (Figure 30E-F-G).  
I observed that, when proteasome is inhibited, GFP-TDP-43 levels in both fractions remain comparable to the untreated 
controls. The autophagy contribution in the GFP-TDP-43 clearance was negligible. In fact, the levels of GFP-TDP-43 in 
both insoluble and soluble NP-40 fractions remained unchanged after 3MA treatment.  
By silencing HSPB8 endogenous expression, the Hsp70-Bag3-HSPB8 is no more formed, thus preventing the routing of 
protein/aggregates to autophagy. Even blocking this routing pathway by HSPB8 siRNA, did not produce any variation in 
GFP-TDP-43 protein levels in both NP-40 soluble and insoluble fractions analysed by FRA (Figure 30E). 
Looking at the NP-40 soluble fraction, GFP-TDP-35 levels in FRA were significantly increased when autophagy (3MA 
treatment) and routing to autophagy (HSPB8 silencing) were inhibited (* p< 0.05). MG132 inhibition of proteasome did 
not produce any variation in NP-40 soluble levels of GFP-TDP-35. On the other side, analysing GFP-TDP-35 NP-40 
insoluble fraction, I observed increased GFP-TDP-35 levels in FRA only after proteasome inhibition (** p<0.001), while 
3MA treatment and HSPB8 silencing caused no variation in its NP-40 insoluble levels. (Figure 30F). 
GFP-TDP-25 NP-40 insoluble levels were significantly increased only when proteasome was inhibited by MG132 (** 
p<0.01). 3MA treatment produced no variation both in the NP-40 soluble and NP-40 insoluble levels of GFP-TDP-25. 
HSPB8 silencing increased the levels of the protein retained in FRA only in the NP-40 soluble fraction (* p<0.05), while 
the insoluble fraction was comparable to the control conditions (Figure 30G). 
I conclude that at basal levels HSPB8 is able to drive soluble toxic proteins, such as GFP-TDP-25, to autophagy in order 
to prevent their accumulation inside cell cytoplasm and thus their aggregation. 
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Figure 29: HSPB8 affects the accumulation of GFP-TDP-35 and GFP-TDP-25 fragments. (A,B) Confocal microscopy analysis (63X magnification) of NSC34 cells transiently co-
transfected with plasmids coding for GFP-TDP-43, GFP-TDP-35 or GFP-TDP-25 and pCDNA3 (A) or hHSPB8 plasmid (B). DAPI: nuclei staining. RED: murine endogenous HSPB8 
(mHSPB8) or human transfected HSPB8 (hHSPB8). A 2.5X magnification of selected areas is shown. (C)WB of the NP40-soluble extracts of mouse motor neurone NSC34 cells 
transiently overexpressing GFP-TDP-43, GFP-TDP-35 or GFP-TDP-25 and human HSPB8. (D): WB of the NP40-insoluble extracts. E-G: Representative FRA (upper panels) and FRA 
quantification (lower panels) of the NP40-soluble and NP40-insoluble extracts of mouse motor neurone NSC34 cells stably overexpressing GFP-TDP-43 (E), GFP-TDP-35 (F) or GFP-
TDP-25 (G), induced for 72h with 1 µg/ml doxycycline and transfected with scramble or siRNA-HSPB8; the cells were treated with 10lMMG132 and 10mM3-MA for the last 16h prior 
to extraction. The optical densities of GFP-TDPs were expressed relative to the mean optical densities of the corresponding samples treated with doxycycline and a scramble RNAi 
sequence, taken as internal references. The data represent the mean ± sem of n=3 independent samples. (*P<0.05 vs scramble; ** P<0.01 vs scramble).  
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TDP dynamics are not influenced by GFP-tag 
The green fluorescent protein (GFP) is a protein of 29 kDa and when is fused to endogenous protein (such as TDP-43) it 
might influence protein behaviour. To test if GFP tag was influencing somehow the biochemical behaviour observed for 
TDPs species, I produced three plasmids coding for TDP-43, TDP-35 and TDP-25 tagged with FLAG, a smaller tag than 
GFP. I cloned the three TDP sequences in plasmid with a tag 2xFLAG. I obtained three different plasmids coding for the 
three TDPs species carrying a 2xFLAG tag at the N-terminus. 
I transfected NSC34 cells with 2xFLAG-TDPs plasmids and performed an (IF) against the tag-FLAG (Figure 31A). I 
observed that FLAG-TDP-43 was localized in the nucleus, not forming aggregates, but in a diffuse way, and this 
behaviour correlates with GFP-TDP-43 behaviour. FLAG-TDP-35 was partially mislocalized in the cytoplasm, but 
differently from the results obtained with GFP-TDP-35, it did not form aggregates in the cytoplasm. FLAG-TDP-25 is only 
localized in the cytoplasm, but differently from GFP-TDP-25, it did not form aggregates, but rather it was found diffuse 
in the cytoplasm.  
Then, to check total protein levels of 2xFLAG-TDPs, I performed FRA and WB analysis on NSC34 samples transfected 
with FLAG-TDPs (Figure 31B). PBS extracts analysed by FRA showed that 2xFLAG-TDP-43 was heavily retained on the 
membrane compared with the other two proteins (** p<0.01 vs FLAG-TDP-35 and FLAG-TDP-25). The two fragments 
were barely visible in FRA, with FLAG-TDP-25 even less detectable then FLAG-TDP-35 (° p<0.05). The differences 
observed in FRA could be ascribed to different protein turnover and, to investigate FLAG-TDPs turnover, NSC34 cells 
were transfected with FLAG-TDPs and treated with MG132, to inhibit proteasome and 3MA to inhibit autophagy (Figure 
31C-D-E) and PBS extracts were analysed by FRA and WB. FLAG-TDP-43 levels increased in FRA following proteasome 
and autophagy inhibition (* p<0.01 vs NT), while in WB I detected only a slight increase in protein levels (Figure 31C). 
FLAG-TDP-35 showed the same trend as FLAG-TDP-43 in FRA: the amount of protein retained in FRA was increased by 
MG132 and 3MA (*p<0,05). At variance of FLAG-TDP-43, in WB blot FLAG-TDP-35 levels were greatly increased after the 
inhibition of both the degradative systems (Figure 31D).  
By analysing the extracts of FLAG-TDP-25 in FRA PBS, I noted that the most of the protein, that is not detectable in basal 
condition, is recovered after blocking the degradative pathways with MG132 and 3MA (**p<0.01). WB analysis on the 
same samples revealed that the treatment with MG132 led to the recovering of the soluble form of FLAG-TDP-25, while 
3MA treatment had no effects on the soluble levels of monomeric TDP-25 (Figure 31E).  
Since TDP-43 fragments are misfolded and toxic proteins, I wanted to evaluate if HSPB8 pro-degradative role was 
comparable to the one observed for GFP-TDPs. I co-transfected HSPB8 with FLAG-TDPs to assess HSPB8 pro-degradative 
role with FLAG-TDPs. When HSPB8 is overexpressed in presence of FLAG-TDPs, TDPs levels in FRA were significantly 
decreased in the case of TDP-43 (**p<0.01) and of TDP-35 (**p<0.01). FLAG-TDP-25 was not significantly reduced but I 
could detect only a slight decreased in protein levels in FRA (Figure 31 F-G-H-I). Since protein levels are very low, it is 
possible that a strong decrease is not detectable. By analysing the PBS extracts in WB, I observed that the total protein 
levels of FLAG-TDP-43 were reduced in presence of HSPB8; while in the case of FLAG-TDP-35 and FLAG-TDP-25, I only 
observed a little variation in total protein levels, with HSPB8 overexpression (Figure 31F). 
Overall these results demonstrated that GFP tag impact on TDPs rate of aggregation; indeed, I found that TDP-25 
aggregation is different if GFP is present, and it seems that GFP enhances TDP-25 aggregation. Probably its effect on 
TDP-25 is due to the weight of the two proteins that is almost the same. Another explanation is that GFP makes 
degradation of TDPs less easy than FLAG tag. Nevertheless, even if the amount of aggregation is different in presence of 
GFP, HSPB8 maintains it capacity of routing misfolded proteins to degradation.  
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Figure 30: Accumulation and clearance of FLAG-tagged TDP-43, TDP-35 and TDP-25. (A) Confocal microscopy analysis (63x magnification) of mouse motor neurone NSC34 control 
cells or cells transiently overexpressing 2xFLAG-TDP-43, 2xFLAG-TDP-35, 2xFLAG-TDP-25. DAPI: nucleic acid staining. A 2.5x magnification image of selected areas is shown. (B) WB 
(upper insets) and FRA (lower insets and FRA quantification, bar graph) of the PBS extracts of mouse motor neurone NSC34 cells transiently overexpressing the 2xFLAG-TDP-43, 
2xFLAG-35 or 2xFLAG-TDP-25. The data represent the mean ± sem of n=3 independent samples. ** P<0.001 vs 2xFLAG- TDP-43; ° P<0.05 vs 2xFLAG-TDP-35. (C-E): WB (upper insets) 
and FRA (lower insets and FRA quantification, bar graph) of the PBS extracts of mouse motor neurone NSC34 cells transiently overexpressing 2xFLAG-TDP-43 (C), 2xFLAG-35 (D) or 
2xFLAG-TDP-25 (E) and treated with 10mM MG132 for 16h or 10mM 3-methyladenine (3-MA) for 32h (**P<0.001 or * P<0.01 vs untreated controls). The data represent the mean ± 
sem of n=3 independent samples. (F-I): NSC34 cells transiently co-transfected with plasmids coding for 2xFLAG-TDP-43, 2xFLAG-TDP-35 or 2xFLAG-TDP-25 and pCDNA3 or hHSPB8. 
WB and representative FRA (F). FRA quantification (G, TDP-43; H, TDP-35; I, TDP-25) (**P<0.001 vs pCDNA3 transfected cells). The data represent the mean ± sem of n=3 
independent samples 
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CHAPTER 2: TDP-43 PATHOLOGY IN MUSCLE CELLS: DIFFERENCES AND COMMUNALITIES WITH 
MOTOR NEURON TDP-43 PATHOLOGY 
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Introduction  
The role of muscle tissue in the pathogenesis of ALS has not been clearly defined. There are many works that 
demonstrated that during ALS, muscle tissue is damaged. On the other hand muscle importance during the onset of the 
pathology is very controversial. In this context many works have been carried out in SOD1 mouse model. Some studies 
demonstrated that SOD1 restricted expression in muscle cells, caused muscle atrophy but not ALS. On the other side 
there are other works that claim that overexpression of IGF-1 is able to mildly rescue ALS phenotype.  
In this second chapter, I compared TDP43 and its disease associated fragments behaviour in both motor neuronal cell 
line NSC34 and immortalized murine myoblast C2C12. Subsequently, I analysed which degradative system degrades 
TDP43 species inside muscle cells. In the last part, I analysed the protective effect of HspB8 in muscle cells in presence 
of TDP43 species.  
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Materials and methods 
 
CHEMICALS 
NSC34 and C2C12 were treated with the same chemicals described in the previous chapter. 
 
CELL CULTURES 
NSC34 were cultured as described in the previous chapter. 
C2C12 were used a muscle model. Cells were maintained in high glucose medium completed with glutamine, penicillin, 
streptomycin and 10% of fetal bovine serum (GIBCO, Thermo Scientific Life Sciences Research, Waltham, MA, USA). 
Cells are growth at 37°C at 5% CO2. 
 
TRASFECTION METHOD 
NSC34 were transfected using Lipofectamine® Transfection Reagent as described in the previous chapter 
C2C12 cells were transfected with Lipofectamine® 2000 Transfection Reagent (Invitrogen) following manufacturer 
instructions. Briefly DNA was incubated with Lipofectamine® 2000 reagent and the mix was added to cells directly in 
medium deprived of serum and antibiotics. After 5 hours medium was replaced with fresh one supplemented with 
serum and treatment. 
For these experiments the same plasmids used in the chapter above were utilized. 
 
FRACTIONATION 
Both cell lines were plated in 6-well plate (NSC34 100,000 cells/mL; C2C12 65,000 cells/mL). 48 hrs after transfection 
cells were harvested and centrifuged at 100 rcf at 4° for 5 min. Cells were then diluted in 100µL PBS (Euroclone) added 
with protease inhibitor cocktail (Sigma-Aldrich), sonicated (3 hits at lowest intensity) and centrifuged for at maximum 
speed at 4°C for 15min. Supernatant was then transferred in a new tube and pellet was rinsed in 100 µL of 1% TRITON 
X-100 (Sigma-Aldrich) solution in PBS. Suspension was slightly sonicated and centrifuged at maximum speed at 4°C for 
15 min. The supernatant (that corresponds to TRITON X-100 soluble fraction) is placed in a new tube. Pellet was rinsed 
in 100µL of a solution of PBS and 5% SDS (Sigma-Aldrich) sonicated and centrifuged as previously described to obtain 
TRITON X-100 soluble fraction. The SDS soluble fraction is transferred in a new tube and the pellet was rinsed in 100µL 
of a solution of 88% formic acid (FA) (Sigma-Aldrich) in PBS, sonicated and centrifuged with same protocol used to 
obtain TRITON X-100 and SDS soluble fraction. The FA soluble fraction is transferred in a new tube and the remaining 
pellet is discarded. PBS soluble fraction and TRITON X-100 soluble fraction were quantified using bicinchoninic acid 
(BCA) (Euroclone) assay. SDS soluble fraction and FA soluble fraction were loaded as equal volume to PBS soluble 
fraction. 
 
NP40 EXTRACTION, FILTER RETARDATION ASSAY AND WESTERN BLOT 
NP40 extraction was performed as described in chapter one. NSC34 were plated at 90,000 cell/mL and C2C12 were 
plated at 65,000 cell/mL in 12-well plate. Filter retardation assay (FRA) was performed as already described (see Cap. 1): 
NP40 extracts were loaded after BCA quantification: 1.5 µg of soluble extracts for NSC34 and 6µg for C2C12. Insoluble 
fraction was loaded as equal volume. For WB analysis of both NP-40 extracts 15µg of soluble fraction of both cell lines 
were loaded. Insoluble fraction was loaded as equal volume. For WB analysis of fractionation 15µg of PBS and TRITON 
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X100 extracts of both cell lines were loaded. SDS and FA extracts were loaded as equal volume counted on PBS extracts 
quantification.  
 
ANTIBODY DILUTION 
The following primary antibodies were used: HRP-conjugate anti-GFP antibody (MB-0712; Vector Laboratories, 
Burlingame, CA, USA) for TDPs detection in FRA and WB (1:10,000 for NSC34; 1:2,000 for C2C12); home-made rabbit 
polyclonal anti-HSPB8 (1:2,000); home-made polyclonal anti-Bag3 (1: 3,000); rabbit polyclonal anti-HA (Santa Cruz 
Biotechnology, sc-7392) (1:500); goat polyclonal anti-ACTIN (Santa Cruz Biotechnology, sc-1616) (1:1,000); rabbit 
polyclonal anti GAPDH (Santa Cruz Biotechnology, sc-25778) (1:1,000); mouse monoclonal anti-α-tubulin (Sigma-Aldrich 
T6199) (1:2,000). The following secondary antibodies were used: goat anti-rabbit HRP-conjugate secondary antibody 
(Santa Cruz Biotechnology, sc-2004); goat anti-mouse HRP-conjugate secondary antibody (Santa Cruz Biotechnology, sc-
2005); donkey anti-goat HRP-conjugate secondary antibody (Santa Cruz Biotechnology, sc-2020) 
 
IMMUNOFLUORESCENCE 
Cells were seeded on coverlips in 24-well plate (NSC34 70,000 cell/mL; C2C12 55,000 cell/mL). After transfection cells 
were fixed in paraformaldehyde 4% and methanol. Immunofluorescence was carried out as previously described.  
For aggregates counting, microscope was supported with a grind ocular. For each cells, in the field chosen, small and big 
aggregates were counted. 3 fields for each sample were analysed, and for each condition 3 samples were prepared.  
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Muscle cells are a site for TDP-25 aggregation 
Since little is known about muscle response in presence of misfolded and aggregation prone proteins, I investigated the 
behaviour of misfolded proteins in C2C12 muscle cell model. 
I transfected in parallel NSC34 cells and C2C12 cells with GFP-TDP-43, GFP-TDP-35 and GFP-TDP-25. Cells were fixed and 
nuclei stained for microscope acquisition.  
As previously observed in NSC34 cells, GFP-TDP-43 in muscle cells was retained in the nucleus, and it formed no 
aggregates. As in NSC34 cells, GFP-TDP-35 was partially mislocalized in the cytoplasm of muscle cells (Figure 32A-C). In 
both cell models, few aggregates were observed in presence of GFP-TDP-35. Conversely, in both cell models GFP-TDP-
25 is completely mislocalized in the cytoplasm where it was found in its aggregated form. I observed that aggregates in 
NSC34 cells were bigger and more numerous than in muscle C2C12 cells (Figure 32A-C). Counting aggregates per cells I 
found that in C2C12 cells the number of big and small aggregates was fewer than in NSC34 cells (Figure 32E).  
To further investigate and to better characterize the solubility of the different GFP-TDPs species, I performed a 
fractionation in four buffers with increasing solubility power (PBS < TRITON X100 < SDS < FA) (Figure 32B-D). Western 
blot (WB) results showed that, in NSC34 cells, GFP-TDP-43 was equally found in PBS, TRITON X100, and SDS, while in 
C2C12 cells it is mainly solubilized by PBS and TRITON X100 and only a little fraction appear in SDS soluble fraction. GFP-
TDP-35 in both cell lines was equally distributed in the PBS, TRITON X100, and SDS. GFP-TDP-25, on the other hand, is 
poorly present in PBS and TRITON X100 fractions compared to the other two species; the most of the GFP-TDP-25 
protein was detected in the SDS fractions. Noteworthy, in NSC34 cells, GFP-TDP-25 can also be found in the FA fraction. 
I also investigate the biochemical behaviour of the autophagic receptor p62; p62 is a protein that recognizes substrates 
and facilitates internalization of these substrates into autophagic vesicles. I observed that in NSC34 cells, p62 was found 
in all fractions and its expression did not change in presence of the different TDPs. However, in NSC34 cells expressing 
GFP-TDP-25, p62 was found also in the FA fraction (Figure 32B-D), while in C2C12 cells p62 was equally found in PBS, 
TRITON and SDS fractions, but not in the FA fraction, even when GFP-TDP-25 was expressed.  
This first observation shows that the three GFP-TDPs species have the same localization in both cell lines: TDP-43 forms 
no aggregates and remains in the nucleus, GFP-TDP-35 mislocalizes in the cytoplasm where it aggregates and GFP-TDP-
25 (that completely loses the NLS) is found aggregated in the cytoplasm. I also observed that all the three GFP-TDPs 
species have comparable biochemical behaviours in NSC34 cells and in C2C12 cells: GFP-TDP-43 and GFP-TDP-35 are 
more soluble than GFP-TDP-25 that is almost exclusively found in the SDS (or FA) fractions. Most importantly, I also 
noted a significant difference between the two models: in fact, GFP-TDP-25 aggregates are more numerous and bigger 
in NSC34 cells than in C2C12 cells, while GFP-TDP-25 aggregates are smaller and fewer compared to aggregates 
detected in NSC34 cells. 
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Figure 31: TDP-43 variants show different behavior in mouse motor neurone NSC34 and C2C12 cells. (A) Confocal microscope analysis. Mouse motor neurone NSC34 cells were 
transiently transfected with GFP-TDP-43, GFP-TDP-35, GFP-TDP-25. Nuclei were stained with DAPI. Images were acquired using confocal microscope with 63X magnification. (B) 
Western blot (WB) shows PBS, TRITON X-100, SDS and formic acid (FA) extracts. Actin was used as loading control.(C) Confocal microscope analysis. Immortalized mouse myoblast 
C2C12 cells were transiently transfected with GFP-TDP-43, GFP-TDP-35, GFP-TDP-25. Nuclei were stained with DAPI. Images were acquired using confocal microscope with 63X 
magnification. (D) WB shows PBS, TRITON X-100, SDS and FA extracts.(E) Quantitation of small and big aggregates per cells was performed with ImageJ. Graph bar shows the 
medium number of small and big aggregates per cell in mouse motor neurone NSC34 and C2C12 transiently transfected with GFP-TDP-25. **p<0.01; ***p<0.001 vs C2C12. 
  
Part one: PQC system in ALS 
Chapter Two 
74 
 
GFP-TDP-25 aggregates are equally isolated by fractionation and NP-40 extraction  
With fractionation I set a valuable method for correctly visualizing GFP-TDP-25 aggregates. Since fractionation is a long 
time-requiring procedure, for routine comparison of both cell lines, I decided to adopt the fractionation method based 
on NP-40 extraction (Figure 33).  
I transfected both cell line with GFP-TDP-25 and then I performed in parallel fractionation and NP-40 extraction. WB 
results on different extracts showed that the most of the GFP-TDP-25 in both cell lines was retained in the SDS soluble 
fraction and in the NP-40 insoluble fraction and the amount of GFP-TDP-25 was comparable in these two fractions (SDS 
soluble fraction and NP-40 insoluble fraction). P62 levels were also analysed and I found that in NSC34 cells, p62 levels 
were higher in the SDS-soluble and NP-40 insoluble fractions, following GFP-TDP-25 distribution. In C2C12 cells, p62 
levels did not change among different fractions. Tubulin was used as a control for a proper extraction since it appeared 
in PBS, TRITON X100 and NP-40 soluble fractions, while it was absent in SDS soluble and NP-40 insoluble fractions. 
I confirmed that to correctly visualize TDP-25 aggregates I can mutually use fractionation and NP-40 extraction. 
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Figure 32: Comparison between fractionation and NP-40 extraction. (A) Western Blot shows both extracts of fractionation and extracts from NP-40 extraction of mouse motor 
neurone NSC34 transiently overexpressing GFP-TDP-25. (B) Western Blot shows both extracts of fractionation and extracts from NP-40 extraction of immortalized mouse myoblast 
C2C12 transiently overexpressing GFP-TDP-25. 
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Proteasome and autophagy relevance in degradation of TDPs species in muscle cells. 
Previous experiments showed that the three GFP-TDPs species behaved differently in the two cell models. Indeed, I 
found that in NSC34 cells the aggregation propensity of GFP-TDP-25 was greater than in C2C12 cells. To investigate the 
reason of this difference, I analysed the contribution of the two degradative systems in C2C12 cells in presence of GFP-
TDPs. 
I transfected C2C12 cells with GFP-TDP-43, GFP-TDP-35 and GFP-TDP-25. To evaluate the contribution of each 
degradative system, I treated cells with MG132 overnight to inhibit the proteasome and with 3MA for 48 hrs to inhibit 
autophagy. Samples were analysed with FRA and WB (Figure 34) following an NP-40 extraction. 
Analysing the NP-40 soluble fractions in FRA, revealed that proteasome inhibition by MG132 caused a reduction in GFP-
TDP-35 and GFP-TDP-25 protein, while protein levels of GFP-TDP-43 did not change upon MG132 treatment (Figure 
34A). On the other side inhibition of autophagy did not cause changes in protein amount retained in FRA related to 
GFP-TDP-43, GFP-TDP-35 and GFP-TDP-25. When looking at the soluble protein levels in WB, I observed that 
proteasome inhibition by MG132 caused an increased only in GFP-TDP-25 protein levels, while GFP-TDP-35 and GFP-
TDP-43 soluble protein levels were not affected by proteasome inhibition. WB analysis of extracts after autophagy 
inhibition reflected FRA analysis showing no changes in protein amount after autophagy inhibition. 
Analysing the NP-40 insoluble fraction by FRA I observed that following proteasome inhibition with MG132, GFP-TDP-35 
and GFP-TDP-25 accumulated at higher levels compare to control conditions (*** p<0.001 vs control condition), while 
GFP-TDP-43 levels in FRA did not change upon MG132 treatment (Figure 34B). Notably, inhibition of autophagy with 
3MA produced no significant effect on insoluble species retained in FRA for all the three insoluble species. WB analysis 
confirmed the trend observed with FRA analysis: MG132 produced an increase in GFP-TDP-25 NP-40 insoluble species, 
while GFP-TDP-35 and GFP-TDP-43 levels remained unaffected (Figure 34B); on the other side, autophagy inhibition did 
not produce changes in NP-40 insoluble protein levels analysed in WB. 
The ratio between the insoluble and the soluble fractions analysed in FRA showed that, after MG132 treatment, there 
was a significant shift towards the insoluble species for GFP-TDP-35 and GFP-TDP-25 (p<0.05 vs control condition) 
(Figure 34C). In addition, the GFP-TDP-43 ratio suggested that there were more insoluble species, but the differences 
with the control were not significant. Conversely, 3MA produce no change in the solubility of GFP-TDPs; indeed, there is 
no shift towards the insoluble NP-40 species for all the GFP-TDPs species.  
These results show that in muscle cells the proteasome is apparently more relevant in the degradation of toxic 
fragments of TDP-43; indeed when proteasome is pharmacologically inhibited I found the formation of more NP-40 
insoluble species. On the other hand, autophagy at basal levels is poorly involved in GFP-TDPs degradation, since its 
inhibition with 3MA did not produce any change in GFP-TDPs protein levels.  
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Figure 33: Degradative systems involvement in C2C12 with GFP-TDPs species. immortalized mouse myoblast C2C12 were transiently transfected with GFP-TDP-43, GFP-TDP-35 and 
GFP-TDP-25. Treatments for 10 hours with MG132 (10µM) or for 36 hours with 3MA (10mM). (A) Panel shows NP-40 soluble extracts WB analysis (upper inset), NP-40 soluble 
extracts FRA analysis (middle inset) and quantification of NP-40 soluble extracts FRA assay (** p<0.01 vs untreated GFP-TDP-25) (lower inset); (B) Panel shows NP-40 insoluble 
extracts WB analysis (upper inset), NP-40 insoluble extracts FRA analysis (middle inset) and quantification of NP-40 insoluble extracts FRA assay (** p<0.01 vs corresponding 
untreated GFP-TDP-35 and GFP-TDP-25) (lower inset); (C) Panel shows quantification of insoluble/soluble ratio (* p<0.05 vs respective untreated GFP-TDP-35 and GFP-TDP-25).  
Part one: PQC system in ALS 
Chapter Two 
78 
 
Autophagic routing of TDPs fragments reduces aggregation in muscle cells. 
Since proteasome has a low capacity to degrade misfolded species and the presence of ALS related misfolded proteins 
can overwhelm and damage the system, I perform some experiments aimed to direct insoluble species to the more 
capable autophagy system, with the goal to reduce the load on proteasome and the aggregation of misfolded proteins. 
To achieve this aim I overexpressed HSPB8, whose role in directing misfolded species to autophagy is well assessed in 
motor neurons. In fact, HSPB8 is part of a complex that recognized misfolded species and brought them directly in to 
the autophagic vesicles. I overexpressed HSPB8 in C2C12 cells in presence of GFP-TDP-43, GFP-TDP-35 and GFP-TDP-25 
and NP-40 extracts were analysed by FRA and WB.  
Both in FRA and WB, GFP-TDP-43 and GFP-TDP-35 protein levels in NP-40 soluble fractions slightly changed when HSPB8 
is overexpressed compared to control condition (pcDNA3) (Figure 35A). Interestingly, in FRA NP-40 soluble levels of 
GFP-TDP-25 were significantly decreased in presence of HSPB8 (** p<0.01 vs control condition) while in WB soluble 
levels of GFP-TDP-25 were not affected by HSPB8 activity (Figure 35A).  
In FRA, GFP-TDP-43 proteins levels in NP-40 insoluble fraction were not affected by the presence of HSPB8. On the 
other side, HSPB8 produced a significant reduction in GFP-TDP-35 and GFP-TDP-25 species isolated in NP-40 insoluble 
fraction (** p<0.01 vs control condition; *** p<0.001 vs control condition) (Figure 35A). GFP-TDP-43 NP-40 insoluble 
levels in FRA were not change after HSPB8 overexpression. WB analysis of NP-40 insoluble fraction showed diminished 
levels only of the GFP-TDP-25 protein in the NP-40 insoluble fraction when HSPB8 is overexpressed (Figure 35A). 
Noteworthy, it seems that the levels of the overexpressed HspB8 change depending on which TDP specie is present. 
I also performed an IF co-transfecting HSPB8 with GFP-TDPs. I observed that in muscle cells, GFP-TDP-43 localization 
and quantity was unaffected by HSPB8 overexpression. The few aggregates formed by GFP-TDP-25 were completely 
cleared by HSPB8 overexpression (Figure 35B). 
With this experiment I observed that even if autophagy is not involved at basal level (see Figure 34), it is possible to 
route misfolded species to autophagy, reducing the loading of proteasome and thus increasing the clearance of 
misfolded proteins. Indeed, HSPB8 overexpression increased the clearance of GFP-TDPs species, directing misfolded 
species towards autophagy. 
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Figure 34: HSPB8 overexpression counteracted GFP-TDP-25 accumulation in C2C12. Immortalized mouse myoblast C2C12 transiently overexpressing GFP-TDP-43, GFP-TDP-35 and 
GFP-TDP-25, and co-transfected with pCI- hHSPB8 or pcDNA3 as control vector. (A) NP-40 extraction: left panel NP-40 soluble extracts WB analysis (upper inset), NP-40 soluble 
extracts FRA analysis (middle inset) and quantification of NP-40 soluble extracts FRA analysis (** p<0.01 vs GFP-TDP-25 co-transfected with control vector) (lower inset). Right panel 
shows NP-40 insoluble extracts WB analysis (upper inset), NP-40 insoluble extracts FRA analysis (middle inset) and quantification of NP-40 insoluble extracts FRA analysis (**p<0.01; 
*** p<0.001 vs relative GFP-TDPs co-transfected with control vector).(B) Immortalized mouse myoblast C2C12 transiently overexpressing GFP-TDP-43, GFP-TDP-35 and GFP-TDP-25, 
and co-transfected with pCI- hHSPB8 or pcDNA3 as control vector analysed with confocal microscope. 63X magnification. Green: GFP-TDPs; Red: hHSPB8; nuclei staining: DAPI. 
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CHAPTER 3: DIFFERENTIAL ROUTE TO PROTEASOME AND AUTOPHAGY IN ALS IN MOTOR 
NEURON AND MUSCLE CELLS  
  
Part one: PQC system in ALS 
Chapter Three 
81 
 
Introduction  
Proteasome and autophagy are the two main degradative systems in charge of maintaining the correct protein 
homeostasis inside cell environment. Both misfolded protein and aggregates are toxic to cells if they are not correctly 
removed from cells. It has been postulated that in the last stages of ALS, degradative systems are no more functional 
and misfolded proteins lead to motor neuron death. Both proteasome and autophagy are able to sense the presence of 
misfolded, toxic proteins and the presence of aggregates and protein inclusions. The chaperone system helps the 
degradative systems in recognising misfolded proteins and aggregates. In particular Hsp70, which can recruits 
substrates to be degraded, forms a complex with an ubiquitin ligase, named CHIP, and alternatively with Bag1 or Bag3-
HspB8. Bag1 directs the complex and the bound substrates to proteasome while Bag3-HspB8 drives the complex to 
autophagy. 
In this last part, I analysed the effect of Bag1 and Bag3 on TDP43 species in both motor neurons and muscle cells. 
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Materials and methods 
 
All the experiments were performed following protocols described in the previous chapters. 
For these experiments GFP-TDPs plasmids were co-transfected with pCI-6xHis-FL-Bag3 which codes for the human form 
of full length BAG3 and pCDNA/HA-Bag1 which codes for the human form of BAG1, that are all kindly provided by Dr. 
H.H. Kampinga; pcDNA3 was used as control plasmid. To detect the proteins encoded by these antibody the following 
antibody were used: home-made rabbit polyclonal anti-Bag3 (1:3,000 for WB, 1:500 for IF; kindly provided by), rabbit 
polyclonal anti-HA (1:500 for WB, 1:250 for IF; Santa Cruz, sc-805). 
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BAG3 role in autophagy routing of misfolded proteins 
BAG3 is HSPB8 co-chaperone in the HSP70-HSPB8-BAG3 complex, which has a double function: it helps HSPB8 in cargo 
recognition and, after association with HSP70, BAG3 regulates the release from HSP70 of the cargo at the MTOC. Since I 
already tested the protective of HSPB8 in motor neuronal and muscle cells in presence of misfolded proteins, I analysed 
BAG3 role in presence of GFP-TDPs species. 
NSC34 cells and C2C12 cells were transfected with BAG3 and with GFP-TDP-43, GFP-TDP-35 and GFP-TDP-25 (pCDNA3 
was taken as control) and NP-40 extracts were analysed by FRA and WB (Figure 36A-C). 
In NSC34 cells, FRA performed on NP-40 soluble extracts showed that BAG3 overexpression reduced the amount of 
GFP-TDP-25 retained on the membrane compared to control condition (* p<0.05 vs control). In FRA, the levels of GFP-
TDP-43 and GFP-TDP-35 were not reduced by BAG3 overexpression. WB analysis confirmed the trend observed in FRA 
of the NP-40 soluble GFP-TDPs species: GFP-TDP-25 monomeric form was mildly decreased in presence of BAG3 
overexpression while GFP-TDP-43 and GFP-TDP-35 levels remained unaffected. BAG3 overexpression also reduced the 
amount of GFP-TDP-25 in NP-40 insoluble fraction analysed in FRA (* p<0.05 vs control). The levels of GFP-TDP-43 in NP-
40 insoluble fraction were not changed with BAG3 overexpression, while GFP-TDP-35 levels were reduced, but not in a 
significant manner (Figure 36A); WB analysis of the NP-40 insoluble fraction showed that there was no differences in 
GFP-TDPs presence in this fraction, when BAG3 is overexpressed compare to control conditions. IF analysis co-
expressing BAG3 and GFP-TDPs species (Figure 36B) revealed that, in presence of BAG3 (BAG3 is stained in red when 
overexpressed), GFP-TDP-25 aggregates were smaller and fewer in number if compared to control condition, confirming 
the results obtained with NP-40 extraction. In parallel, I was unable to detect changes of the presence and localization 
of GFP-TDP-43 and GFP-TDP-35. 
In C2C12 cells, the soluble NP-40 extracts analysed in FRA showed a significant decreased of GFP-TDP-25 amount after 
BAG3 overexpression (*** p<0.001 vs control) (Figure 36C), while the amount of GFP-TDP-43 and GFP-TDP-43 in the NP-
40 soluble fraction was not affected by BAG3 overexpression. WB analysis showed the same trend observed in FRA 
analysis. Indeed, GFP-TDP-25 levels, in presence of BAG3, changed while GFP-TDP-43 and GFP-TDP-35 protein levels 
remained unaffected (Figure 36C). 
In order to test the effect of BAG3 on insoluble, HMW formations, insoluble NP-40 fraction was analysed. FRA showed a 
significant reduction of GFP-TDP-25 species (* p<0.05) in presence of overexpressed BAG3 while GFP-TDP-43 and GFP-
TDP-35 amount in this fraction was no affected by BAG3 overexpression (Figure 36C). Also IF analysis performed C2C12 
transfected with BAG3 and GFP-TDPs species showed that BAG3 overexpressing cells were completely cleared by GFP-
TDP-25 aggregates, while GFP-TDP-43 and GFP-TDP-35 remained unchanged in presence of BAG3 overexpression 
(Figure 36D). 
These results suggest that BAG3 has a pro-degradative role against GFP-TDP-25 aggregates in both cell models, indeed 
aggregation of GFP-TDP-25 measured by FRA on NP-40 extracts or IF is reduced by BAG3 overexpression. On the other 
side it has no effect on GFP-TDP-43 and GFP-TDP-35 protein levels and protein aggregation.  
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Figure 35: Co-chaperone BAG3 counteracts GFP-TDP-25 aggregation in NSC34 and C2C12 (A) mouse motor neurone NSC34 transiently overexpressing GFP-TDP-43, GFP-TDP-35 and 
GFP-TDP-25, and co-transfected with pCI-6xHIS-Bag3 or pcDNA3 as control vector. Left panel shows NP-40 soluble extracts WB analysis (upper inset), NP-40 soluble extracts FRA 
analysis (middle inset) and quantification of NP-40 soluble extracts FRA analysis (* p<0.05 vs GFP-TDP-25 co-transfected with control vector) (lower inset). Right panel shows NP-40 
insoluble extracts WB analysis (upper inset), NP-40 insoluble extracts FRA analysis (middle inset) and quantification of NP-40 insoluble extracts FRA analysis (*p<0.05 vs GFP-TDP-25 
co-transfected with control vector) (lower inset). (B) mouse motor neurone NSC34 transiently overexpressing GFP-TDP-43, GFP-TDP-35 and GFP-TDP-25, and co-transfected with pCI-
6xHIS-Bag3 or pcDNA3 as control vector analysed with confocal microscope. 63X magnification. Green: GFP-TDPs; Red: hBAG3; nuclei staining: DAPI.(C) Immortalized mouse 
myoblast C2C12 transiently overexpressing GFP-TDP-43, GFP-TDP-35 and GFP-TDP-25, and co-transfected with pCI-6xHIS-Bag3 or pcDNA3 as control vector. Left panel shows NP-40 
soluble extracts WB analysis (upper inset), NP-40 soluble extracts FRA analysis (middle inset) and quantification of NP-40 soluble extracts FRA analysis (*** p<0.001 vs GFP-TDP-25 
co-transfected with control vector) (lower inset). Right panel shows NP-40 insoluble extracts WB analysis (upper inset), NP-40 insoluble extracts FRA analysis (middle inset) and 
quantification of NP-40 insoluble extracts FRA analysis (*p<0.05 vs GFP-TDP-25 co-transfected with control vector).(D) Immortalized mouse myoblast C2C12 transiently 
overexpressing GFP-TDP-43, GFP-TDP-35 and GFP-TDP-25, and co-transfected with pCI-6xHIS-Bag3 or pcDNA3 as control vector analysed with confocal microscope. 63X 
magnification. Green: GFP-TDPs; Red: hBAG3; nuclei staining: DAPI.  
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Routing to proteasome, through Bag1 activity prevents the formation of GFP-TDPs aggregates.  
BAG1 is another member of the BAG family and its role is different from BAG3. In fact, BAG1 binds HSP70 and routes 
misfolded proteins to proteasome rather than to autophagy. Its potential role against misfolded proteins has been 
poorly assessed. Since GFP-TDPs species are substrates of the UPS, I investigate the role of BAG1 on the degradation of 
GFP-TDPs species. 
NSC34 and C2C12 cells were transfected with BAG1 and GFP-TDP-43, GFP-TDP-35 and GFP-TDP-25; NP-40 soluble and 
insoluble fractions were analysed by FRA and WB. 
FRA analysis of NSC34 NP-40 soluble extracts showed that levels of GFP-TDP-43 and GFP-TDP-35 remained unchanged 
upon BAG1 overexpression (Figure 37A). Notably, GFP-TDP-25 levels in NP-40 soluble fraction were reduced in FRA by 
BAG1 overexpression. WB analysis in which the monomeric form of NP-40 soluble species were detectable, showed 
that all the three GFP-TDPs monomers were reduced by BAG1 overexpression. 
By Analysing NP-40 insoluble extracts by FRA I found a significant reduction of GFP-TDP-25 species in presence of BAG1, 
while GFP-TDP-43 and GFP-TDP-35 protein levels remained similar to those found in control samples. WB analysis of the 
same NP-40 insoluble extracts, showed that in presence of BAG1 overexpression all the three GFP-TDP species were 
reduced (Figure 37A). 
IF analysis on NSC34 cells transfected with GFP-TDPs and BAG1 showed that this co-chaperone counteracts GFP-TDP-25 
aggregation. Indeed, these aggregates appeared smaller in size and in a lower number when BAG1 is overexpressed 
compared to control condition. Also GFP-TDP-35 mislocalization was partially rescued (Figure 37B) by BAG1 
overexpression since many GFP-TDP-35 aggregates disappeared from cell cytoplasm; while GFP-TDP-43 was not 
affected by BAG1 presence. 
BAG1 overexpression in muscle cells reflected the observation obtained in motor neurons. Indeed, C2C12 NP-40 soluble 
extracts analysed in FRA showed a significant reduction of GFP-TDP-25 accumulation after BAG1 overexpression (** 
p<0.01); GFP-TDP-43 and GFP-TDP-35 amount in NP-40 soluble fraction was not affected by BAG1 overexpression. WB 
analysis on the same extracts showed that BAG1 overexpression produced no change in the amount of the monomeric 
GFP-TDPs (Figure 37C). 
NP40 insoluble extracts analysed in FRA revealed that BAG1 overexpression reduced also the presence of GFP-TDP-25 in 
this fraction (* p<0.05), while the levels of GFP-TDP-43 and GFP-TDP-35 remained unchanged. Surprisingly, WB analysis 
of NP-40 insoluble extracts revealed that in presence of BAG1 overexpression, GFP-TDP-25 and GFP-TDP-35 levels 
increased, while GFP-TDP-43 levels decreased (Figure 37C). 
IF analysis of C2C12 transfected with GFP-TDPs in presence of BAG1 confirmed the pro-degradative activity of BAG1 
against GFP-TDP-25 aggregation. Indeed, cells that displayed high aggregation of GFP-TDP-25 in control condition, in 
presence of BAG1 showed no aggregates. As observed in NSC34, levels of GFP-TDP-35 were lower (Figure 37D) in 
presence of BAG1 while in control condition TDP-35 mislocalization and aggregation was stronger. 
In conclusion, these results show that, both in motor neurons and muscle cells, routing to proteasome by BAG1 
overexpression, is able to counteract/reduce GFP-TDP-25 aggregation, and also GFP-TDP-35 
mislocalization/aggregation. Indeed, I observed that NP-40 insoluble levels of GFP-TDP-25 were reduced by BAG1 
overexpression, while effect on GFP-TDP-35 was not detectable by NP-40 extraction. Overall, these results suggest that 
BAG1, probably acting in complex with HSP70, may have a protective role against  the formation of TDP-25 toxic 
species. 
  
Part one: PQC system in ALS 
Chapter Three 
86 
 
 
Figure 36: Proteasome rerouting is beneficial to GFP-TDP-25 aggregation. (A) mouse motor neurone NSC34 transiently overexpressing GFP-TDP-43, GFP-TDP-35 and GFP-TDP-25, 
and co-transfected with pCI-HA-Bag1 or pcDNA3 as control vector. Left panel shows NP-40 soluble extracts WB analysis (upper inset), NP-40 soluble extracts FRA analysis (middle 
inset) and quantification of NP-40 soluble extracts FRA analysis (* p<0.05 vs GFP-TDP-25 co-transfected with control vector) (lower inset). Right panel shows NP-40 insoluble extracts 
WB analysis (upper inset), NP-40 insoluble extracts FRA analysis (middle inset) and quantification of NP-40 insoluble extracts FRA analysis (*p<0.05 vs GFP-TDP-25 co-transfected 
with control vector) (lower inset).(B) mouse motor neurone NSC34 transiently overexpressing GFP-TDP-43, GFP-TDP-35 and GFP-TDP-25, and co-transfected with pCI-HA-Bag1 or 
pcDNA3 as control vector analysed with confocal microscope. 63X magnification. Green: GFP-TDPs; Red: hBag1; nuclei staining: DAPI. (C) Immortalized mouse myoblast C2C12 
transiently overexpressing GFP-TDP-43, GFP-TDP-35 and GFP-TDP-25, and co-transfected with pCI-HA-Bag1 or pcDNA3 as control vector. Left panel shows NP-40 soluble extracts WB 
analysis (upper inset), NP-40 soluble extracts FRA analysis (middle inset) and quantification of NP-40 soluble extracts FRA analysis (** p<0.05 vs GFP-TDP-35 co-transfected with 
control vector) (lower inset). Right panel shows NP-40 insoluble extracts WB analysis (upper inset), NP-40 insoluble extracts FRA analysis (middle inset) and quantification of NP-40 
insoluble extracts FRA analysis (*p<0.05 vs GFP-TDP-25 co-transfected with control vector).(D) Immortalized mouse myoblast C2C12 transiently overexpressing GFP-TDP-43, GFP-
TDP-35 and GFP-TDP-25, and co-transfected with pCI-HA-Bag1 or pcDNA3 as control vector analysed with confocal microscope. 63X magnification. Green: GFP-TDPs; Red: hBag1; 
nuclei staining: DAPI. 
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DISCUSSION 
Amyotrophic lateral sclerosis is a fatal motor neuron disease that still lacks a proper therapy. The primary target of the 
pathology are motor neurons, but recent evidence suggest that also oligodendrocytes and astrocytes could be directly 
involved in the diseases (Taylor et al. 2016). Moreover, these cells could play a role in the onset and in the progression 
of the pathology. Muscle is directly connected to motor neurons and thus is the tissue more affected by motor neuronal 
loss, becoming atrophic and loosing strength when disease progresses. In fact, patients die for respiratory failure. Even 
if muscle degenerates during ALS progression, its involvement in ALS pathogenesis is still unclear (Dobrowolny et al. 
2008; Pansarasa et al. 2014). There are still no evidence in favour of a muscle involvement at the beginning of the 
pathology; what we know till now is that muscle atrophy is a consequence of motor neuron degeneration. Motor 
neuron degeneration could be ascribed to several factors; one of these is the presence of proteins that lose their 
conformation and misfold (Gendron et al. 2014). TDP-43 is a protein found misfolded and mislocalized both in familial 
and sporadic case of ALS. Moreover, TDP-43 is aberrantly cleaved in two major fragments of 35 and 25 kDa (Neumann 
et al. 2006; Zhang et al. 2009; Yamashita et al. 2014). TDP-43 inclusions, found in almost all patient tissue (apart from 
SOD1 and FUS patients), are enriched by these two fragments. These fragments do not properly fold and are highly 
aggregation prone. Indeed, I found that these TDP-43 fragments are partially (TDP-35) or completely (TDP-25) 
mislocalized and aggregated in the cytoplasm of both motor neuronal and muscle cells. Obviously, the aggregation 
propensity of these fragments is increased when the protein are fused with eGFP protein. On the other hand, TDP-43 
with both tags is completely retained in the nucleus in a soluble form in both cell line. The protein quality control (PQC) 
system is the first defence against the presence of misfolded proteins. PQC system exerts its action by re-folding or 
degrading substrates thanks to a chaperone network and the degradative systems (Ciechanover & Kwon 2015; 
Ciechanover & Kwon 2017). I found that TDP-43, TDP-35 and TDP-25 are mainly degraded by the proteasome system, 
which acts on substrates in their monomeric state. Proteins like TDP-43 and its fragments accumulate in cells when 
proteasome is inhibited. Proteasome degrades these proteins both in motor neuron and muscle cells, probably 
recruiting them when they are not yet in inclusions. It is possible that, if the load of misfolded proteins (TDP-43 
fragments) saturate the proteasome, this degradative system becomes overwhelmed and loses its degrading capacity, 
leading to protein aggregation. The second intracellular degradative pathway is autophagy, whose role on TDP-43 
fragments degradation has yet to be assessed. By investigating the involvement of autophagy in presence of misfolded 
proteins, I observed that in NSC34 cells autophagy is involved only in the degradation of TDP-25, while TDP-43 and TDP-
35 are not degraded by autophagy. On the contrary, in muscle cells autophagy is not involved in the degradation of any 
of the various TDP species considered. Indeed, the inhibition of autophagic vesicles formation did not cause 
accumulation of the various TDPs species analysed. Routing of toxic species to the degradative systems is achieved 
through the formation of specific complexes that recognize misfolded protein by exposure of particular sequence or by 
post-translational modifications. One of the most important pathways of routing to degradation is based on HSP70 
activity. HSP70 activity relies on BAG3 co-chaperone that rules the nucleotide exchange of ATP essential for HSP70 
activity. HSPB8 is a chaperone that recognized misfolded proteins or substrates, with a still unknown mechanism. BAG3 
has also a domain that binds HSPB8 (harbouring misfolded substrates) and another domain that binds p62 autophagic 
receptor to internalize substrates into autophagic vesicles in formation. This system is a way of selective autophagy and 
is thus called chaperone assisted selective autophagy (CASA). 
Instead of directly activating degradative systems, routing the protein to degradation could be an efficient way to 
enhanced protein degradation. In fact, in several in vitro and in vivo models, the direct stimulation of degradative 
pathway produced detrimental effect (Zhang et al. 2011).  
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To increase misfolded proteins recognition, I enhanced the formation of CASA-complex by overexpressing HSPB8. I 
found that HSPB8 overexpression in motor neurons is able to decrease the accumulation of TDP-25 and TDP-35. 
Surprisingly, it also diminishes TDP-43 fraction, even if it is not forming aggregates. It I possible that TDP-43 is a 
substrate of the CASA-complex and thus I boosted a mechanism that is responsible of a correct protein homeostasis. 
Importantly, HspB8 pro-degradative role was confirmed also against the oligomeric form formed by TDPs tagged with 
FLAG. 
In muscle cells, I also found that the overexpression of HSPB8 reduces the accumulation of TDP-25 and TDP-35 (NP-40 
insoluble fraction in FRA), while TDP-43 levels were not affected by HSPB8. Importantly, results in muscle cells suggest 
that HspB8 expression could be modulate by which TDP specie is present; this difference could be a first explanation at 
the basis of the difference in aggregation between motor neurons and muscle cells.  
I also overexpressed BAG3 and the results slightly differed from those obtained with HSPB8 overexpression. Indeed, the 
two proteins have different function inside the CASA-complex (Gamerdinger, Kaya, et al. 2011; Minoia et al. 2014; Behl 
2011). The difference between HSPB8 and BAG3 overexpression is that BAG3 does not directly recognize the target, 
while HSPB8 has this ability. Moreover, BAG3 is responsible for association of HSPB8 and HSP70, and thus it enhances 
degradation of substrates already bound to HSPB8. I found that both in motor neuron and in muscle cells BAG3 
overexpression was able to reduce the accumulation of TDP-25, but the amount of the other two species (TDP-43 and 
TDP-35) remained unaffected.  
With this result I showed that, even if autophagy is not physiologically involved, it still has the capacity of degrading 
substrates when routing to autophagy is boosted (i.e. by BAG3 or HSPB8 overexpression). 
Lastly, I also enhanced the routing of misfolded substrates to proteasome. To this purpose I overexpressed BAG1, 
which, by associating to HSP70, drives proteins to proteasome instead of autophagy. I found that BAG1 was able to 
reduce TDP-25 accumulation, while TDP-43 and TDP-35 protein amount does not change upon BAG1 overexpression. 
From data collected in these experiments, it seems that the effect of proteasome routing is less efficient than the 
routing to autophagy. This is probably due to the different capacity of the two systems. Proteasome could be partially 
overwhelmed when misfolded protein are present in the cells (transient expression of TDP-35 and TDP-25) and the 
capacity of the system is not very high. On the contrary, autophagy is a system with a very high capacity and routing to 
autophagy demonstrates to be efficient in removing highly aggregation-prone species.  
In conclusion with these results I showed that also muscle cells are a site for TDP-25 aggregation, even if aggregation of 
misfolded species is less heavy, probably because degradative systems are more active in muscle cells. 
I also showed that the PQC system is important in presence of misfolded proteins in both motor neuron and muscle 
cells. Indeed, degradative systems maintain a correct protein concentration preventing protein aggregation, since 
misfolded proteins load saturates them. Most importantly, I found that forcing the routing of misfolded substrates 
towards one of the degradative pathways exerts beneficial effect against protein aggregation. These strategy is 
particularly efficient when substrates are routed to autophagy that has the capacity of degrading large substrates.  
With this work, I highlight the possibility of boosting routing systems to degrade misfolded proteins whose presence 
and aggregation is detrimental for cells. Even if we are far away from suggesting a cure for ALS, I showed the 
importance of the routing systems in order to reduce the amount of misfolded proteins, and drugs that induce these 
pathways could have beneficial effect in ALS developing.  
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Part Two: Aims and introduction  
Spinal and bulbar muscular atrophy (SBMA) is a neurodegenerative disease caused by a mutation on the androgen 
receptor (AR) gene. Normally in the exon one of AR gene there is a polyCAG tract of 23-39 repetition, that encodes for a 
polyglutamine (polyQ) tract whose role is not clear. In SBMA patients, the polyCAG tract spans up to 60 repetition. The 
AR protein bearing this elongation is toxic and is highly aggregation prone thanks to the hydrophobic polyQ tract. 
SBMA has been recently defined as a neuromuscular disease. Indeed, in the first stage of the pathology muscle 
contribute is strikingly important even more relevant than motor neuronal contribution (Lieberman et al. 2014; Cortes 
et al. 2014). Indeed, it has been clearly demonstrated that the expression of ARpolyQ in muscle is able to induce onset 
of SBMA, while ARpolyQ expression in motor neurons is not able to cause SBMA insurgence. Motor neuron contribution 
increases in the later stage of the pathology, causing paralysis and then death.  
In this context, in the part two of this thesis, I studied the aggregation of the androgen receptor in muscle cells and the 
effect of ARpolyQ on muscle cells viability. Subsequently, I studied which degradative system (proteasome or 
autophagy) is in charge of degrading ARpolyQ present in muscle cells. In the last part I focused on the effect of a drug, 
trehalose, that could enhance the activity of autophagy. I studied the effect on autophagy activation and on ARpolyQ 
aggregation. Lastly, I study the role of HspB8 that is a protein induce by trehalose treatment.  
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Materials and methods 
CHEMICALS. 
All the following treatments were obtained by Sigma-Aldrich (St. Louis, MO, USA). Cells were treated with: 
 Testosterone (10nM) usually for 48 hrs (ethanol was used as control) 
 Z-Leu-Leu-Leu-al or MG132 (10µM) for 16 hrs (DMSO was used as control) 
 Bafilomycin A1 from Streptomyces griseus (100µM) for 16 hrs (DMSO was used as control) 
 D-(+)-Trehalose dihydrate (100mM) for 48 hrs (diluted directly in the cell medium) 
CELL CULTURES  
Immortalized mouse myoblast C2C12, stably transfected respectively with ARQ24 and ARQ100, were kindly obtained 
from Dr. M. Pennuto (CIBIO, Trento, Italy). Briefly C2C12 were transfected with the lentiviral vector 
#945.PCCL.sin.cPPT.SV40ployA.eGFP.minCMV.hPGK.deltaLNGFR containing the cDNA encoding full length ARQ24 and 
elongated ARQ100 (Milioto et al. 2017). Green Fluorescent Protein (GFP) was cloned under the CMV promoter. After 
transfection cells were sorted using the fluoresce emitted by GFP to select positive cells. Sorted cells of both the two 
lines were cultured with D-MEM high glucose medium (Euroclone, Pero, MI, Italy) supplemented with glutamine 1mM 
(Euroclone), penicillin (SERVA, Electrophoresis GmbH, Heidelberg, Germany), streptomycin (SERVA), and 10% fetal 
bovine serum (GIBCO, Thermo Scientific Life Sciences Research, Waltham, MA, USA). Cells were maintained at 37°, with 
5% CO2. For splitting cells were detached using trypsin (Euroclone) 
TRANSFECTION, PLASMIDS AND SIRNA. 
Lipofectamine
®
 2000 Transfection Reagent (Invitrogen, Thermo Scientific Life Sciences Research, Waltham, MA, USA) 
was used to transfect cells with 1µg of plasmids DNA or with 40pmol of custom siRNA following manufacturer 
instruction. The following plasmids were used: pCI-neo-HSPB8, coding for human HSPB8. To silence the expression of 
endogenous genes, custom duplex siRNAs were used with the following sequence: siRNA_mHSPB8 (sense: 5’-
CGGAAGAGCUGAUGGUAAAUU-3’; antisense: 5’-UUUACCAUCAGCUCUUCCGUU-3’). Treatments were always added 
during medium change after 5-6 hrs from transfection. 
CELL VIABILITY ASSAY 
Cells were plated at 1,500 cells/mL in a 24-well plate and treated with testosterone for 7 days (ethanol was used as a 
control) or at 45,000 cells/mL in a 24-well plate and treated with testosterone and trehalose for 48 hours. After 
treatment cells were incubated for 30 minutes at 37° C at 5% CO2 with 300µL/well of a solution of medium and 3-(4,5-
dimethyl-2-thiazolyl)-2,5 diphenyl-2H-tetrazolium bromide (MTT, Sigma-Aldrich) at a concentration of 1.5 mg/mL. 
Medium was then removed and cells were lysated in 500µL of isopropyl alcohol. The optical density (OD) of each well 
was measured by Enspire (Perkin Elmer, Waltham, MA, USA) at a wavelength of 550nm.  
PROPIDIUM IODIDE ASSAY 
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To measure cell mortality Propidium Iodide assay was performed. Cells were plated in 12-well plate at 1,500 cell/mL 
and treated with testosterone or ethanol for 7 days. Cells were harvested, centrifuged (100 rcf for 6 min at 4°) and 
diluted in a solution of PBS and 50 µM propidium iodide (Sigma-Aldrich). Cells displaying red fluorescence were 
analysed and counted by NovoCyte Flow Cytometer 3000 (ACEA Biosciences, San Diego, CA 92121, USA).  
PREPARATION OF PBS PROTEIN EXTRACTS 
Cells were plated in 12-well plate at 65,000 cell/mL. After transfection and/or treatment cells were harvested, 
centrifuged (100 rcf for 6 min at 4°) and diluted in 60µL of PBS (Euroclone) added of protease inhibitor cocktail (Sigma-
Aldrich). After slight sonication (3 hits at 10% of intensity), the protein content of each sample was quantified by 
bicinchoninic acid (BCA) assay (Euroclone). 
NP-40 SOLUBLE-INSOLUBLE EXTRACTION 
Cells were plated in 6-well plate at 65,000 cell/mL. After treatments cells were harvested, centrifuged (100 rcf for 6 min 
at 4°) and diluted in 65µL of a solution made by NP-40 extraction buffer (150 mM NaCl (Sigma-Aldrich); 20mM TrisBase 
(Sigma-Aldrich); Nonidet P-40 (NP-40) 0.5% (Sigma-Aldrich); 1.5 mM MgCl2 (Sigma-Aldrich); Glycerol 3% (Sigma-
Aldrich), pH 7,4), added of protease inhibitors (cOmplete EDTA-free Tablet 25X (Sigma-Aldrich)), and 1,4-Dithioteitol 
1Mm (Sigma-Aldrich). Cells were lysated by passage in 1 mL syringe. Sample were then centrifuged (maximum speed for 
15 min at 4°). Supernatant was transferred in a new tube and the pellet was rinse in 65µL of NP-40 extraction buffer. 
Protein content of the NP-40 soluble fraction was quantified by bicinchoninic acid (BCA) assay (Euroclone). The 
insoluble fraction was sonicated (3 hits at 10% of intensity). 
FILTER RETARDATION ASSAY 
Filter retardation assay (FRA) was carried out using Bio-Dot SF Microfiltration Apparatus (Bio-Rad, Hercules, CA, USA). 
6µg of both PBS and NP-40 soluble extracts were loaded on a cellulose acetate membrane with pores of 0,22 µm. For 
NP-40 insoluble extracts an equal volume to NP-40 soluble extracts were loaded on the membrane. Samples were 
filtered on the membrane applying vacuum at the apparatus. Protein were fixed at the membrane using methanol and 
the membrane was incubated for 1 hr in blocking solution (5% dried non-fat milk (Euroclone) in T-BST 1X). The 
membrane was then incubated with rabbit polyclonal AR-H280 antibody (Santa-Cruz, sc-13162) 1:1,000 in blocking 
solution for at least 2 hrs. After two washes with TBS-T 1X the membrane was incubated for 1 hr with goat anti-rabbit 
HRP-conjugate secondary antibody (Santa Cruz Biotechnology, sc-2004) 1:5,000 in TBS-T 1X. After three washes in TBS-T 
1X signal was revealed with Clarity
TM
 Western ECL Blotting Substrate (Bio-Rad) and optical densitometry was acquired 
by ChemiDoc XRS System (Bio-Rad). Results were analysed using Prism 4.0 applying the two-way ANOVA test. Each 
result represent mean ± SEM of three biological replicates.  
WESTERN BLOT 
Western blot experiments were carried out using 10% acrylamide gels. To visualize androgen receptor protein, 15µg of 
each PBS extract or 30µg of each NP-40 soluble and insoluble extracts were loaded on gels. Following electrophoresis, 
proteins were transferred over night at 4° on nitrocellulose membrane. Membrane was then incubated for 1 hr at RT 
and then overnight at 4° with primary antibody diluted in blocking solution (5% dried non-fat milk (Euroclone) in T-BST 
1X). After two washes with TBS-T 1X the membrane was incubated for 1 hr with secondary antibody diluted in TBS-T 1X. 
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Signal was revealed using Clarity
TM
 Western ECL Blotting Substrate (Bio-Rad) and images were acquired by ChemiDoc 
XRS System (Bio-Rad). The following primary antibody were used: rabbit polyclonal AR-H280 antibody (1:1,000, Santa-
Cruz Biotechnology, sc-13162), rabbit polyclonal anti-LC3-B antibody (1:1,000, Sigma-Aldrich, L8918), rabbit polyclonal 
anti-p62/SQSTM1 antibody (1:3,000, Abcam, Cambridge, UK, ab91526), home-made rabbit polyclonal anti-HSPB8 
(1:2,000), rabbit polyclonal anti-GAPDH (1:1,000, Santa Cruz Biotechnology, sc-32233), goat polyclonal anti-ACTIN 
(1:1,000, Santa Cruz Biotechnology, sc1615), mouse monoclonal anti-α-tubulin (1:3,000, Sigma-Aldrich, T6199). The 
following secondary antibodies were used: goat anti-rabbit HRP-conjugate secondary antibody (1:10,000, Santa Cruz 
Biotechnology, sc-2004), goat anti-mouse HRP-conjugate secondary antibody (1:10,000, Santa Cruz Biotechnology, sc-
2005), donkey anti-goat HRP-conjugate secondary antibody (1:10,000, Santa Cruz Biotechnology, sc-2020) 
IMMUNOSTAINING AND CONFOCAL MICROSCOPE ANALYSIS 
Cells were seeded on coverslips at 55,000 cells/mL. After treatments cells were fixed at 37° using a solution 1:1 of 
paraformaldehyde 4% in PB 0.2 M (Sigma-Aldrich) and sucrose 4% in PB 0.2 M (Sigma-Aldrich). After 25 min fixing 
solution was removed and ice methanol was added to complete the fixation. Cells were permeabilized using a solution 
of TRITON X100 (Sigma-Aldrich) 0.2% in PBS. Cells were than incubated for 1 hr in blocking solution (5% dried non-fat 
milk in T-BST 1X), and then incubated over night at 4°C with the primary antibody. After three washes with PBS cells 
were incubated for 1 hrs with a fluorophore-tagged secondary antibody. Nuclei were stained with Hoechst. The 
following primary antibodies were used: rabbit polyclonal AR-H280 antibody (1:500, Santa-Cruz Biotechnology, sc-
13162), rabbit polyclonal anti-LC3-B antibody (1:500, Sigma-Aldrich, L8918), rabbit polyclonal anti-p62/SQSTM1 
antibody (1:500, Abcam, ab91526). The following secondary antibodies were used: goat anti-rabbit Alexa 594 (1:1,000, 
Life technologies, Thermo Scientific, A-11012). All the primary and secondary antibodies were diluted in blocking 
solution. Coverslips were mounted on a glass support using MOWIOL. All the images were acquired using LSM510 Meta 
system confocal microscope (Zeiss, Oberkochen, Germany) and processed with the Aim 4.2 soft- ware (Zeiss). 
REAL TIME PCR 
Cells were plate in 6-well plate at 65,000 cell/mL. After treatment or transfection cells were harvested, centrifuged (100 
rcf for 6 min at 4°) and lysed using TRI Reagent (Sigma-Aldrich). mRNA was extracted following manufacturer 
instructions and quantified using NanoDrop 2000 spectrophotometer (Thermo Scientific). After DNA decontamination 
using DNase I (Sigma-Aldrich) 0.5µg of the total mRNA was reverse-transcribed using High-Capacity cDNA Archive Kit 
(Life technologies, Thermo Scientific). mRNA levels were assayed using iTaq SYBR Green Supermix (Bio-Rad) on CFX 96 
Real-Time System (Bio-Rad). All results were normalized to mRplP0 control. All the primers used were obtained by 
Eurofins Genomics. The following primers were used:  
Target Gene Sequence Forward Sequence reverse 
hAR 5’-AAGGATGGAAGTGCAGT-3’ 5’-GATGGGCTTGGGGAGAACCA-3’ 
mBeclin 1 5′ -TGAAATCAATGCTGCCTGGG-3′ 5′-CCAGAACAGTATAACGGCAACTCC -3′ 
mTFEB 5’-GCGGCAGAAGAAAGACAATC-3’ 5’-CTGCATCCTCCGGATGTAA-3’ 
mBag3 5’-ATGGACCTGAGCGATCTCA-3’ 5′-CACGGGGATGGGGATGTA-3′ 
mBag1 5’-GAAACACCGTTGTCAGCACT-3’ 5′-GCTCCACTGTGTCACACTC-3′ 
mHspB8 5’-ATACGTGGAAGTTTCAGGCA-3’ 5′-TCTCCAAAGGGTGAGTACGG-3′ 
mMAP-LC3-B 5′-CGTCCTGGACAAGACCA-3′ 5′-CCATTCACCAGGAGGAA-3′ 
mSQSTM1/p62 5′-AGGGAACACAGCAAGCT-3′ 5′-GCCAAAGTGTCCATGTTTCA-3′ 
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mVCP 5’-TGCCATCCTAAAAGCCAATC-3’ 5’-TCAGCTCCAGAAAAGCCATT-3’ 
mAchR 5’-GTGCTGGGCTC TTTCATCTC -3′ 5′ -TTCTGTGCGCGTTCTCATAC -3′ 
mRplp0 5’-GGT GCC ACA CTC CAT CAT CA-3’ 5′ -AGG CCT TGA CCT TTT CAG TAA GT-3′ 
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Muscle cells are a site for androgen receptor aggregation and toxicity 
C2C12_ARQ24 and C2C12_ARQ100 were plated and treated with testosterone for 48 hrs (to activate androgen receptor 
(AR)) and protein samples were extracted in PBS. Western blot (WB) results showed that both ARQ24 and ARQ100 were 
stabilized by testosterone treatment. In fact, I observed an increased amount of AR when cells were treated with 
testosterone respect to control condition with ethanol (Figure 38A). Interestingly, filter retardation assay (FRA) showed 
that ARQ100 formed high molecular weight (HMW) species only following testosterone treatment (*** p<0.001 vs 
control cell line; °° p<0.01 vs ethanol) (Figure 38A). On the contrary, ARQ24 did not form HMW species detectable in 
FRA even after activation with testosterone. Immunofluorescence (IF) analysis showed that both ARQ24 and ARQ100 
translocated into the nucleus upon testosterone treatment, and levels of the soluble protein was increased both cell 
line (Figure 38C). In C2C12_ARQ100 cell line, I could not detect any visible aggregates or inclusions after testosterone 
treatment. To better characterize the HMW species observed in FRA but not visible in IF, I performed a NP-40 extraction 
on both cell line. By FRA analysis I found that testosterone triggered the formation of NP-40 insoluble species of 
ARQ100, while these species were not formed by ARQ24 (** p<0.01 vs control cell line) (Figure 38B). I also observed 
that WB of the NP-40 insoluble extracts showed a great amount of ARQ100 compared to the control condition (ethanol) 
and compared to the control cell line (C2C12_ARQ24) (Figure 38B). To assess the expression levels of AR in these cells I 
performed an RTq-PCR on extracts of both cell lines in presence and absence of testosterone. I found that in 
C2C12_ARQ100 AR gene expression is significantly higher than in C2C12_ARQ24 (*** p<0.001; ** p<0.01 vs same 
condition in the control cell line) (Figure 38D). I also investigated if the presence of the activated ARpolyQ caused 
mortality or atrophy in muscle cells. MTT assay was performed on both cell line treated with and without testosterone. 
To amplify testosterone effect for the following experiments, treatment was maintained for 7 days. I observe that the 
presence of ARQ100 caused a reduction in cell viability even without testosterone (*** p<0.001; ** p<0.01 vs same 
condition in the control cell line) (Figure 38E). To assess if this difference was linked to cell mortality, I performed an 
analysis by flow-cytometry, staining dying cells with propidium iodide. I found that after testosterone treatment 
C2C12_ARQ100 showed an increased mortality respect to the control line treated with testosterone (* p<0,05 vs 
control cell line in same condition) (Figure 38F). Finally, in order to characterized ARpolyQ contribution to muscle 
atrophy I analysed the expression of the acetyl-choline receptor (AchR). AchR is a denervation marker, whose 
expression is increased when muscle are denervated.  
I found that C2C12_ARQ100 expressed these receptor at lower levels respect to C2C12_ARQ24 (*** p<0.001 vs same 
condition in the control cell line) (Figure 38G). I observed that in C2C12_ARQ100 treated with testosterone the 
expression of the AchR was increased compared to control condition with ethanol (*** p<0.001 vs control condition) 
(Figure 38G). I also noticed that levels of mAchR in C2C12_ARQ100 were significantly lower than in C2C12_ARQ24 (°°° 
p<0.001). Since in this model, muscle cells are not part of a neuromuscular junction, these results describe only what 
happen in muscle following testosterone treatment and in presence of the polyQ tract. 
In conclusion, I observed that ARQ100 forms HMW species in presence of testosterone, that are detectable in FRA both 
in PBS extracts and in NP-40 insoluble extracts. These HMW species are not detectable in IF, probably because they are 
not yet in a fibrillary state, but still in an small oligomeric state. I also evaluated ARQ100 toxicity on muscle cells and I 
found that testosterone causes only a mild increased in cell mortality. On the other hand, these results suggest that 
ARQ100 may cause atrophy in muscle cells, even without testosterone.  
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Figure 37: Characterization of the cellular model. (A) Western blot (upper inset) and Filter retardation assay (FRA) (middle inset) of PBS extracts. Optical densitometry quantification 
of FRA (lower inset). *** p<0.001 vs ARQ24+T; °° p>0.01 vs ARQ100-T. (B) Western blot (upper inset) and FRA (middle inset) of NP-40 extracts. Optical densitometry quantification of 
FRA (lower inset). ** p<0.01 vs ARQ24+T. (D) RTqPCR quantification of hAR levels. ** p<0.01; ***p<0.001 vs ARQ24 in the same conditions. hAR expression levels were normalized 
on p0 expression levels (C) Immunostaining for androgen receptor. Nuclei staining: Hoechst. 63X magnification. (E) MTT assay. ** p<0.01; ***p<0.001 vs ARQ24 in the same 
conditions. (F) Propidium Iodide Assay. ** p<0.01 vs ARQ24+T. (G) RTqPCR quantitation of mAchR levels normalized on p0 levels. ***p<0.001 vs ARQ24 in the same conditions; °°° 
p<0.001 vs ARQ100-T.  
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The role of the degradative pathways in presence of ARQ100 
Misfolded proteins are substrates of the protein quality control (PQC) system. PQC system relies on a chaperone 
network that maintains proteins in the correct conformation or drives them to the degradative pathways: proteasome 
and autophagy. To investigate PQC system activation in presence of mutated ARpolyQ, I performed an RTq-PCR on 
mRNA samples from both cell line treated with ethanol or testosterone (Figure 39A). I analysed the expression of Tfeb, 
Beclin1, Lc3 and p62 (involved in autophagy activation), Bag3, HspB8, (part of the complex that routes aggregates to 
autophagy), Bag1 (that routes misfolded proteins to proteasome), and VCP (involved in protein extraction from 
membranes). I observed that there were no differences in the expression of Tfeb, Beclin1, Lc3 and p62, between the 
two lines (C2C12_ARQ24 vs C2C12_ARQ100) or following AR activation by testosterone. Bag3, but not its partner 
HspB8, was decreased in C2C12_ARQ100; Bag1 levels did not changed between cell lines and conditions; VCP levels 
decreased in C2C12_ARQ100 with both treatments. Even if the presence of the mutated protein was not able of 
inducing an activation of the PQC system, I investigated which degradative pathway is responsible for ARQ24 and 
ARQ100 degradation. I inhibited the degradative pathway in both cell lines using MG132 (proteasome inhibitor) and 
bafilomycin (autophagic inhibitor) and I extracted samples in PBS. I observed that following proteasome inhibition both 
ARQ24 and ARQ100 accumulated in FRA (Figure 39B). The levels of FRA accumulation upon MG132 treatment were the 
same with or without testosterone (** p<0.01; *** p<0.001 vs same condition and cell line without testosterone). 
Protein levels in WB remained unchanged in presence of MG132, but in both cell lines the activation of AR following 
testosterone treatment was clearly detectable (Figure 39B). Upon autophagic inhibition by bafilomycin, I found that 
there was no increased in ARQ24 HMW species retained in FRA (Figure 39B) compared to control condition. On the 
contrary, inhibiting autophagy caused a significant increase of HMW species of ARQ100, following testosterone 
treatment. Analysis in WB did not show any increase caused by bafilomycin treatment in both cell lines (Figure 39B).  
I also performed and NP-40 extraction on the same samples and, analysing samples in FRA, I found that ARQ24 was 
detectable mainly in the NP-40 soluble fraction even after inhibition of proteasome and autophagy (Figure 39C). WB 
analysis of both the NP-40 soluble and insoluble fractions showed that testosterone stabilized the receptor in any 
conditions, but that there was no change in the amount of ARQ24 protein even upon degradative systems inhibition 
(Figure 39C).  
FRA performed on NP-40 soluble and insoluble extracts of C2C12_ARQ100, showed that after proteasome inhibition 
most of the protein was found in the NP-40 insoluble fraction (Figure 39C) and WB reflected this shift toward the 
insoluble fraction. When autophagy was inhibited by bafilomycin, I found that ARQ100 was mainly present in the NP-40 
insoluble fraction forming HMW species clearly detectable also in WB in the upper part of the gel (Figure 39C). 
IF analysis, performed after proteasome and autophagy inhibition, revealed that, in both cell lines, levels of AR were 
increased after MG132 treatment, but still no aggregates were detectable in cell cytoplasm and nucleus. Despite the 
increase of the total protein levels, there were no visible inclusions in C2C12_ARQ100 even after bafilomycin treatment 
(Figure 39D). 
In summary, these results show that at basal levels there is no PQC system activation in presence of activated ARQ100. 
It is possible that, in normal condition, muscle cells have the PQC system already robustly activated and the presence of 
the misfolded protein is not able to cause a further activation. Indeed, when degradative systems are inhibited, ARQ100 
degradation is blocked, and consequently ARQ100 accumulates in FRA. Interestingly, proteasome is involved in the 
degradation of both ARQ24 and ARQ100, while autophagy is involved only in presence of ARQ100. 
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Figure 38: Degradative systems involvement. (A) RTqPCR of PCQ system related genes. *p<0.05; ** p<0.01; *** p<0.001 vs ARQ24 in the same conditions. (B) Left Panel: Western 
blot (WB) (upper inset) and Filter retardation assay (FRA) (middle inset) of PBS extracts. Optical densitometry quantification of FRA (lower inset). ** p<0.01; ***p<0.001 vs relative 
control conditions –T/+T. Middle and right panels: WB (upper inset) and FRA (middle inset) of NP-40 extracts of C2C12_ARQ100 treated with testosterone 10nM, MG132 10µM, and 
Bafilomycin 100µM. Optical densitometry quantification of FRA (lower inset). ** p<0.01; ***p<0.001 vs relative control conditions –T/+T; ° p<0.05 vs control condition –T. (C) 
Immunostaining for androgen receptor on fixed C2C12_ARQ24 and C2C12_ARQ100 cells. 
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Autophagy induction is protective against ARQ100 aggregates. 
Since autophagy is an important player in ARQ100 degradation, compounds that target this process gained importance 
as therapeutic possibility. I tested a well known autophagic activator, trehalose, that is an mTOR independent 
autophagic activator. Trehalose was already tested in HD models and also in SBMA motor neuronal models, and it was 
demonstrated that trehalose has a beneficial effect against mutated proteins (Giorgetti et al. 2014; Rodrìguez-Navarro 
et al. 2010). I tested trehalose also in muscle C2C12 cells, expressing mutated AR. 
C2C12_ARQ100 cells were treated with trehalose and autophagic activation was tested by RTq PCR. I observed that 
trehalose treatment increased the expression of many genes involved in the protein quality control (PQC) system 
(Figure 40A). FOXO3, Tfeb, Beclin1, Lc3 and p62, genes involved in regulation of autophagy and in autophagic machinery 
were all increased in a significant fashion (* p<0.05; ** p<0.01; *** p<0.001 vs untreated samples). In addition, I found 
that the expression of genes involved in autophagic routing such as Bag3 and HspB8 were dramatically after trehalose 
treatment (*** p<0.001 vs untreated samples). Interestingly also Bag1 and VCP expression increased was increased by 
trehalose (*** p<0.001 vs untreated samples), even if these genes are not directly correlated to autophagy. I also 
evaluated the expression of the AchR and I found that following trehalose treatment the expression of the AchR was 
greatly increased (*** p<0.001). As already mentioned, results obtained looking at AchR expression give as a suggestion 
of how trehalose affect AchR expression; since a neuromuscular junction is not present, these results are not an 
indication on deneravation (Tsay & Schmidt 1989; Rusmini et al. 2015). 
By IF I analysed LC3 and p62 localization and distribution. I found that trehalose produced an increase in LC3 puncta 
indicating an increased formation of autophagic vesicles. Trehalose also caused the formation of p62 bodies, structures 
that rise after by p62 dimerization upon autophagy activation (Figure 40B).  
C2C12 cells were then treated with trehalose and co-treated with bafilomycin. Protein samples were extracted in PBS 
and analysed in FRA and WB (Figure 40C). I found that trehalose treatment counteracted the formation of ARQ100 
HMW species produced after testosterone activation. Furthermore, the monomeric fraction of AR in WB was reduced 
by trehalose. Trehalose also causes the formation of LC3-II, detectable in WB. FRA analysis also showed that co-
treatment of trehalose with bafilomycin recovered ARQ100 aggregation, after testosterone treatment, at levels 
comparable to control samples; also ARpolyQ protein levels, detected in WB, returned comparable to untreated 
control, when cell were treated with trehalose and bafilomycin. In WB I detected an increased in LC3-II formation and in 
p62 expression in presence of the co-treatment of trehalose and bafilomycin.  
These results show that trehalose enhances autophagy in C2C12 cells and that it is also able to counteract ARQ100 
aggregation in an autophagic dependent-manner, as demonstrated by bafilomycin treatment that reverts trehalose 
effect. 
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Figure 39: Trehalose activates autophagy and reduces ARQ100 accumulation. (A) RTqPCR of PCQ system related genes. ** p<0.01; ***p<0.001 vs relative untreated control. (B) 
Immunostaining for LC3 (upper inset) and p62 (lower inset) of C2C12_ARQ100 in presence of trehalose. (C) MTT assay of C2C12_ARQ100 in presence of trehalose. (D) Western Blot 
(upper inset) Filter retardation Assay (FRA) (middle inset) of PBS extracts of C2C12_ARQ100 treated with trehalose and bafilomycin. Optical densitometry quantification of FRA 
(lower panel) ** p<0.01 vs relative untreated control; ***p<0.001 vs trehalose +T.  
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Autophagy routing counteract ARQ100 aggregates formation 
Previous result shows that trehalose treatment enhanced the expression of chaperones involved in the complex that 
routes aggregates to autophagy. HSPB8 is highly involved in autophagic routing of misfolded proteins and it has already 
been demonstrated that it plays a protective role in motor neuronal models of SBMA.  
I overexpressed HSPB8 in C2C12_ARQ100 cells and protein samples were extracted in PBS. FRA showed that HSPB8 
overexpression reverted ARQ100 aggregation caused by testosterone treatment (** p<0.01 vs pcDNA3) (Figure 41A). 
Also monomeric ARQ100 was reduced by HSPB8 overexpression.  
To further test the importance of HspB8 in ARpolyQ degradation, I silenced the endogenous HspB8. C2C12_ARQ100 
cells were transfected with a specific siRNA that target HspB8 mRNA. Samples were extracted in PBS and FRA analysis 
showed that when HSPB8 was silenced, ARQ100 aggregation was exacerbated in a significant fashion (**p<0.001 vs 
scramble) (Figure 41B). I tested by WB that HSPB8 was silenced in presence of its specific siRNA. Monomeric AR was 
mildly reduced in WB by HSPB8 silencing.  
With these experiments, I demonstrated that HSPB8 plays a protective role against ARQ100 aggregation also in muscle 
cells. I also observed that at basal levels HSPB8 in muscle cell works to maintain ARQ100 aggregation at low levels, 
probably directing misfolded ARQ100 species to autophagy. 
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Figure 40: Role of HspB8 in counteracting ARpolyQ aggregation. Right panel: Western Blot (WB) and Filter Retardation Assay (FRA) of PBS extracts of C2C12_ARQ100 overexpressing 
HspB8, upper and middle insets. Optical densitometry quantification of FRA (lower inset) ** p<0.01 vs pcDNA3 transfected control. Left panel: Western Blot (WB) and Filter 
Retardation Assay (FRA) of PBS extracts of C2C12_ARQ100 with silencing of endogenous mHspB8, upper and middle insets. Optical densitometry quantification of FRA (lower inset) 
** p<0.01 vs SCRAMBLE transfected control  
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DISCUSSION 
SBMA has been regarded for years as a motor neuron disease (Grunseich et al. 2014), but recent works have defined it 
a neuromuscular disease (Giorgetti & Lieberman 2016b). Indeed, it was recently demonstrated that muscle tissue is a 
primary site for SBMA toxicity. Muscle atrophy often precedes motor neuron loss, and the onset of the pathology could 
be rescued if ARpolyQ is specifically deleted in muscle cells and preserved in motor neurons (Lieberman et al. 2014; 
Cortes et al. 2014). Even if these studies were carried out in murine model and findings remain to be confirmed in 
human, there are strong evidence that support direct muscle involvement in SBMA onset and progression. I observed 
that muscle cells are a site for ARpolyQ aggregation. Indeed, following testosterone activation, ARQ100 was retained in 
FRA while ARQ24 was not, despite testosterone activation. I also observed that the presence of the ARpolyQ, even 
without testosterone treatment caused a mild atrophy and an increase in mortality. A possible reason that should be 
taken in account to correctly understand these results, is that experiments were carried out in undifferentiated muscle 
cells and not on mature myotubes.  
As ARpolyQ is a mutated protein, it tends to misfold; misfolded soluble form of ARQ100 is the one associated to toxicity 
even before forming aggregates (Poletti 2004). The presence of misfolded protein is stressful to cells and, potentially, 
they can activate the protein quality control (PQC) system as a defense against the presence of these toxic proteins 
(Rusmini et al. 2016). Controversially, I observed that neither the presence of the ARpolyQ nor its activation by 
testosterone caused an increase in the activity of the PQC system. It is possible that activity of the degradative pathway 
is already sufficient for managing the presence of misfolded proteins, without a further activation of one particular 
degradative pathway. Indeed, I found that ARQ24 and ARQ100 are substrates of proteasome in muscle cells, and if 
proteasome is damaged both proteins aggregate (ARQ100 in a more massive fashion). Interestingly, autophagy, that is a 
system with a higher capacity, degrade only ARQ100, probably when it is yet in oligomeric status (high molecular weight 
(HMW) species). In fact, inhibition of autophagy caused an increased in the formation of activated ARQ100 insoluble 
species while levels of activated ARQ24 remain equal to control after autophagy inhibition. These results suggest that, 
in muscle cells, autophagy is a specific pathway for the degradation of ARQ100 insoluble species. In this context 
targeting autophagy could be an efficient strategy to reduce the accumulation of ARQ100, without affecting the 
concentration of wild type soluble proteins, thus impairing other cell functions. Trehalose activates autophagy in mTOR 
independent manner and, in muscle cells, it caused the reduction of ARpolyQ insoluble species. I found that trehalose 
also increased the expression of key factors of the CASA-complex (chaperone assisted selective autophagy), like HspB8, 
that probably helps in the recognition of selected cargo avoiding the uncontrolled degradation of every intracellular 
element. A possible way for the routing of ARQ100 HMW species to autophagy involved HSPB8. Indeed, when HSPB8 is 
silenced, ARpolyQ insoluble species increase; on the other hand, when HSPB8 is overexpressed (by trehalose treatment 
or by plasmid transfection), ARpolyQ aggregation upon testosterone treatment is counteracted. 
Overall these results show that ARpolyQ aggregation happens also in muscle cells, and is hallmark of the disease. 
Targeting aggregation of ARpolyQ could play beneficial effect, since the permanence of inclusions in the cells could 
cause the damage of several pathways and the recruitment of other soluble proteins, impairing other pathways. 
Autophagy appears as a valuable pathway for the degradation of ARpolyQ HMW species; in this context, trehalose 
played beneficial effect on ARpolyQ aggregation. In parallel and supporting this study, there are several ongoing studies 
that are testing, in in vivo models, novel compounds that will address the protein quality control system, to reduce the 
presence of the misfolded toxic protein.  
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CHAPTER 5: DEVELOPING OF CRISPR/CAS9 SYSTEM TO CREATE AN ISOGENIC STEM CELL LINES 
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Short overview on CRSIPR/Cas9 system 
CRISPR/cas9 system is the most recent addition to genome-editing toolbox. In recent years the need of modifying 
genome of various and different organisms has grown, and in parallel has grown the need to find a method easy to 
handle and that would guarantee an high specificity (D’Agostino & D’Aniello 2017; Gaj et al. 2016). 
The first system used for genome editing was Zinc Finger Nuclease (ZFN) (Figure 42). This system is based on a fusion 
protein made of FokI subunit, containing the restriction catalytic site, and of a zinc finger subunit; this fusion protein is 
called zinc finger endonuclease (Carroll 2011; Kim et al. 2009; Gaj et al. 2016). Zinc finger subunits recognize the specific 
DNA sequence and their dimerization is allowed by FokI cleavage domain. Zinc finger recognized the target DNA. 
Structural analysis reveal that the interaction site between aminoacids and DNA is composed of β-sheet and α-helix; in 
particular a specific combination of these secondary structures could recognize specific DNA triplets. These structures 
were fused together in tandem, in order to recognize a specific and desired sequence. After DNA recognition FokI 
produces a double strand break (DSB) on DNA 5-7 bp upstream the targeted sequence. ZFN has two main negative 
sides: it is difficult to realize and to use due to the complexity of the design; moreover it produces a high number of off-
target effects. 
The second system developed was transcription activator-like effector nucleases (TALEN) system (Figure 42). TALEN 
system has many commonalities with ZFN: it is composed of a DNA recognition domain that dimerizes with another 
thanks to the action of FokI cleavage domain (Boch et al. 2009; Gaj et al. 2016). The interaction domain of TALEN 
proteins with DNA is made of repeat domains that recognize only a single nucleotide. This feature makes TALEN system 
easier to use and more efficient compared to ZFN. 
In this context, CRIPSR/Cas9 represent a great step forward in the spreading genome editing, since it does not require a 
specific expertise and is very efficient. It was discovered in bacteria as a defense mechanism against viruses (Figure 42-
43) . When foreign DNA is integrated in CRISPR (clustered regularly interspaced short palindromic repeats) locus, all the 
region is transcribed and is called crRNA (crisprRNA) (Horvath & Barrangou 2010; Ratner et al. 2016; Jiang & Doudna 
2015). Then, these segments of DNA associate with trans-activating crRNA (transcrRNA) to direct sequence-specific DSB 
mediated by Cas9 (endonuclease belonging to larger family of Cas proteins). During years it has been found that the 
Cas9 protein only requires the seed sequence among the crRNA (called guide RNA, gRNA) and a protospacer adjacent 
motif (PAM) sequence on the targeted sequence. The PAM sequence for the Streptococcus pyogenes Cas9 is 5’-NGG-3’. 
The Cas9 nuclease catalytic sites are called RuvC and HNH that recognized the hetero-duplex, positively charged, 
formed by the DNA and the gRNA (Jinek et al. 2012; Mojica et al. 2009).  
 CRISPR/Cas9 system has been further modified to reduce the number of off target genes, for example by mutating the 
catalytic site transforming Cas9 from a nuclease to nickase. To introduce a double strand break (DSB) two nickases will 
be directed on the target sequence, one cutting the plus strand and one cutting the minus strand (Ran et al. 2013; Cong 
et al. 2013).  
After introducing DSB, by mean of one of the above described systems, DNA repair system are activated (Figure 44). 
During DNA repair, some nucleotide can be lost; this event can cause various effects on the target genes: knock-out, 
insertion of mutation (frame-shift), insertion of stop codon. This process is called non-homologous end joining (NHEJ) 
repair, and is often used to insert mutation, to silence a gene, to have truncated protein, etc. 
There is a second mechanism that allows the insertion of a wanted sequence and is called homologous end joining 
repair (HDR). It relies on an exogenous DNA sequence, containing the corrected sequence, that acts as template to 
direct the repair systems towards the wanted correction (Gaj et al. 2016; Wiles et al. 2015).  
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Figure 41: Genome editing tools evolution (Chen & Knoepfler 2016) 
 
Figure 42 CRISPR/Cas9 biology (Jiang & Doudna 2015) 
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Figure 43 Genome editing by CRISPR/Cas9 (D’Agostino & D’Aniello 2017) 
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Developing elements for CRISPR/Cas9 system 
CRISPR/Cas9 system is based on the activity of a Cas9 protein that produces a double strand break on a target region. 
The target region is recognized by the single guide RNA (sgRNA) associated to Cas9. An essential element that allows 
Cas9 activity is the presence of a PAM sequence on the target DNA; Cas9 cuts dsDNA three nucleotides upstream the 
PAM sequence (Horvath & Barrangou 2010). Without a PAM sequence Cas9 cannot work. Our system is based on a 
Cas9 whose catalytic site has been modified (D10A): this modified Cas9D10A is turned from an endonuclease to a 
nickase (that insert a single strand break also called “nick”) (Cong et al. 2013; Ran et al. 2013). The presence of a single 
nick on one DNA strand is immediately repaired, but if two nicks are closed to each other (distance between the nicks is 
called offset) DNA repair system sense these two nicks as a DSB. To obtain these two nicks two sgRNA are needed: a 
first sgRNA (guide1) that drives the Cas9 to the plus strand and a second sgRNA (guide 2) that drives Cas9 to the minus 
strand (Figure 45A-B). I used a plasmid, named pX335B that encodes for Cas9D10A that also contains two restriction 
sites (BbsI and SapI) used for guides cloning (Figure 45A). These restriction sites are downstream to two hU6 promoters 
to ensure sgRNA expression. This system based on the use of two nickase instead of an endonuclease was developed to 
reduce the number of off target genes; since the guide is a short oligonucleotide (20 nt) Cas9 could be direct in many 
sites on many different genes. If two different sgRNA are involved, the DNA regions containing both the sequences are 
drastically lower. Moreover, if the Cas9D10A is directed in an unwanted region, it will produce a nick that is 
immediately repaired without causing any genome mutation. 
The aim of the targeting that I developed was to reduce the length of the poly-CAG tract in a human induced 
pluripotent stem cell (hiPSCs) line derived from a SBMA patient. To obtain this modification I needed the Cas9 system 
and a donor template. 
sgRNA design: I used an open source http://crispr.mit.edu/ to design the guide. This tool screens the sequence that 
should be targeted and find all the PAM sequences. Then it designs the sgRNA that should target the sequence. It gives 
a score to each guide for position among the analysed sequence, 3’ stability, GC% etc. This software makes also a 
second analysis in order to find the best couple of sgRNA for targeting the wanted sequence. It also gives a score to the 
various sgRNA couple analysed on the basis of offset length, quality of the guides and number of off-target genes. I 
chose to design a pair of guide to target a region upstream the polyQ and another pair of guides to target a region 
immediately downstream the polyQ (Figure 45 B-C-D). 
I cloned the two pairs of guides in pX335B plasmid, and I created two different plasmids targeting regions upstream or 
downstream the polyQ. 
Donor template design: donor template is a long sequence of DNA that acts as template for DNA polymerase that 
repair the DSB; in this way is obtained a homologous end joining repair (HDR). Since it should mimic sister chromatid 
invasion (mechanism of DNA repair during mitosis), it must have two long homology arms of at least 500-600 bp, 
upstream and downstream the DSB (Figure 46). These two homology arms will form a tertiary structure with the target 
DNA; the region between these two homology arms will act as a template for DNA polymerase that will introduce the 
wanted correction. I also introduced a selection cassette to facilitate colony screening (Figure 46). Selection cassette is 
flipped, so that the promoter of the antibiotic resistance will not influence the expression of the downstream exon. I 
chose to use a selection cassette coding for zeocin resistance. I also mutated the PAM sequence on the donor template 
so that the remaining Cas9 protein would not target the corrected sequence.  
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Figure 44: (A) schematic representation of guide expression vector (B) schematic representation of how double nickase works and where guides are giong to target the DNA (C) 
sequence of exon1 of the hAR gene. In pink are underlined the couple of guide that target upstream the polyQ and in blue the couple of guide that will target downstream the polyQ. 
polyQ tract is highlighted in light blue and ATG codon in green (D) representation of oligonucleotide design for guides insertion in plasmid vector.  
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Figure 45: Schematic representation of donor template  
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Targeting of polyglutamine tract in SBMA derived human induced pluripotent stem cells 
hiPSCs derived from SBMA patients were routinely seeded on Matrigel® Matrix (Corning Incorporated, NY, USA) and 
cultured in E8 medium (Life Technologies, Thermo Scientific Life Sciences Research, Waltham, MA, USA) supplemented 
with ROCK-I (Y27632, Tocris Bioscince, Bristol, UK) during splitting and reseeding procedures. Splitting was performed 
using accutase (Life Technologies, Thermo Scientific Life Sciences Research, Waltham, MA, USA) E8 composition is now 
known and the eight components are: insulin, selenium, transferrin, L-ascorbic acid, FGF2, and TGFβ in DMEM/F12 
(Chen et al. 2011). For thawing, clonal dilution at single cells and picking procedures E8 medium was replaced with 
mTeSR™1 medium (Stemcell technologies, Vancouver, Canada). 
Here I summarized the procedure I followed to target ARpolyQ with CRISPR/Cas9 system (Figure 47A). 
Day 0: hiPSCs were seeded as single cell in mTeSR™1 medium with ROCK-I. I seeded 175,000 cells per well (6well-plate).  
Day1: cells were transfected with guide-plasmid and donor template (2µg of total DNA; I chose 1:1 ratio guide plasmid 
vs donor template). Cell were transfected using FuGENE® HD Transfection Reagent (Promega Corporation, Madison, WI, 
USA), following manufacturer instruction. To target both upstream and downstream two different transfections were 
performed. 
Transfection A: guides to target upstream + donor template 
Transfection B: guides to target downstream + donor template 
Day 2: cells were treated with puromycin to get rid of not transfected cells (puromycin resistance is present on the 
pX335B plasmid). Puromycin (Sigma Aldrich, Merck, Darmstadt, Germany) was used 0.5ug/mL overnight. 
Day 4-5: when cells recovered from puromycin treatment, they were seeded at clonal dilution as single cells in 
mTeSR™1 medium. I seeded 500/750 cells per well (6-well plate).  
Day 9-10: when few colonies started forming, cells were treated with zeocin 0.75 µg/mL for 4 days. 
Day 11-20: colonies were grown and when they reached a proper dimension, colonies were picked. Each picked colony 
was split in two: the first part was re-plated in 48-well plate with mTeSR™1 supplemented with ROCK-I; the second part 
was used for DNA extraction and PCR screening  
Primers for screening were routinely used in our lab and were designed to amplify a region containing the polyCAG 
expansion (FW 5’-CCAGAATCTGTTCCAGAGCGTG-3’; RV 5’-TGTTCCCCTGGACTCAGATG-3’). I picked more than one 
hundred colonies for each transfection and I found two positive clones from transfection B (Figure 46B) with (CAG)1 
instead of (CAG)51. 
Positive colonies were grown, amplified and frozen. 
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Figure 46: (A) Protocol for CRISPR/Cas9 gene editing on hiPSCs. (B) PCR on hiPSCs (SB1SG1 1Q) 
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DISCUSSION 
CRISPR/Cas9 system has gained importance in the fields of hereditary disease since it allows the generation of isogenic 
cell line. Isogenic cell line means that two cell line differs only by the presence of a mutation (point mutation, deletion, 
expansion etc..) while genetic and historical background are the same. CRISPR/Cas9 technique is a genome editing tool 
easy to use and that gives results with very high efficiency. SBMA is a X-linked hereditary disease caused by a CAG 
abnormal repetition in the androgen receptor gene. I aimed to obtain from hiPSCs obtained from SBMA patient, an 
isogenic cell line with normal CAG, using CRISPR/Cas9 system. I obtained two clones that, by PCR, display a shorter 
(physiological) CAG tract;  the obtained cell line will be the control cell line for studying the effects of ARpolyQ in cells. 
Moreover, differentiating hiPSCs into motor neurons and muscle will let me study ARpolyQ effect directly in affected 
cell type. 
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My work in these three years focused on the study of the protein quality control system in two neurodegenerative 
diseases: amyotrophic lateral sclerosis and spinal and bulbar muscular atrophy. I studied the PQC system in muscle 
cells, to investigate the behavior of these cells in presence of misfolded aggregation prone proteins. 
My work is divided in three main parts 
i) Studying amyotrophic lateral sclerosis (ALS): I observed that TDP-43 fragments of 35 and 25 kDa aggregate in 
muscle cells, even if in a slower rate than in motor neurons. To explain this difference, I investigate the 
involvement of degradative systems in presence of these misfolded aggregation prone proteins. It resulted that 
proteasome was highly involved in degradation of these toxic species linked to ALS. Even if autophagy seems 
not involved at basal levels in the degradation of these species, I noted that routing of misfolded proteins to 
autophagy reverts or slows down the formation of aggregates and reduce the presence of the 
oligomeric/monomeric proteins. Routing to autophagy was achieved by overexpression of key components of 
the CASA-complex such as HspB8 and Bag3.  
ii) Studying spinal and bulbar muscular atrophy: I studied the effect of trehalose, inducer of autophagy, on muscle 
cells in presence of ARpolyQ. Since autophagy is highly involved in the degradation of the oligomeric species of 
ARpolyQ formed in muscle cells. Trehalose was able to reduce the aggregation of ARpolyQ induced by 
testosterone. Moreover, trehalose in these cells also induces the expression of autophagy-related genes, 
beneficial for degrading ARpolyQ oligomeric species as demonstrated by the overexpression of one of these 
factors, such as HspB8. 
iii) Generation of a human model to further study SBMA: I generate a cell line bearing a normal CAG tract (CAG1) by 
editing a hiPSCs line derived from SBMA patient (CAG51). For genome editing a used CRISPR/Cas9 system that is 
and easy and efficient genome editing tool. The two cell line obtained are called isogenic, since the historical 
and genetic background is the same between the two cell lines, since they differ only for the presence of the 
polyCAG tract. 
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